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Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, claiming 
approximately 17.9 million lives annually. The last few decades have seen an exponential 
increase in the prevalence of major CVD risk factors, such as obesity, insulin resistance 
(IR), and type 2 diabetes mellitus (T2DM) in underdeveloped countries, including South 
Africa. This increase is concomitant to escalating CVD incidence and in part due to 
increased consumption of diets high in fat and sugar, and sedentary lifestyles. Several 
mechanisms have been implicated in the pathogenesis of diabetic-induced CVD and 
recently, increasing evidence suggests that dysregulation of the epigenome may play an 
important role in the development of T2DM and related cardiac complications. More 
specifically, aberrant DNA methylation has been extensively investigated and implicated in 
the development of chronic diseases such as obesity, T2DM and CVD. Nonetheless, it has 
been suggested that some active dietary compounds may reverse this epigenetic 
phenomenon which allows for the modification of the transcription of critical genes 
associated with the progression of CVD. Several plant-polyphenols have been reported to 
influence gene transcription by altering DNA methylation status. Thus, targeting DNA 
methylation could provide a promising approach for alternative prevention strategies.  
This study explored the gene expression networks activated during diet-induced CVD and 
the ability of a green rooibos extract, Afriplex GRT, to alter this consequence. In addition, 
the study aimed to evaluate aberrant DNA methylation associated with diet-induced CVD to 
further elucidate pathophysiology. To this end, cardiomyocytes exposed to high glucose and 
palmitate (HG + Pal) displayed a diminished antioxidant defence system, mitochondrial 
dysfunction and increased apoptosis, indicative of cardiac stress. Additionally, the 
combinatory treatment with HG + Pal induced transcriptional changes associated with 
inflammation, oxidative stress, altered lipid metabolism and increased contractile 
dysfunction, ultimately promoting the development of atherosclerosis and hypertrophic 
cardiomyopathy. Interestingly, post treatment with Afriplex GRT or Aspalathin had no 
significant effect on the metabolic and molecular derangements induced under HG + Pal 
stress. Similarly, RNA sequencing conducted on cardiac tissue of Wistar rats that received 
a high fat, high sugar (HFHS) diet, revealed the downregulation of differentially expressed 
genes (DEGs) involved in host antioxidant activity and inflammatory response, accompanied 
with an increase in hypertrophic gene expression possibly affecting cardiac muscle 




the amelioration of the transcriptomic signatures resulting from HFHS diet feeding. To profile 
DNA methylation throughout disease progression, cardiac tissue of male Wistar rats 
maintained on a HFHS diet were subjected to whole genome bisulfite sequencing (WGBS). 
The latter revealed aberrant DNA methylation of genes linked to the phagosome, platelet 
activation, toll-like receptor signalling and diabetic cardiomyopathy. Furthermore, 
hypomethylation within the intergenic and gene body regions of several differentially 
methylated genes (DMGs) overlapped with DEGs identified in the RNA sequencing analysis. 
Collectively these results demonstrate the ability of the HFHS diet to act as a pathological 
stimulus capable of inducing altered gene expression and DNA methylation associated with 








Kardiovaskulêre siektes (KVSs) bly wêreldwyd die grootste oorsaak van sterftes en eis 
jaarliks ongeveer 17,9 miljoen lewens. Die afgelope paar dekades het 'n eksponensiële 
toename in die voorkoms van belangrike KVS-risikofaktore, soos vetsug, 
insulienweerstandigheid (IW) en tipe 2-diabetes mellitus (T2DM) in onderontwikkelde lande, 
insluitende Suid-Afrika, plaasgevind. Hierdie toename gaan gepaard met die toenemende 
voorkoms van KVS, en is deels die gevolg van verhoogde verbruik van diëte met baie vet 
en suiker, en onaktiewe lewenstyle. Verskeie meganismes is in die patogenese van 
diabetes-geïnduseerde KVS geïmpliseer en onlangs het toenemende bewyse daarop gedui 
dat wanregulering van die epigenoom 'n belangrike rol in die ontwikkeling van T2DM en 
verwante hartkomplikasies kan speel. Meer spesifiek is afwykende DNA-metilering 
breedvoerig ondersoek en in die ontwikkeling van kroniese siektes soos vetsug, T2DM en 
KVS geïmpliseer. Nietemin word dit voorgestel dat sommige aktiewe dieetverbindings 
hierdie epigenetiese verskynsel kan omkeer en die transkripsie van kritieke gene, wat 
verband hou met die progressie van KVS, kan modifiseer. Daar word berig dat verskeie 
plant-polifenole geentranskripsie beïnvloed deur die status van DNA-metilering te verander. 
Dus, deur te fokus op DNA-metilering kan dit 'n belowende benadering tot alternatiewe 
voorkomingstrategieë bied. 
Hierdie studie het ondersoek ingestel na die gene uitdrukkings netwerke wat geaktiveer 
word tydens dieet-geïnduseerde KVS en die vermoë van 'n groen rooibos-ekstrak, Afriplex 
GRT, om hierdie gevolg te verander. Daarbenewens het die studie ten doel gehad om 
afwykende DNA-metilering geassosieer met dieet-geïnduseerde KVS te evalueer om 
patofisiologie verder toe te lig. Vir hierdie doel het kardiomiosiete wat aan hoë glukose en 
palmitaat (HG + Pal) blootgestel was, 'n verminderde antioksidant-verdedigingstelsel, 
mitochondriale disfunksie en verhoogde apoptose getoon, wat dui op kardiale spanning. 
Verder het die kombinasiebehandeling met HG + Pal transkripsionele veranderinge 
veroorsaak wat verband hou met inflammasie, oksidatiewe spanning, veranderde 
lipiedmetabolisme en verhoogde kontraktiele disfunksie, wat uiteindelik die ontwikkeling van 
aterosklerose en hipertrofiese kardiomiopatie bevorder.  
Dit was interessant dat post-behandeling met Afriplex GRT of Aspalatien geen 
noemenswaardige effek op die metaboliese en molekulêre afwykings wat onder HG + Pal 
spanning veroorsaak is, gehad het nie. Net so het RNA-volgordebepaling, wat uitgevoer 




het, die afregulering van differensieel uitgedrukte gene (DUG'e) wat betrokke is by die 
gasheer-antioksidantaktiwiteit en inflammatoriese reaksie, aan die lig gebring, met 'n 
gepaardgaande toename in hipertrofiese geenuitdrukking wat moontlik die hartspier 
funksionaliteit kon beïnvloed. 
Aanvulling met Afriplex GRT™ het geen hoë vertrouensresultate opgelewer in die 
verbetering van die transkriptomiese aanwysings as gevolg van HVHS-dieetvoeding nie. 
Om die DNA-metilering profiel gedurende die hele siekteprogressie te neem is hartweefsel 
van manlike Wistar-rotte, wat op 'n HVHS dieet gehou was, onderwerp aan 'n volledige 
genoom-bisulfiet-volgordebepaling. Laasgenoemde het afwykende DNA-metilering van 
gene aan die lig gebring wat gekoppel is aan die fagosoom, bloedplaatjie-aktivering, tol-
agtige reseptor seinpaaie en diabetiese kardiomiopatie. Verder het hipometilering in die 
intergeniese streke en geenliggaam van verskeie differensieel gemetileer gene (DMG’e) 
oorvleuel met DUG'e wat geïdentifiseer is in RNA-volgordebepaling. Gesamentlik toon 
hierdie resultate die vermoë van die HVHS-dieet om as 'n patologiese stimulus op te tree 
wat veranderende gene-uitdrukking en DNA-metilering kan veroorsaak, wat gepaard gaan 
met verhoogde inflammatoriese reaksies en lipiedmetabolisme wat uiteindelik die risiko vir 
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Chapter 1: Introduction  
1.1 Research rationale  
Cardiovascular diseases (CVDs) involving the heart and blood vessels, are the leading 
cause of mortality worldwide (Benjamin et al., 2019; NHS, 2018; WHO, 2021). According to 
the latest World Health Organization (WHO) report, an estimated 17.9 million people died 
from CVD in 2019, representing approximately 32% of all global deaths (WHO, 2021). 
Alarmingly, CVD is projected to claim 23.6 million lives by 2030 (Benjamin et al., 2017; 
Donnan et al., 2006; Kucharska-Newton et al., 2010; Lloyd-Jones et al., 2010). Over the 
past few years, the historical association of CVD with developed nations has shifted towards 
underdeveloped countries such as South Africa (WHO, 2021; Yusuf et al., 2014). This 
increase in CVD prevalence in low- and middle-income countries can in part be attributed to 
a rise in the incidence of known CVD risk factors such as obesity and type 2 diabetes mellitus 
(T2DM) (Cavan et al., 2016; Humphries et al., 2010; Kim et al., 2010; Yusuf et al., 2004). 
Urbanisation and sedentary lifestyles bring about a nutritional shift, characterised by the 
increased consumption of western diets rich in dietary fat, sugar and carbohydrates (Cavan 
et al., 2016; Humphries et al., 2010; Kim et al., 2010; Stelmach-Mardas et al., 2016; Walsh 
et al., 2017; Zong et al., 2016). This transition in diet results in metabolic distortions such as 
increased production of reactive oxygen species (ROS), development of insulin resistance 
(IR) and low-grade inflammation, ultimately increasing CVD risk (Kruger et al., 2005; 
Micklesfield et al., 2013; Mirmiran et al., 2017; Oikonomou et al., 2018).  
Despite the implementation of global initiatives aimed at reducing CVD prevalence through 
lifestyle and nutritional interventions, South African women have amongst the highest rates 
of obesity worldwide (Joubert et al., 2007; Ng et al., 2014; Zhou et al., 2017). Presently, T2D 
is the leading cause of micro- and macro vascular complications, with diabetic 
cardiomyopathy (DCM) being one of the major causes of end stage heart failure throughout 
the world. Furthermore, there is no pharmacological treatment to avert the onset of CVD 
and drug therapies aimed at treating primary conditions such as T2DM tend to lose their 
efficacy to protect the diabetic heart over time. From a South African perspective, the 
increased mortality associated with the poor prognosis of diabetic heart failure does not only 
impose a heavy cost in terms of suffering and death, but also places a colossal financial 
burden on individuals (poor households), the health system as well as the national budget. 





is constantly growing, driving the need for a more thorough understanding of disease 
pathophysiology.  
Several mechanisms have been implicated in the pathogenesis of diabetic-induced cardiac 
dysfunction and recently, increasing evidence suggests that dysregulation of the epigenome 
may play an important role in disease development (Baccarelli et al., 2010; Meaney, 2014). 
More specifically, aberrant DNA methylation has been extensively investigated and 
implicated in the development of chronic diseases such as obesity, T2DM and CVD (Kim et 
al., 2010; Khalil, 2014, Meany, 2014; Ramos et al., 2016; Stenvinkel et al., 2007). Of 
particular interest to this study is the role of altered DNA methylation associated with 
hyperglycaemia and glucose intolerance resulting from increased dietary fat intake as 
reported in human and animal fetal programming models (Cannon et al., 2014; Moody et 
al., 2017; Seki et al., 2017; Soubry et al., 2015; Zang et al., 2019). Furthermore, the adverse 
effects brought on by increased sugar intake, specifically fructose, has also been suggested 
to be mediated by DNA methylation (Davegårdh et al., 2018; Yamanda et al., 2017). 
However, limited evidence exists evaluating the combinatory ability of high fat and high 
sugar to stimulate DNA methylation-induced transcriptional changes. Nonetheless, it has 
been suggested that some active dietary compounds may reverse this epigenetic 
phenomenon which allows for the modification of the transcription of critical genes 
associated with CVD (Crider et al., 2012; Jamaluddin et al., 2007; Nazki et al., 2014). In 
particular, several plant-polyphenols have been reported to influence gene transcription by 
altering DNA methylation status (Crescenti et al., 2013; Feil & Fraga, 2012; Pan et al., 2013; 
Pandey et al., 2009; Parks & Booyse, 2002; Schiano et al., 2015; Switzeny et al., 2012). 
Thus, targeting DNA methylation signatures associated with CVD could provide a promising 
approach for developing early prognostic or diagnostic markers to aid alternative prevention 
strategies.  
The use of indigenous medicines for health and custom purposes is not a foreign concept 
for South Africans, highlighting the need to further tap into South Africa’s rich biodiversity to 
develop safe and cost-effective natural products with the ability to effectively reduce the risk 
of cardiac dysfunction. Of interest to this study is the indigenous plant, rooibos (Aspalathus 
linearis), known for its antioxidant and anti-inflammatory properties. Previous research 
demonstrated the ability of rooibos and its polyphenolic constituents to exert protective 
effects against metabolic disorders such as insulin resistance (IR) and T2DM, both risk 
factors of CVD (Dludla et al., 2014; Johnson et al., 2017; Mazibuko et al., 2013; Son et al., 





metabolic ailments and cardiac complications, research providing a better understanding of 
disease pathophysiology and how metabolic factors contribute to the clinical manifestation 
of CVD is necessary.  
The evolution of next generation sequencing (NGS) has significantly impacted genomic 
research, aiding the comprehension disease aetiology and the identification of diagnostic, 
prognostic, and therapeutic markers. Concerning CVD, NGS technologies have been 
utilised to demonstrate the association of aberrant gene expression and genetic variants 
with underlying CVD pathophysiology (Jneid et al., 2012; Liao et al., 2019; Lundmark et al., 
2015). Coupling RNA sequencing with whole genome bisulfite sequencing (WGBS) as 
applied in this study, allows for the evaluation of genome wide interactions between 
transcriptomic and epigenetic alterations. Exploration the correlation of these alterations 
with CVD not only adds towards understanding of the disease pathology, but also provides 
possible new therapeutic targets. 
 
1.2 Aims and Objectives 
This study aimed to explore the gene expression networks associated with cardiac 
dysfunction in a high fat, high sugar (HFHS) diet Wistar rat model, and the ability of a green 
rooibos extract, Afriplex GRT, to alter these consequences. Additionally, this study aimed 
to evaluate aberrant DNA methylation during the development and progression of HFHS 
diet-induced CVD to further elucidate pathophysiology.  
In order to achieve these aims, the following objectives were identified: 
• To evaluate the effect of combinatory treatment with high glucose plus palmitate (HG + 
Pal) using an in vitro, rat derived H9c2 cardiomyocyte model and the ability of Afriplex 
GRT and Aspalathin to mitigate these effects.  
• To utilise an in vivo, HFHS diet-induced IR Wistar rat model in order to characterise 
CVD development and progression. 
• To profile transcriptional changes associated with HFHS diet-induced CVD and Afriplex 
GRT supplementation using RNA sequencing. 
• To profile genome wide DNA methylation changes related to HFHS diet-induced CVD 






1.3 Dissertation Structure 
This dissertation is comprised of seven, individually introduced chapters. Supplementary 
information relating to the individual chapters is provided at the end of the thesis.  
1.3.1 Chapter 1: Introduction 
A general introduction to the study and its implication, including an overview of the aims and 
objectives, layout as well as research outputs. 
1.3.2 Chapter 2: Literature Review 
An overview of the literature pertaining to this study is provided including the underlying 
pathophysiology of CVD, metabolic risk factors, epigenetic modifications and the high 
throughput technologies used to investigate the discussed abnormalities.  
1.3.3 Chapter 3: High glucose and palmitate-induced decrease in antioxidant capacity 
and mitochondrial bioenergetics in H9c2 cardiomyocyte: the role of Afriplex GRT 
This chapter describes the metabolic and molecular derangements in cardiomyocytes 
exposed to a combined insult of high glucose plus palmitate (HG + Pal). Additionally, the 
effect of Afriplex GRT or Aspalathin treatment on HG + Pal induced stress is discussed. 
1.3.4 Chapter 4: A high fat, high sugar model to investigate diet-induced CVD in Wistar 
rats 
The influence of a high fat, high sugar (HFHS) diet on physiological parameters of male and 
female Wistar rats is described. The use of this model as a diet-induced CVD risk model 
and the effect of Afriplex GRT on the described changes was also evaluated.  
1.3.5 Chapter 5: Transcriptome profiling of diet-induced CVD in Wistar rats through 
high-throughput mRNA sequencing 
This chapter describes the use of transcriptome sequencing to evaluate the cardiac gene 
expression profile associated with high fat, high sugar (HFHS) diet feeding and the ability of 





1.3.6 Chapter 6: Whole genome bisulfite sequencing to assess aberrant DNA 
methylation associated with diet-induced CVD in Wistar rats 
The cardiac DNA methylation profiles of HFHS diet fed male Wistar rats, was surveyed using 
whole genome bisulfite sequencing (WGBS). The differentially methylated cytosines 
(DMCs), overlapping transcripts and pathway enrichment is described. A comparison of 
WGBS and transcriptome sequencing data is also provided.  
1.3.7 Chapter 7: Conclusions, limitations, and prospects  
A concluding summary describing the main study findings, along with the strengths and 
limitations of this study. Proposals for future research is also provided. 
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Chapter 2: Literature Review 
2.1 Cardiovascular disease  
Cardiovascular disease (CVD) is a blanket term used to refer to a group of disorders which 
either results from narrowed or blocked blood vessels or involves defects of the heart muscle 
(Benjamin et al., 2019; Lloyd-Jones et al., 2010; WHO, 2021). These disorders include, but 
are not limited to cerebrovascular disease (e.g., stroke); coronary artery disease (CAD); 
myocardial infarction (MI); hypertensive heart disease (e.g., aneurysm); peripheral arterial 
disease; venous thrombosis; atrial fibrillation; rheumatic heart disease; inflammatory heart 
disease (e.g., pericardial disease); cardiomyopathy; congenital heart disease; cardiac 
arrhythmias; and heart failure (HF) (Benjamin et al., 2019; Wattanapitayakul & Bauer, 2001; 
WHO, 2021). Amongst the afore-mentioned, CAD and stroke are the two most prevalent 
types, accounting for approximately 42% and 38% of CVD cases respectively (Benjamin et 
al., 2019; NHS, 2018; WHO, 2021). CVDs irrespective of the origin are the leading causes 
of premature mortality, responsible for more deaths than cancer worldwide (Benjamin et al., 
2019; WHO, 2021). Over the past few decades there has been an increase in CVDs in 
developing nations with over three quarters of all CVD deaths occurring in low- and middle-
income countries such as South Africa (WHO, 2021; Yusuf et al., 2014).  
 
2.2 Risk factors 
Since the Framingham study, the concept of factors increasing the risk of developing CVD 
has played an integral role in prevention and treatment strategies (Mahmood et al., 2014). 
The various risk factors for CVD can broadly be classified into those that can be managed, 
referred to as modifiable, and those which cannot be managed, known as non-modifiable 
risk factors. Some of the non-modifiable risk factors include gender, race, genetic 
predisposition, and aging (IDF, 2019; Pencina et al., 2019; WHO, 2021). In contrast, 
hypertension, smoking, obesity, unhealthy diets, metabolic disorder, diabetes, and physical 
inactivity form part of the modifiable risk factors (Díaz-Vegas et al., 2018; Mandini et al., 
2018; WHO, 2021). While possessing multiple risk factors does increase the possibility of 






2.2.1 Non-modifiable risk factors 
The rise in population aging observed globally, accompanies increased prevalence in non-
communicable diseases including CVD. The risk of developing CVD has been proven to 
increase proportionally with age, with the lifetime risk of developing CAD and stroke doubling 
after the age of 40 and 50, respectively (ADA, 2018; Brown et al., 2020; Sanchis-Gomar et 
al., 2016). Likewise, men tend have greater risk of developing CVD than a premenopausal 
woman, possibly linked to the protective role of female cyclic hormones. Ongoing research 
further supports the concept of certain CVD risk factors being more prevalent or having a 
more prominent effect in certain genders (ADA, 2018; Maas & Appelman, 2010; Möller-
Leimkühler, 2007; Regitz-Zagrosek et al., 2016). Additionally, the influences of ethnicity and 
family history cannot be underestimated as risk factors for diseases with a known genetic 
component such as CVD. To this end, higher risk of CVD mortality has been observed in 
individuals with a family history of premature CVD, as well as those of African, Asian, or 
Caribbean ancestry (Allport et al., 2016; Carnethon et al., 2017; Chaturvedi, 2003; 
Rodriguez et al., 2014; Volgman et al., 2018). Other non-modifiable determinants of CVD 
include socioeconomic status with specific emphasis on stress and limited access to proper 
nutrition.  
 
2.2.2 Modifiable risk factors  
Modifiable risk factors, often referred to as behavioural risk factors, are characterised by 
their ability to be reduced or controlled through the effective implementation of lifestyle 
modifications. As is the case with numerous other diseases, the use of tobacco products 
has been shown increase the risk of CVD development and mortality (BHF, 2021; Mons et 
al., 2015; Pan et al., 2015). This increased risk, to a lesser extent, is also often conveyed to 
individuals regularly exposed to second-hand smoke (BHF, 2021; Critchley & Capewell, 
2003; Japuntich et al., 2015). Another prominent modifiable risk factor is physical inactivity, 
often promoted by sedentary lifestyles. According to the WHO, there has been an increase 
in sedentary behaviours with approximately 31% of the population participating in insufficient 
physical activity (Park et al., 2020; WHO, 2010; WHO, 2020). Furthermore, with clinical 
recommendations aimed at increasing physical activity levels rather than addressing forces 
driving sedentary behaviour, these modifiable risk factors continue to affect global mortality 
(ADA, 2018; Brown et al., 2020; Yusuf et al., 2004). The consequences of modifiable risk 





or obesity, hypertension and elevated blood glucose or lipid levels (Ades & Savage, 2017; 
Bastien et al., 2014; Wilson et al., 2002). These intermediate risk factors often act as 
independent modifiable risk factors of cardiovascular events, while simultaneously 
increasing the risk of developing other CVD risk factors (Brown et al., 2020; Poirier et al., 
2009; Romero-Corral et al., 2006). While numerous studies have revealed that the onset of 
CVD in individuals can be prevented through lifestyle interventions, adherence to such 
recommendations remains suboptimal (Gleissner et al., 2007; WHO, 2021). In a developing 
country such as South Africa, the vulnerabilities related to modifiable CVD risk factors are 
further heightened by an overburdened health care system (StatisSA, 2020). For the 
purpose of the current study, the focus will be on diet-induced metabolic syndrome as a risk 
factor for type 2 diabetes mellitus (T2DM) and related cardiovascular complications.  
 
2.2.3 Metabolic syndrome as a risk factor 
The last few decades have seen an increase in the consumption of unhealthy diets and the 
development of metabolic syndrome in underdeveloped countries, including South Africa 
(Brunner et al., 2007; Ng et al., 2013; Retelny et al., 2008). This increase is concomitant to 
escalating CVD incidence and in part due to increased urbanisation (Maruthur et al., 2009; 
Retelny et al., 2008; Stenvinkel et al., 2007; Vorster, 2002). Both clinical and basic research 
has shown that diets rich in fat and sugar lead to elevated blood glucose levels, obesity, 
hypertension, and hyperlipidaemia (Amani et al., 2010; Arnett et al., 2019; Brown et al., 
2020; Chobanian et al., 2003; Jang & Serra, 2014; Narain et al., 2016). These conditions 
often cluster together as metabolic syndrome, known to predispose individuals to the clinical 
manifestation of T2DM and CVD (Kim et al.,2010; Zong et al., 2016). Per the American Heart 
Association, diabetic adults are two to four times more likely to die from cardiovascular 
complications, making it the primary cause of diabetic-related deaths. IR, which is 
characterised by the compromised ability of cells to respond to insulin, is often considered 
as the driving force behind T2DM and is accompanied by an increase in cytokines, free fatty 
acids (FFAs), and oxidative stress (Bian et al, 2008; Inoguchi et al., 2000; Rutter et al., 
2005). The latter leads to the activation of damaging pathways involved in impaired 
endothelial function, inflammation, and apoptosis (Festa et al., 2003; Frankel et al., 2008; 
Laakso, 2010). Chronic elevated blood glucose levels as a result of T2DM further augments 
these irregularities, ultimately leading to diabetes-induced cardiac dysfunction (Bruno et al., 
2005; de Jager et al., 2006; Soinio et al., 2006; Voelter-Maholknecht, 2016). Additionally, IR 





in thrombotic events and the suppression of fibrinolysis (high PAI-1 concentrations), even in 
non-diabetic subjects (Grant, 2007; Laakso, 1996; Laakso, 2010; Natali et al., 2006; Turner 
et al., 1998).  
 
2.3 CVD pathophysiology  
2.3.1 Shift in substrate preference 
The antagonistic relationship between the use of FFA or glucose as the preferred metabolic 
substrate in the heart is depicted by the Randle cycle (Bae et al., 2021; Hue & Taegtmeyer, 
2009; Kolwicz et al., 2013; Marcelino et al., 2013). Under normal physiological conditions, 
FFAs are the preferred substrate for ATP production in the adult heart, accounting for 
approximately 60-70% of the energy generation (Chanda et al., 2016; Lopaschuk, et al., 
2010; Ragavan et al., 2017; Stanley et al., 2005). The remaining energy is acquired from 
the oxidation of glucose, lactate and to a lesser extent, amino acids, and ketone bodies 
(Abdurrachim et al., 2015; Chanda et al., 2016; Lei et al., 2004; Ormazabal et al., 2018; 
Stanley et al., 2005). The cardiac network alternates between these various substrates 
depending on numerous factors including substrate availability, energy demand, 
physiological and pathological conditions (Abdurrachim et al., 2015; Akki et al., 2008; 
Bastiaansen et al., 2016; Goodwin & Taegtmeyer, 2000).  
Under cardiac stress such as exercise, hypertrophy and diabetic-induced cardiac 
dysfunction, glucose becomes the preferred substrate to accommodate the increased 
energy demand (How et al., 2006; Mandavia et al., 2013; Nagoshi et al., 2011; Ormazabal 
et al., 2018; Shao & Tian, 2015). This adaptive metabolic shift relies heavily on efficient 
transport of glucose into cardiac cells, which is mediated by two major glucose transporter 
(GLUT) proteins namely, GLUT1 and GLUT4 (Figure 2.1). While GLUT1 is predominantly 
responsible for the uptake of basal glucose, GLUT4 is the more prominent mechanism of 
glucose uptake in the heart (Augustin, 2010; Shao & Tian, 2015; Tsirka et al., 2001). 
Research has shown that insulin stimulates the translocation of GLUT4 from intracellular 
vesicles to the plasma membrane when there is an increased demand for glucose 
metabolism (Goodwin & Taegtmeyer, 2000; Malfitano et al., 2015; Ormazabal et al., 2018; 
Stanley et al., 2005;). Similarly, increased glucose uptake has been associated with GLUT4 
overexpression in the heart under the above-mentioned stress conditions, simulating a fetal-





observations are further supported by the reappearance of a fetal-like gene expression 
profiles, which play a vital role in pathological cardiac remodelling (Doenst et al., 2010; 
Kolwicz & Tian, 2011; Razeghi et al., 2001).  
 
 
Figure 2.1. Schematic diagram illustrating the metabolic shift in cardiac energy metabolism in favour of glucose 
utilisation. Under cardiac stress such as hypertrophy and heart failure (HF) glucose becomes the preferred 
substrate for energy generation. Increased glucose uptake is mediated by the main glucose transporter in the 
heart, GLUT4. GLUT4 is translocated from intracellular compartments to the cell membrane through insulin 
stimulation. Altered glucose metabolism inhibits fatty acid (FA) oxidation to accommodate for the increased 
energy demand during cardiac hypertrophy. Red arrow labelling illustrates the effect on the respective 
components or genes where an up-arrow indicates increase, and a down-arrow represents decrease. IR, 
insulin receptor; GLUT4, glucose transporter 4; ATP, adenosine triphosphate; FA, fatty acid. Adapted from 





During IR however, the heart is nested in an environment characterised by elevated FFAs 
and glucose levels resulting in the inhibition of glucose uptake and the generation of energy 
almost exclusively ( 90% ATP) through FFA uptake and oxidation (Figure 2.2) (Aroor et al., 
2012; How et al., 2006; Mandavia et al., 2013; Marfella et al., 2009; Wright et al., 2009). Of 
interest to this study is the demonstration of decreased glycolysis concomitant with 
increased FFA oxidation specifically in diabetic animal models utilising a high fat diet (Belke 
et al., 2000; Nisr & Affourtit, 2010; Sikder et al., 2018; van den Brom et al., 2009; van den 
Brom et al., 2010). Increased FFA uptake into cardiac cells is facilitated through the 
upregulation of the cluster of differentiation 36 (CD36) transporter protein and leads to 
activation of genes encoding proteins responsible for intracellular FFA transport and 
oxidation (Ajith & Jayakumar, 2016; Kolwicz et al., 2013; Lopaschuk et al., 2010; Malfitano 
et al., 2015; Ormazabal et al., 2018; Su & Abumrad, 2009). Following entry into cardiac cells, 
fatty acids are often transformed into triacylglycerols (TAGs), also known as triglycerides 
(DeGuire & Weiler, 2013; Kaçar, 2019; Naviglio et al., 2017; Van Der Vusse et al., 2000).  
As the disease phenotype continues to progress or additional stresses are introduced, the 
heart’s ability to utilise FFAs as a metabolic substrate decline, consequently leading to 
intracellular accumulation of lipids such as ceramide and diacylglycerol (DAG) (D’Souza et 
al., 2016; Oakes et al., 2006; Park et al., 2008). The latter has been shown to induce protein 
kinase C (PKC) activation, mediating altered insulin signalling, inflammation, and apoptosis, 
ultimately contributing to contractile dysfunction and cardiomyopathy (Connelly et al., 2009; 
Geraldes & King, 2010; Goldberg et al., 2012; Kota et al., 2011; Liu et al., 2016; Salabei et 
al., 2016; Unger & Orci, 2002). Conversely, the continued inhibition of glycolysis can lead to 
the induction of glucotoxicity through the excess accumulation of advanced glycation end-
products (AGEs) and the activation of detrimental pathways including the polyol- and 
hexosamine pathway within the heart (Daroux et al., 2010; Folli et al., 2011; Kresge et al., 
2005; Ormazabal et al., 2018).  
Collectively, investigations regarding the use of FFAs as a metabolic substrate compared to 
glucose suggest that the ability of the heart to alternate between multiple substrates 
depending on the energy demands is essential for normal function. Therefore, therapeutic 
interventions should aim to modify cardiac substrate utilisation to increase metabolic 






Figure 2.2. Overview of metabolic derangements during insulin resistance (IR) facilitated by an abnormal 
increase in FFA oxidation. Increased FFA uptake through the CD36 transporter activates PPAR-mediated 
signalling, leading to the upregulation of genes involved in FA oxidation. Concurrently, the accumulation of 
intracellular lipids such as DAG and ceramide is associated with lipotoxicity. Impaired insulin signalling further 
decreases the uptake and oxidation of glucose. This shift in substrate preference plays a critical role in 
activating pathways involved in diabetes-induced cardiac dysfunction including reduced ATP production and 
cardiac muscle contraction, as well as increased fibrosis and apoptosis. Red arrow labelling illustrates the 
effect on the respective components or genes where an up-arrow indicates increase, and a down-arrow 
represents decrease. FFAs, free fatty acids; IR, insulin receptor; GLUT4, glucose transporter 4; CD36, cluster 
of differentiation 36; PPAR-α, peroxisome proliferator activated receptor alpha; FA, fatty acid; TAG, 
triacylglycerol; DAG, diacylglycerol; PKC, protein kinase C. Adapted from “Insulin Pathway”, by 





2.3.2 Oxidative stress 
Indeed, reactive oxygen species (ROS) such as superoxide and hydrogen peroxide are 
naturally generated during anaerobic energy production, with basal levels being an essential 
requirement for biological functions (Finkel, 2011; Goszcz et al., 2015; Senoner & Dichtl, 
2019). The increased production of ROS has been extensively implicated in the 
pathogenesis of numerous diseases including CVD (Guldiken et al, 2009; Lapolla et al., 
2007; Senoner & Dichtl, 2019; van Campenhout et al., 2006). Mitochondria, along with the 
oxidative enzyme, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX), 
are considered major driving forces of intracellular ROS production (Bedard & Krause, 2007; 
Holmström et al., 2014; Zhou et al., 2016). Following a cardiac insult such as chronic 
hyperglycaemia, the shift in substrate metabolism increases ability of mitochondria to 
produce energy which also increases ROS production. These elevated ROS levels results 
in a state of oxidative stress capable of triggering detrimental effects on cellular function 
(Zhou et al., 2018). In addition to oxidative stress leading to the depolarisation of the 
mitochondrial membrane, it is also a major stimulator of pro-inflammatory responses which 
further augments mitochondrial dysfunction and induces apoptosis within the heart (Kim et 
al., 2005; Montaigne et al., 2013; Sabri et al., 2003; Sack, 2009; Zorov et al., 2014).  
Indeed, oxidative stress has been associated with endothelial dysfunction, atherosclerosis, 
diabetic cardiomyopathy, cardiac hypertrophy, hypertension, and heart failure (Boudina & 
Abel, 2010; Dludla et al., 2014; Ingwall, 2009; Joseph et al., 2014; Kattoor et al., 2017; 
Kuroda et al., 2010; Mapanga & Essop; 2016; Senoner & Dichtl, 2019; Tahhan et al., 2017; 
Tarquini et al., 2011). Nonetheless, the body is equipped with an endogenous antioxidant 
defence network, comprised of both enzymatic and non-enzymatic compounds with the 
potential to circumvent free radical damage (Balaban et al., 2005; Senoner & Dichtl, 2019). 
These protective measures, however, have been known to become deficient following 
chronic exposure to pathological stimuli such as hyperglycaemia (Bhatt et al., 2013; 
Marnewick et al., 2011; Padmalayam, 2012). This imbalance in favour of pro-oxidants 
significantly contributes to continued stress induction through the activation of 
proinflammatory cytokines and chemokines, and myocardial apoptosis (Kim et al., 2005; 






As an integral part of the immune response, inflammation has been associated with the 
pathophysiology of numerous diseases including obesity, metabolic disorder, T2DM and 
CVD (Buckley et al., 2013; Hansson, 2005; Medzhitov, 2008; Sastre et al., 2011; Willerson 
& Ridker, 2004). More specifically, vascular inflammation has been extensively investigated 
for its underlying role in the development of atherosclerosis and cardiac remodelling 
(Montecucco et al., 2017; Packard & Libby, 2008; Sharma et al., 2016). The activation of 
inflammatory responses is often facilitated by the inflammasome multi-protein platform 
which consists of three proteins namely NOD-like receptor (NLR), apoptosis-associated 
speck-like protein (ASC) and cysteine-aspartic protease (Caspase) (Broz & Dixit, 2016; 
Kanneganti, 2015; Mariathasan et al., 2004; Martinon et al., 2002). Of interest to the current 
study is the widely evaluated NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) 
inflammasome as increase in its function has been suggested to play a role in diabetes, 
atherosclerosis, hypertrophy, ischemia, and cardiomyopathy (Duewell et al., 2010; 
Kawaguchi et al., 2011; Liu et al., 2014; Mezzaroma et al., 2011; Sandanger et al., 2013; 
Shaw et al., 2010; Toldo et al., 2016; Vandanmagsar et al., 2011). In the absence of a 
microbial pathogen, as is the case with CVD, several signals resulting from cardiac injury 
and apoptotic or necrotic cells can activate the NLRP3 inflammasome (Beg, 2002; Chen et 
al., 2018; Opie et al., 2006). While the presumed role of the NLRP3 inflammasome in cardiac 
cells has been poorly defined, the complete signalling cascade has been shown to be active 
in cardiac fibroblasts (Kawaguchi et al., 2011; Sandanger et al., 2013). 
The binding of injury associated ligands to the toll-like receptor 4 (TLR4) mediates pro-
inflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
signalling pathway, inducing the transcription of NLRP3 (Lawrence, 2009; Lorenzo et al., 
2011; Miguel-Carrasco et al., 2010). Furthermore, stimuli such as increased intracellular 
calcium and ROS facilitates NLRP3 inflammasome assembly and the activation of caspase 
1 (Casp1) (Franchi et al., 2009; He et al., 2016; Lee et al., 2015; Ridker et al., 2008). The 
latter results in increased production of inflammatory cytokines such as tumor necrosis factor 
alpha (TNF-α), interleukin 1 beta (IL-1β) and interleukin 18 (IL-18) which augments 
inflammation, leading to fibrosis, cardiac remodelling and ultimately cell death (Goyal et al., 
2008; He et al., 2015; Lee et al., 2015; Nguyen et al., 2017; Shi et al., 2015; Yu & Finlay, 
2008). Furthermore, while hyperglycaemia is known to promote NLRP3 inflammasome 
assembly through ROS, glucose itself has also been shown to be an activator (Gordon et 





has been associated with increased cardiac NLRP3, ASC, Casp1 and IL-1β expression in 
diabetic rats (Chen et al., 2018; Luo et al., 2014). Along with excessive ROS production, 
increased expression of the NLRP3 inflammasome stimulates inflammation-induced cell 
death, in the form of pyroptosis (Qiu et al., 2019; Yang et al., 2018; Yang et al., 2019). The 
latter is known to play a critical role in the development of T2DM and related cardiovascular 
complications. Emerging studies have suggested the potential of targeting pyroptosis and 
inflammasome signalling pathways as a novel therapeutic avenue worth exploring (Chen et 
al., 2020; Luo et al., 2017; Mamun et al., 2021). 
Considering the overwhelming evidence supporting the role of inflammation in CVD, serum 
inflammation markers such as C-reactive protein (CRP) and TNF-α have been investigated 
for CVD diagnosis and prognosis (Fichtlscherer et al., 2004; Hulthe et al., 2006; Morrow et 
al., 2006; Ridker et al., 2000; Ridker, 2003; Tsmikas et al., 2006). Additional pro-
inflammatory cytokines and chemokines previously shown to be involved in the diabetes-
induced cardiac inflammatory response include interleukin 6 (IL6), chemokine (C-C motif) 
ligand 3 (CCL3) and monocyte chemotactic protein 1 (MCP1) (Goyal et al., 2008; Melter et 
al., 2001; Shanmugam et al., 2003).  
 
2.3.4 Apoptosis 
The regulated activation of signalling cascades leading to programmed cell death in the form 
of apoptosis, is an essential component within biological systems (Renehan et al., 2001; 
Tower, 2015). However, aberrant levels of apoptosis often result in the development 
diseases and has been linked to ischemia, MI, cardiomyopathy, cardiac remodelling, and 
HF (Abbate et al., 2003; Baldi et al., 2002; Cotter, 2009; Cummins & Badley, 2010; Kang & 
Izumo, 2000; Kim & Kang, 2010; Silvestri et al., 2002; Teringova & Tousek, 2017). To this 
end, the chronic elevated glucose levels accompanying IR and T2DM has been shown to 
mediate myocardial apoptosis (Cai et al., 2002; Kang et al., 2000; Rajamani & Essop, 2010). 
The initiation of apoptosis signalling cascades occurs either through the mitochondrial- or 
death receptor pathway, which both have been shown to be involved in diabetic 
cardiomyopathy and HF (Figure 2.3) (Giacco & Brownlee, 2010; Kim & Kang, 2010; Li et al., 
2007).  
The extrinsic death receptor pathway is triggered through the binding of apoptotic ligands 





to their corresponding death receptors located on the cell membrane (Asgeri et al., 2015; 
Fertin et al., 2012; Lee et al., 2003; Monden et al., 2007). This interaction leads to the 
formation of a signalling domain and the activation of caspase 8 (CASP8) (Ashkenazi & 
Dixit, 1998; Kim & Kang, 2010). Downstream effector caspases, CASP3 and CASP7, are 
subsequently cleaved thereby inducing the terminal apoptotic pathway (Elmore, 2007; 
Teringova & Tousek, 2017). Conversely, the intrinsic mitochondrial pathway is stimulated 
by ROS accumulation, resulting in decreased mitochondrial membrane potential and the 
release of apoptotic proteins (Kim & Kang, 2010; Rajamani & Essop, 2010). This insult 
induces the release of cytochrome c (CYCS), which together with caspase 9 (CASP9) and 
apoptotic protein activating factor 1 (APAF1) forms the apoptosome (Acehan et al., 2002; 
Bao & Shi, 2007; Johnson et al., 2016; Reubold et al., 2011; Webster, 2012; Yuan et al., 
2010). The release of CYCS from the mitochondria is known to be regulated by pro- and 
anti-apoptotic proteins such as B-cell lymphoma 2 (BCL2) and BCL2 associated X (BAX) 
(Brocheriou et al., 2000; Chen et al., 2001; Hochhauser et al., 2007; Youle & Strasser, 
2008). Interestingly, increased intracellular CYCS, even in the absence of mitochondrial 
membrane depolarisation, has been associated with apoptosis during ischemic and 
hyperglycaemic conditions (Borutaite & Brown, 2003; Yu et al., 2008). The apoptosome 
activation complex subsequently promotes the cleavage of downstream caspases including 
CASP3 (Kim & Kang, 2010; Teringova & Tousek, 2017). It therefore becomes evident that 
the extrinsic and intrinsic pathways intersect at a terminal effector, CASP3 or CASP7, to 
implement apoptotic mediated changes within in the cell. Consequently, increased caspase 
activity in animal models have been associated with mitochondrial dysfunction, cardiac 
remodelling, hypertrophy, and ischemia (Cai et al., 2002; Condorelli et al., 2001; Joseph et 
al., 2014; Liu, 2014; Schwarz et al., 2006). The overlap in apoptotic pathway stimuli and 
those involved in oxidative stress and inflammation, suggest a synergetic role of these 
mechanisms in the pathophysiology of diabetes related cardiac complications. Therefore, 
the prevention of cardiomyocyte loss through the inhibition of apoptosis becomes crucial in 







Figure 2.3. The role of apoptosis in diet-induced cardiovascular complications. Initiation of the apoptotic 
signalling occurs either through death receptor- or mitochondrial pathway. While the extrinsic death receptor 
pathway is activated through binding of apoptotic ligands (TNF- α or FAS), the intrinsic mitochondrial pathway 
is initiated through stimuli such as ROS accumulation. TNF- α, tumor necrosis factor alpha; TNFR, tumor 
necrosis factor receptor; BAX, BCL2 associated X; BCL2, B-cell lymphoma 2; APAF1, apoptotic protein 
activating factor 1. Adapted from “Apoptosis Extrinsic and Intrinsic Pathways”, by BioRender.com (2021). 






2.4 Epigenetic modifications and CVD 
The emergence of epigenetics has provided a new approach for the comprehension of 
biology and disease (Feinberg, 2010; Jaenisch & Bird, 2003; Khalil, 2014; Portela & Esteller, 
2010; Stenvinkel et al., 2007).  Epidemiological studies have revealed a definite interaction 
between environmental factors and genetic components in CVD, suggesting that 
epigenetics may play a vital role in disease development (Baccarelli et al., 2010; Meaney, 
2014; Ordovás & Smith, 2010). Epigenetics refer to the ability of alterations in the cell 
environment to trigger in changes in chromosomes without altering the DNA sequence 
(Egger et al., 2004; Rodenhiser & Mann, 2006). These alterations affect the way genes are 
regulated, are stably inherited, and often lead to the development and progression of 
disease (Baccarelli et al. 2010; Beekman et al., 2010; Fraga et al., 2005; Ji et al., 2010; 
Kelsey & Feil Soler, 2013; Miao et al., 2008; Soler-Botija et al., 2019; Ushijima et al., 2003). 
Some of the major epigenetic modifications include histone modifications, DNA methylation 
and microRNA (miRNA) related alterations (Khalil, 2014; Soler-Botija et al., 2019; Wilson, 
2008). These mechanisms have all been directly associated with the development of CVDs 
such as atherosclerosis, CHD, hypertrophy, diabetes induced cardiac complications and HF 
(Baccarelli et al., 2011; El-Osta, 2008; Friso et al., 2012; Latronico & Condorelli, 2009; Mao 
et al., 2013; Movassagh et al., 2010; Pirola et al., 2011; Stenvinkel et al., 2007; Zhang et al., 
2011). Furthermore, several studies have linked alterations in the epigenome with CVD risk 
factors such as diet, smoking, age, IR, T2DM and hypertension (Buro-Auriemma et al., 2013; 
Fuke et al., 2004; Khalil, 2014; Ling et al., 2008; Ordovás & Smith, 2010; Rivière et al., 
2011). Thus, further investigations into the influence of epigenetic modification on CVD 
development may therefore aid in understanding disease pathophysiology. Amongst the 
various epigenetic features investigated, DNA methylation remains the most widely studied 
and the focus of this study (Michels, 2012; Zhong et al., 2016). 
 
2.4.1 DNA methylation  
DNA methylation refers to the addition of a methyl group to the 5th carbon position of the 
cytosine ring, in humans, this primarily occurs in the context of CG dinucleotides referred to 
as CpGs (Figure 2.4) (Bird, 2002; Wilson, 2008). CpGs are unevenly distributed throughout 
the genome and often cluster together forming CpG islands (Khalil, 2014). DNA methylation 
process is catalysed by DNA methyltransferases (DNMTs) and plays an imperative role in 





Kirchner et al., 2013; Kurdyukov & Bullock, 2016). Indeed, DNA methylation also alters 
protein binding sites on DNA, often leading to transcriptional activation or silencing of genes, 
which in turn may affect phenotype and lead to the development of disease (Moore, Le & 
Fan, 2013; Nikitina et al., 2007; Suzuki & Bird, 2008). While DNA methylation within the 
promoter and enhancer regions have been shown to correlate inversely with gene 
expression, current research has also demonstrated the association of inter- and intragenic 
DNA methylation with gene expression (Costantino et al., 2018; Fernández-Sanlés et al., 
2018; Jeschke et al., 2015; Moore et al., 2013; Muka et al., 2016; Shenker & Flanagan, 
2012). Numerous studies have linked altered DNA methylation to biological processes 
underlying CVD such as arrhythmias, inflammation, hypertension, and endothelial 
dysfunction (Baccarelli et al., 2010; Friso et al., 2008; Ikram et al., 2009; Joehaneset al., 
2016; Turunen et al., 2009; Zeilinger et al., 2013). Nonetheless, it has been increasingly 
reported that this process can be reversed to restore normal function through lifestyle 
modifications including diet (Crider et al., 2012; Jamaluddin et al., 2007; Nazki et al., 2014). 
This reversible nature allows for the use of DNA methylation signatures as possible novel 
targets in the development of alternative therapeutic strategies to prevent and treat CVD. 
 
 
Figure 2.4. Schematic diagram illustrating the concept of DNA methylation. A methyl group is added to the 






2.4.2 Measuring DNA methylation 
In addition to its gene regulatory role, DNA methylation also plays a significant role in cellular 
differentiation, and inactivation of the X chromosome (Altun et al., 2010; Condon et al., 2018; 
Beard et al., 1995; Sun et al., 2015). Given its role in cellular processes and disease, the 
accurate identification and quantification of changes in DNA methylation within biological 
ailments has gained considerable attention. One of the first methods used to study DNA 
methylation entailed the use of methylation sensitive, restriction enzymes such as MspI and 
HpaII in restriction fragment length polymorphism (RFLP) analysis (Dupont et al., 2009; Jin 
et al., 2010; Lopez et al., 1997; Vos et al., 1995). While this technique is particularly 
beneficial in organisms lacking a reference genome, it is limited in the depth of information 
provided. Furthermore, several commercial kits currently enable the quantification of overall 
DNA methylation levels using an enzyme-linked immunosorbent assay (ELISA) or 
microarrays (Benoukraf et al., 2013; Fouse et al., 2010). The lack of information regarding 
the context specific methylation (CpG- or non-CpG) and genomic location of methylated 
sites demonstrated by the previously mentioned detection methods has shifted the focus of 
methylation detection towards more sequence-based techniques.  
The advancements in next generation sequencing (NGS) technologies and the availability 
of complete reference genomes have jointly aided the revolution of DNA methylation 
profiling on a genome wide scale (Laird, 2010). These techniques can broadly be classified 
into two categories namely enrichment-based and bisulfite sequencing based methods 
(Harris et al., 2010; Shafi et al., 2018; Sun et al., 2015; Taiwo et al., 2012). Enrichment-
based methods, also referred to as region-based methods, utilise antibodies that bind to 
methylated DNA prior to sequencing and include techniques such as methyl-DNA 
immunoprecipitation (MeDIP) or methyl binding domain sequencing (MBD-seq) (Bock et al., 
2010; Otto et al., 2012; Ruike et al., 2010; Serre et al., 2010; Weber et al., 2005;). These 
techniques provide a cost-effective alternative to assess differential methylation levels but 
are often prejudiced towards highly methylated regions (Lister & Ecker, 2009; Otto et al., 
2012; Shafi et al., 2018; Sun et al., 2015). On the other hand, bisulfite sequencing methods 
entails the sequencing of DNA following chemical modification (i.e., bisulfite conversion), 
allowing for the evaluation of methylation on a single nucleotide resolution. The bisulfite 
treatment involves the conversion of unmethylated cytosines to thymine whereas 
methylated cytosines remain unchanged. The resulting bisulfite converted DNA is then used 
to evaluate the methylation status of cytosines throughout the genome through whole 





or Infinium methylation microarrays (e.g., Illumina’s Methylation450K) (Bock et al., 2010; 
Cokus et al., 2008; Dedeurwaerder et al., 2011; Harris et al., 2010; Meissner et al., 2005; 
Sandoval et al., 2011; Sun et al., 2015). While there has been an increase in the number of 
studies utilising Illumina’s microarrays and RRBS due to its reduced cost, the evolution of 
NGS over the past few years have increased the economic feasibility of WGBS studies. The 
increased resolution and depth of genome coverage afforded by WGBS has led to it being 
considered the gold standard approach to evaluate DNA methylation and therefore the 
method of choice in the present study (Bock et al., 2010; Otto et al., 2012; Shafi et al., 2018; 
Xi & Li, 2009).  
 
2.5 Therapeutic interventions 
2.5.1 Role of anti-glycaemic agents in protecting the heart 
While numerous studies have revealed that the onset of heart failure in diabetic individuals 
can be prevented through lifestyle interventions, adherence to such recommendations 
remains suboptimal (Gleissner et al., 2007; WHO, 2021). There has been an exponential 
increase in research evaluating the use of anti-diabetic therapies, with the primary agenda 
of maintaining normal blood glucose levels, for their ability to prevent or treat related cardiac 
complications. These secondary therapies are particularly relevant to the current study, as 
first line cardio-protective therapies are often limited in their ability to account for the extent 
of environmental influences such as nutritional shifts. The treatment landscape for CVD in 
patients with T2DM has therefore changed tremendously over the past decade, to now 
include well-known biguanides such metformin, as well as novel anti-diabetic medications 
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose 
cotransporter 2 (SGLT-2) inhibitors. As each class of medication varies in their degree of 
efficacy and underlying mechanism of action, they will be discussed separately to 
comprehend their potential cardio-protective effects.  
 
• Biguanides 
Metformin, the only drug in this class currently available on the market, is the first line 
treatment for type 2 diabetes (Inzucchi et al., 2015). This group of drugs primarily target the 
liver to improve sensitivity to insulin and restore glucose metabolism through the reduction 





suggests its glucose-lowering effects result from the inhibition of the mitochondrial enzyme, 
complex I (El-Mir et al., 2000; Miller & Birnbaum, 2010). Although the exact mechanism has 
not been fully elucidated, the interaction of metformin with complex I prohibits the influx of 
reduced nicotinamide adenine dinucleotide (NADH), leading to a reduction in the cellular 
energy charge and ultimately impairing mitochondrial oxidative phosphorylation (ATP 
production) (Foretz et al., 2005; Zhou et al, 2001;). The latter activates adenosine 
monophosphate-activated protein kinase (AMPK), which was shown to be the major 
mediator of the reduced gluconeogenic gene expression and glucose production associated 
with metformin therapy (He et al., 2009; Miller & Birnbaum, 2010; Shaw et al., 2005; Viollet 
et al., 2012). However, over the past few years AMPK-independent mechanisms have also 
been implicated (Foretz et al., 2010; Rena et al., 2017). The activation of the primary kinase 
upstream of AMPK, liver kinase B1 (LKB1), as well as a reduction in the expression of genes 
encoding gluconeogenesis proteins such as PPAR-γ coactivator 1α (PGC-1α) and 
phosphoenolpyruvate carboxykinase (PEPCK), are all examples of the abovementioned 
AMPK-independent pathways (Foretz et al., 2010). These acute changes in gene 
expression levels, however, did not directly cause a reduction in glucose output and 
therefore it’s level of contribution to the pharmacological action of metformin requires further 
investigation (Miller & Birnbaum, 2010). 
Numerous studies have indicated that the cardiovascular benefits associated with metformin 
therapy are significantly greater than those exhibited by other diabetic medications such as 
sulfonylureas (Bennett et al., 2011; American Diabetes Association, 2013; Rao et al., 2008; 
Rena & Lang, 2018; Roumie et al., 2012). The metformin-related cardioprotective benefits 
generally result from its metabolic action to diminish IR, ultimate reducing the risk of HF and 
mortality (Kinsara & Ismail, 2018; Wang et al., 2011). However, studies investigating its role 
in inflammation have revealed the involvement of the suppression of plasma cytokine levels 
and the nuclear NF-κB inflammatory signalling pathway (Cameron et al., 2016; Griffin et al., 
2017). In addition to this, animal studies have demonstrated the ability of metformin to 
reduce TNF-α and fibroblast growth factor, thus reducing left ventricular volume and the 
degree of cardiac remodelling (Eriksson & Nystrom, 2014; Murtaza et al., 2019). Despite the 
multiple benefits of the drug in CVD, further research is required regarding the mechanisms 






• Incretin based therapies (IBT)  
These therapeutics rely on the modulation of two major gut-derived proteins secreted often 
post-meal, namely, GLP-1 and glucose-dependent insulinotropic peptide (GIP) (Baggio & 
Drucker, 2007; Inzucchi & McGuire, 2008; Ussher & Drucker, 2014). Release of these 
incretins occur in a glucose-dependent manner and stimulates insulin output from pancreatic 
beta cells, to regulate blood glucose concentrations (Advani et al., 2013; Campbell & 
Drucker, 2013; Lovshin & Drucker, 2009). The two classes of medicines belonging to this 
therapy method, GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, 
exert their anti-diabetic effects by ameliorating the partially deficient incretin system 
observed in patients with T2DM (Knop et al., 2007; Lovshin & Drucker, 2009). The first drug 
class, GLP-1 analogues, mimics the function of the natural occurring hormone by binding to 
GLP-1 receptors found on pancreatic beta cells (Advani et al., 2013; Garg et al., 2019). 
Incretins are expeditiously degraded by DPP-4 enzymes, expressed in many tissues 
including the kidney, liver, lung, and the small intestine (Ahren, 2007). As such, the second 
class of IBT, DPP-4 inhibitors, act as oral blockades of these enzymes, preventing their 
breaking down and ultimately increasing endogenous concentrations of GLP-1 and other 
incretins (Garg et al., 2019; Inzucchi & McGuire, 2008; Lovshin & Drucker, 2009). The use 
of these incretin-based agents to lower blood glucose levels has been extremely successful 
and they either do not affect body weight (DPP-4 inhibitors) or promote weight loss (GLP-1 
receptor agonists) (Garg et al., 2019; Inzucchi & McGuire, 2008; Lovshin & Drucker, 2009; 
Murtaza et al., 2018).  
Therapy with incretin-based drugs can indirectly affect the cardiovascular (CV) system 
through the metabolic mechanisms resulting from increased insulin levels, as well as 
decreased glucagon and FFA levels (Garg et al., 2019; Murtaza et al., 2018; Ussher & 
Drucker, 2014). By mediating these traditional risk factors for CVD, these agents improve 
myocardial metabolism and alleviate contractile dysfunction (Hernandez et al., 2018; 
Holman et al 2017; Marso et al., 2016a; Marso et al., 2016b; Pfeffer et al., 2015). Through 
acting on inflammatory pathways and GLP-1 receptors that are expressed on vascular 
smooth muscle and myocardial cells, IBT also have the potential to exert direct functional 
effects on cardiac myocytes and coronary vasculature (Garg et al., 2019; Inzucchi & 
McGuire, 2008; Ussher & Drucker, 2014). IBT not only promotes coronary blood flow and 
increases glucose uptake, but also reduces inflammatory myocardial damage (Inzucchi & 
McGuire, 2008; Ussher & Drucker, 2014). Pre-clinical and animal studies have revealed that 





left ventricular function (McMurray et al., 2013; Murtaza et al., 2018). Remarkably, the two 
classes of drugs do not demonstrate the same levels of CV effects in large outcome studies, 
with GLP-1 agonists showing increased efficacy regarding myocardial infarction (MI), stroke 
and CVD death (Gerstein et al., 2018; Hernandez et al., 2018; Holman et al 2017; Marso et 
al., 2016a; Marso et al., 2016b). Whereas DPP-4 inhibitors on the other hand, demonstrate 
the potential to affect additional peptides, including stromal cell derived factor-1 (SDF-1) 
which can have adverse CV effects such as cardiac inflammation, fibrosis, adverse 
remodelling, and increased risk for HF (Meneilly et al., 2003; Schwartz et al., 2010; Xiao et 
al., 2012). The multiple differences in cardiovascular mechanisms of action between 
incretin-based drugs emphasise the importance of individual clinical trials to examine the 
safety and efficacy of each agent and the underlying mechanism involved (Andrew et al., 
2019; Bain et al., 2019).  
 
• Gliflozins  
SGLT-2 inhibitors collectively referred to as gliflozins, represent a relatively new class of 
drugs that exert anti-hyperglycaemic effects by augmenting the occurrence of glucosuria, 
as well as natriuresis in an insulin-independent manner (Anderson & Marrs, 2012; Saleem, 
2017; Shubrook et al., 2015). As the name suggests, this class of medication can bind to 
low affinity SGLT-2 receptors, predominantly situated in the proximal convoluted tubules of 
the kidneys (Chao, 2014; Kalra, 2014; Lytvyn et al., 2017). These transporter proteins are 
responsible for approximately 90% of the kidney’s glucose reabsorption thus through its 
inhibition, gliflozins prevent the reuptake of glucose, promoting the excretion of glucose in 
urine (glucosuria) and subsequently leading to a decrease in blood glucose levels (Anderson 
& Marrs, 2012; Li et al., 2011; Murtaza et al., 2018). Additionally, SGLT-2 receptors also 
facilitate sodium reabsorption at the proximal convoluted tubule, which has been shown to 
be increased under diabetic conditions (Lytvyn et al., 2017). Treatment with SGLT-2 
inhibitors thus increases the concentration of sodium in the tubule and aids its elimination 
from the body in urine (Garg et al., 2019). This natriuretic effect is further supported by a 
decrease in total body sodium content observed in patients receiving SGLT-2 inhibitor 
treatment (Garg et al., 2019; Schneider et al., 2017).  
Gliflozins, although moderate compared to GLP-1 receptor agonists, indirectly reduces CVD 
risk factors such as obesity, hypertension, and hyperlipidaemia in T2DM patients (Buse et 
al., 2013; Kalra, 2014; Katout et al., 2014; Lytvyn et al., 2017; Neal et al., 2017; Pozo et al., 





activation of the renin–angiotensin–aldosterone system (RAAS) leads to an increase in the 
expression of SGLT-2 transcripts (Bautista et al., 2004; Lim et al., 2018). Inhibition of SGLT-
2 could hypothetically have inhibitory effects on the regulation of intravascular system and 
blood pressure (BP) for which the RAAS is responsible (Garg et al., 2019). Numerous 
studies have reported on the ability of SGLT-2 inhibitors to decrease both systolic and 
diastolic BP in T2DM patients with or without hypertension (Frías et al., 2016; Kario et al., 
2018; Neal et al., 2017; Wiviott et al., 2019; Zinman et al., 2015). This phenomenon is 
amplified in the instance of combined therapy with GLP-1 receptor agonists to exceed the 
ability of each medication when administered as a monotherapy (Frías et al., 2016; Kario et 
al., 2018; Tikkanen et al., 2015). Although the exact mechanisms through which SGLT-2 
inhibitors exert direct cardioprotective effects have not been fully elucidated, current 
available clinical and animal study data demonstrates the ability of this therapy to reduce 
the risk of nonfatal MI and stroke, hospitalisation due to HF, as well as CVD mortality (Cheng 
et al., 2019; Neal et al., 2017; Wiviott et al., 2019; Zinman et al., 2015). Further studies 
regarding unravelling the molecular mechanisms and pathways behind the cardiovascular 
benefits of SGLT2 inhibitors will not only contribute to a better understanding of disease 
pathophysiology but will also promote repurposing of gliflozins for the treatment of HF in 
diabetic patients as a potential alternative to metformin.  
Nonetheless, despite availability of various primary and secondary cardioprotective drug 
classes, a significant gap remains in the treatment of CVD. Additionally, current available 
drugs have been reported to have numerous undesirable consequences, therefore 
alternative therapies such as nutraceutical have been identified as promising targets. 
 
2.5.2 Polyphenols as an alternative cardioprotective therapy 
Several clinical and epidemiological studies support the concept that a diet rich in 
polyphenols is associated with reduced metabolic syndrome and CVD risk (Pan et al., 2013; 
Pandey & Rizvi, 2009; Parks & Booyse, 2002; Schiano et al., 2015; Switzeny et al., 2012;). 
These polyphenols are present in dietary components such as fruit, vegetables, herbal tea, 
red wine and cocoa, and their beneficial effects have been attributed to their antioxidant and 
anti-inflammatory capacities (Crescenti et al., 2013; Feil & Fraga, 2012). Correspondingly, 
Mediterranean diets comprising of plant-based fruits and vegetables have been investigated 
for its ability to prevent chronic diseases (Castro-Barquero et al., 2018; Pernice et al., 2006; 





polyphenols have gained much interest for their potential health benefits against the 
development of metabolic complications including diabetes and CVD, possibly through the 
modulation of aberrant DNA methylation (Chen et al., 2013; Feil & Fraga, 2012; Marnewick 
et al., 2011; Muller et al., 2012; Schiano et al., 2015). Indeed, polyphenols have been 
recognised as potent DNMT inhibitors with the ability to modulate the expression of a wide 
range of targets including long interspersed nucleotide repetitive elements-1 (LINE1), 
insulin-like growth factor 2 (IGF2), sirtuin 1 (SIRT1) and TNF-α known to be associated with 
CVD (Baccarelli et al., 2010; Chung, et al., 2010; Hoyo et al., 2011; Zhang et al., 2011). 
Similarly, the plant-derived polyphenol, resveratrol can improve inflammation and CAD 
through the upregulation of SIRT1 (Chung et al., 2010; Xu et al., 2014). Additionally, a recent 
study also reported on the ability of a cocoa extract to inhibit the expression levels of genes 
encoding DNMTs in vitro (Crescenti et al., 2013).  
 
2.5.3 Rooibos as a nutraceutical  
Of particular interest to this study is the potential therapeutic role of rooibos (Aspalathus 
linearis), a fynbos plant indigenous to South Africa used to manufacturer an internationally 
popular herbal tea. Rooibos and its polyphenolic compounds have been shown to exert a 
protective effect on metabolic disorders through its high antioxidant and anti-inflammatory 
properties (Dludla et al., 2014; Joubert & de Beer, 2011; Mazibuko et al., 2013; Son et al., 
2013). Some of the major polyphenolic compounds of therapeutic value in rooibos include 
C-linked dihydrochalcones (Aspalathin and Nothofagin), flavones (e.g., Orientin and 
Apigenin), as well as flavanols (Quercetin and Rutin) (Figure 2.5) (Joubert et al., 2012; 
Shimamura et al., 2006). Amongst these, Aspalathin and Quercetin have been implicated 
as some of the major contributors to the therapeutic potential of rooibos (Joubert et al., 
2009). Following processing, rooibos can be consumed in either its fermented or 
unfermented form, which differ both in colour and phenolic content (Del Rio et al., 2013; 
Joubert & Schulz, 2006; von Gadow et al., 1997). To date, fermented rooibos, characterised 
by its red colour, has been well studied and demonstrated to increase insulin signalling and 
glucose metabolism while decreasing inflammation in pre-clinical as well as human studies 
(Joubert & de Beer, 2011; Kotzé-Hörstmann & Sadie-Van Gijsen, 2020; Marnewick et al., 
2011; Sanderson et al., 2014; Standley et al., 2001; Villano et al., 2010). However, due to 
the known decrease in antioxidant content resulting from the fermentation process, research 
has shifted towards evaluating unfermented, green rooibos for its potentially greater 





Schulz et al., 2003). In this regard, green rooibos extracts have been demonstrated to 
improve ROS, hyperglycaemia and hyperlipidaemia in vitro utilising skeletal muscle, cardiac 
and fat cell lines (Johnson et al., 2016; Mazibuko et al., 2013; Mazibuko et al., 2015; Muller 
et al., 2012). Similarly, numerous studies have also evaluated the role of isolated phenolic 
compounds such as Aspalathin to ameliorate metabolic disorders such as IR and T2DM 
(Dludla et al., 2014; Mazibuko et al., 2013; Son et al., 2013). Taken together, current 
scientific evidence suggests that rooibos and its bioactive compounds exerts its potential 
cardioprotective effect through modulating major CVD risk factors which will further be 
discussed individually.  
 
 
Figure 2.5. The chemical structure of some of the major dihydrochalcones, flavones and flavanols present in 
Aspalathus linearis (rooibos).  
 
2.5.3.1 Effect on hyperglycaemia and hyperlipidaemia 
The evaluation of blood glucose and lipid levels are considered standard practice in CVD 
risk assessment. Several previously described studies have revealed a significant 
association between increased glucose and FFA levels, and diet-induced CVD. The in vitro 
effect of fermented and unfermented rooibos on glucose homeostasis has been 
contradictory, specifically with respect to protein kinase B (PKB) activation which is required 





found no significant differences in PKB activation of normal myocytes, a study performed by 
Mazibuko and colleagues (2013) demonstrated the ability of rooibos to ameliorate 
decreased PKB levels induced by palmitate exposure in skeletal muscle cells, thereby 
facilitating glucose uptake through GLUT4 translocations. Similarly in vivo studies have also 
been conflicting where rats receiving fermented and unfermented rooibos extracts displayed 
no differences in cardiac PKB levels, while mice and humans consuming fermented rooibos 
displayed enhanced glucose uptake resulting in decreased blood glucose levels (Kamakura, 
2015; Marnewick et al., 2011; Pantsi et al., 2011). Furthermore, Aspalathin was able to 
enhance glucose uptake and insulin signalling in vitro as well as in diabetic mouse and rat 
models (Kawano et al., 2009; Mikami et al., 2015; Muller et al., 2012; Smit et al., 2018; Son 
et al., 2013). Interestingly, research comparing the effect of both rooibos extracts and 
Aspalathin, has found the improvement of hyperglycaemia to be more prominent when 
treating with the extract, suggesting that a possible synergistic interaction of the 
polyphenolic compounds in rooibos could be responsible to efficiently execute its glucose 
lowering abilities (Kawano et al., 2006; Mikami et al., 2015; Miller et al., 2018). Additionally, 
treatment with both rooibos and Aspalathin has been shown to improve lipid profiles through 
lowering LDL-cholesterol and triglyceride levels in humans, as well as diabetic mice and 
rats, ultimately reducing CVD risk (Marnewick et al., 2011; Najafian et al., 2016; Son et al., 
2013).  
 
2.5.3.2 Effect on oxidative stress and inflammation 
As previously discussed, oxidative stress and inflammation in response to stress play a vital 
role in the underlying pathophysiology of diet-induced metabolic syndrome and its related 
cardiovascular complications. Briefly, the excessive production of ROS is often 
accompanied by a reduction in naturally occurring antioxidant levels, resulting in increased 
cellular damage in the form of oxidative stress. In vitro experiments conducted using both 
fermented- and unfermented rooibos extracts demonstrated their ability to improve 
antioxidant capacity and reduce intracellular ROS under hyperglycaemic and ischemic 
conditions (Chen et al., 2013; Dudla et al., 2014; Prasad et al., 2002; Son et al., 2013). 
These findings were confirmed in vivo where the consumption of rooibos tea or extracts 
resulted in increased antioxidant levels (SOD and GSH) and decreased lipid peroxidation 
(Akinrinmade et al., 2017; Baba et al., 2009; Marnewick et al., 2011; Orlando et al., 2019; 
Pantsi et al., 2011). Similarly, the polyphenol Aspalathin was also shown to reduce oxidative 





glucose exposed cardiomyocytes as well as diabetic mice (Dludla et al., 2017; Johnson et 
al., 2016; Simpson et al., 2013). Moreover, the consumption of rooibos tea has also been 
associated with reduced expression of proinflammatory cytokines TNF-α and IL-6 in an in 
vitro and animal model (Smith & Swart, 2016). Considering the close interaction between 
oxidative stress mediated mechanism and the inflammatory response in CVD, these findings 
further support the concept of the antioxidant and anti-inflammatory properties of rooibos 
contributing to its potential cardioprotective effect.  
 
2.5.3.3 Cardioprotective effect 
In addition to exhibiting protective effects against cardiac dysfunction through modulating 
underlying mechanisms of metabolic risk factors such as obesity, IR and T2DM, rooibos has 
also been shown to improve cardiac function. Treatment with rooibos extracts have been 
shown to prevent ischemic damage and inhibit apoptosis by decreasing the activity of 
apoptotic proteins such as poly ADP ribose polymerase (PARP) and CASP3 (Dludla et al., 
2014; Pantsi et al., 2011). Similarly, a recent study performed by Johnson et al. (2017), 
reported on the ability of Aspalathin to attenuate doxorubicin-induced cardiotoxicity through 
increased autophagy, while simultaneously increasing the expression of the anti-apoptotic 
BCL2 protein, suggesting its involvement in regulation of cell death processes in 
cardiomyocytes (Johnson et al., 2017).  
Although several studies have provided evidence that polyphenols mediate their 
ameliorative effects against disease through epigenetic mechanisms, particularly by 
reversing aberrant DNA methylation, the transcriptional and epigenetic mechanism(s) by 
which rooibos mediates its protective effects against diseases remains to be fully elucidated. 
 
2.4 Conclusions 
The detrimental impact of non-communicable diseases such as CVD on the health care 
sector thus drives the need for a more comprehensive understanding of disease 
pathophysiology and in the role of environmental factors such as diets comprising of excess 
fat and sugar in disease development. While several underlying mechanisms have been 
implicated in CVD pathogenesis including oxidative stress, inflammation and apoptosis, 
there is still a need for investigating the gene regulatory networks and epigenetic 





technologies provides approaches with the required sensitivity to facilitate detailed research 
regarding these associations. Additionally, the potential cardioprotective properties of plant 
polyphenols described in this review, further strengthens the evaluation of the Afriplex 
GRT extract in the current study as a nutraceutical to be used as an adjuvant to existing 
medications in the treatment of diabetic-induced cardiac dysfunction.  
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Chapter 3: High glucose and palmitate-induced decrease in 
antioxidant capacity and mitochondrial bioenergetics in H9c2 
cardiomyoblasts: the role of Afriplex GRT  
3.1 Introduction 
Cardiovascular disease (CVD), collectively referring to a group of disorders that affect the 
heart tissue or involve the obstruction of blood vessels, is the leading cause of premature 
mortality worldwide (Benjamin et al., 2019; Lloyd-Jones et al., 2010; WHO, 2021). An 
estimated 17.7 million people died from CVDs in 2015, representing 31% of all global deaths 
and it has been projected to claim 23.6 million lives by 2030 (Benjamin et al., 2019; Donnan 
et al., 2006; Lloyd-Jones et al., 2010; WHO, 2021). Over the past few decades, CVD 
incidence in developing nations has escalated tremendously in low- and middle-income 
countries such as South Africa (Stenvinkel et al., 2007; Vorster, 2002). This increase was 
concomitant with an increase in the prevalence of major CVD risk factors, including obesity, 
insulin resistance (IR), and type 2 diabetes (T2D). Increased urbanisation and sedentary 
lifestyles bring about a nutritional shift, characterised by increased dietary fat and energy-
dense diet (Cavan et al., 2016; Humphries et al., 2010; Kim et al., 2010; Stelmach-Mardas 
et al., 2016; Zong et al., 2016). The latter has previously been linked to both glucose and 
lipid overload which is associated with decreased cardiac efficiency and subsequent 
hyperlipidaemic-induced cardiac dysfunction (Kruger et al., 2005; Micklesfield et al., 2013).  
A large body of evidence suggests that chronic hyperglycaemia, linked to augmented 
reactive oxygen species (ROS) levels and oxidative stress, plays a significant role in the 
development and progression of deteriorating cardiac function (Davargaon et al., 2019; 
Giacco & Brownlee, 2010; Kayama et al., 2015; Tiwari et al., 2013). The chronic glucose 
exposure is accompanied by an increase in the release of proinflammatory markers, 
diminished cytosolic adenosine triphosphate (ATP) production, depolarisation of the 
mitochondrial membrane and ultimately myocardial apoptosis (Johnson et al., 2016; 
Johnson et al., 2017; Thomas et al., 2014; Yu et al., 2016). Similarly, the excessive intake 
of diets high in saturated fatty acid content, such as palmitic acid, has been implicated in the 
underlying pathology of CVDs (Cetrullo et al., 2020; Haffar et al., 2016; Nobuhara et al., 
2013). Both in vitro and in vivo studies have demonstrated the ability of increased palmitic 
acid concentrations to result in the accumulation of lipotoxic intermediates, ultimately 





van de Weijer et al., 2011). Furthermore, free fatty acids (FFA) become the preferred energy 
substrate in the failing heart, which further exacerbates the decline in heart function (Giacco 
& Brownlee, 2010; Schulze et al., 2016). Understanding the mechanisms by which saturated 
fatty acids such as palmitate induces cardiac dysfunction, may lead to the identification of 
prognostic markers and/or putative therapeutic targets that can prevent premature heart 
failure. Furthermore, whilst both high levels of saturated fatty acids (such as palmitate) and 
chronic glucose exposure, have been individually associated with the impairment of 
cardiovascular functions, very few studies have evaluated their combinatory effect on 
markers of oxidative stress, inflammation and hypertrophic cardiomyopathy using an in vitro 
H92 cell culture model (Yang et al., 2019).  
In the last decade, there has been significant interest in the health benefits of dietary plant 
polyphenols and their potential to ameliorate diet-induced glucolipotoxicity by increasing the 
body’s endogenous antioxidant defence network (Bahadoran et al., 2013; Darvesh et al., 
2010; Feil & Fraga, 2012; Pandey & Rizvi, 2009; Schiano et al., 2015). Of particular interest 
to the current study is the polyphenolic compounds found in the popular herbal tea, rooibos 
(Aspalathus linearis), which have previously been demonstrated to reduce oxidative stress 
and exhibit glucose-lowering, anti-inflammatory as well as cardioprotective properties (Baba 
et al., 2009; Chen et al., 2013; Dludla et al., 2014; Muller et al., 2012; Son et al., 2013). 
Therefore, this study proposed to 1) explore whether the combination of high glucose and 
palmitate induces increased oxidative stress, mitochondrial dysfunction, and cardiomyoblast 
apoptosis; 2) determine if Afriplex GRT™ and Aspalathin can ameliorate these events; and 
3) provide a better understanding of the cardiac gene regulatory network activated. Taken 
together, the results provided by this study could aid the identification of signatures that 
could potentially serve as biomarkers for drug targets against diabetes-induced cardiac 
dysfunction.  
 
3.2 Material and Methods 
3.2.1 Cell culture and stress induction 
Embryonic-derived rat cardiomyoblasts, H9c2 cells (American Type Culture Collection, 
CRL-1446), were cultured and maintained under standard conditions (37°C in humidified air 
and 5% CO2) in Dulbecco’s Modified Eagle Medium (DMEM) (Lonza BioWhittaker, Verviers, 





UK). The growth medium (DMEM + 10% FBS) contained 25 mM glucose which is the basal 
glucose level present in all the conditions listed. Cells were allowed to grow to a confluency 
of 70 – 80%, with the growth medium replenished every 2 to 3 days. Depending on the assay 
performed, cells were seeded into the appropriate plates at the required seeding densities 
specified in the sections below. Stock solutions of palmitic acid (50 mM) were prepared by 
dissolving the appropriate amount of palmitic acid in absolute ethanol. Prior to treatment 
experiments, working solutions of palmitic acid (0.5 mM) were prepared in high (33 mM) 
glucose treatment media, containing 2% fatty acid-free bovine serum albumin (BSA) 
(Sigma-Aldrich Corp., St. Louis, MO, USA) and heated to 37°C for an hour to facilitate the 
conjugation of palmitic acid with BSA. Confluent H9c2 rat cardiomyoblasts were then 
exposed to media containing either i) normal (5.5 mM) glucose which served as the control 
group or ii) high (33 mM) glucose and 0.5 mM palmitic acid specified as the stress-induced 
group, for 24 hours (Sigma-Aldrich Corp., St. Louis, MO, USA) (Jadaun et al., 2018). All 
treatments were performed in triplicate (n = 3 technical replicates), and each complete 
experiment was repeated three times (n = 3 biological replicates). Cell growth and integrity 
were monitored with microscopy during the growth phase and after the addition of the 
previously described treatment media. The treatment dosages used for the control and the 
stress-induced group were based on results obtained from previous studies (Davargaon et 
al., 2019; Dludla et al., 2017; Johnson et al., 2016; Johnson et al., 2017).  
 
3.2.2 Post-treatment with Afriplex GRT™ and Aspalathin 
The effects of an Aspalathin-rich green rooibos extract, Afriplex GRT™ (Afriplex® 
Pharmaceuticals, Paarl, South Africa) and its major phenolic compound, Aspalathin (Asp) 
were evaluated on glucolipotoxic conditions in cardiac cells. To this end, stock solutions of 
Afriplex GRT™ (10 mg/mL) and Asp (22.10 mM) were prepared in dimethyl sulfoxide 
(DMSO) and diluted to working concentrations using the high glucose plus palmitate (HG + 
Pal) treatment media (Muller et al., 2012). The toxic effect of DMSO at 0.001% was tested 
and ruled out in all the experiments performed. Cells pre-treated with HG + Pal for 24 hours 
were then treated with either Afriplex GRT™ (10 µg/mL) or Asp (1 µM) for an additional six 
hours. Treatment doses were obtained from previously performed in-house time and dose 






3.2.3 Measurement of cellular metabolic activity  
Adenosine triphosphate (ATP) content was used as a determinant of cellular metabolic 
activity and measured using the ViaLight™ plus ATP kit (Lonza, Basel, Switzerland), 
according to the manufacturer’s instructions. Briefly, H9c2 cells were cultured in 96-well, 
white-walled luminometer plates at a density of 0.8 x 105 cells/mL. Upon completing stress 
induction and treatment reactions, the cells were lysed with 50 µL of the supplied cell lysis 
reagent and incubated at room temperature (RT) for approximately 10 min. Subsequently, 
100 µL of the ATP monitoring agent, AMR plus, was then added to the lysate and the 
luminescence was quantified after approximately 2 min using a BioTek® FLx800 plate reader 
and Gen 5® software (BioTek Instruments Inc., Winooski, VT, USA).  
 
3.2.4 Reactive oxygen species (ROS) detection 
It is well established that the excessive production and accumulation of ROS molecules are 
responsible for oxidative stress-mediated cellular damage (Uy et al., 2011; Tiwari et al., 
2013; Davargaon et al., 2019). The ability to detect and estimate ROS levels thus provides 
a valuable tool to assess the underlying mechanisms involved in the pathogenesis of 
disorders such as CVD (Giacco & Brownlee, 2010; Kayama et al., 2015). As per the 
guidelines of a previously established protocol, the intracellular production of ROS was 
detected in H9c2 cardiomyoblasts seeded in 24-well plates (1 x 105 cells/mL) using the 
Oxiselect™ Intracellular ROS Assay Kit (Cell Biolabs Inc., San Diego, CA, USA). This kit 
involves the exposure of cells to 20 µM 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-
DA) fluorescent dye solution for 30 min, in the absence of light and under standard tissue 
culture conditions. Following incubation and aspiration of the fluorescent dye, the reaction 
was terminated by the addition of 150 µL Hank's balanced salt solution (HBBS). Cells were 
then dissociated from the plate surface using trypsinisation and collected using 400 µL 
DMEM medium (without FBS). To remove trypsin residue, the collected cell suspension was 
subjected to centrifugation at 390 rpm for 5 minutes and the cell pellet retained. After 
resuspension of the cell pellet in 150 µL Dulbecco's phosphate-buffered saline (DPBS) 
(Lonza, Basel, Switzerland), the DCFH-DA fluorescence was determined using a BD 
Accuri™ C6 flow cytometer (BD Biosciences, Franklin Lakes, New Jersey, USA) and 






3.2.5 Assessment of mitochondrial membrane potential (ΔΨM) 
Over the past years, evaluating the ΔΨM with the labelling of fluorescent dyes has become 
a widely used technique as an indication of mitochondrial health. For the purpose of this 
study, the green, fluorescent dye, JC-1 (5,5,6,6’-tetrachloro-1,1’,3,3’ tetraethylbenzimi-
dazoylcarbocyanine iodide) was used to assess mitochondrial depolarisation in H9c2 
cardiomyoblasts following culturing and treatment in black, 96-well plates at a density of 0.8 
x 105 cells/mL, as previously described (Shabalala et al. 2019). Briefly, upon completion of 
stress induction and treatment, the cells were washed with 100 µL DBPS before staining 
with 100 µL of 8 µM JC-1 solution reconstituted in glucose-free DMEM without phenol red 
(Sigma-Aldrich, Saint Louis, MO, USA). Following incubation for 45 min under standard 
culturing conditions, in the absence of light, the cells were washed with 100 µL DPBS once 
again and the fluorescence was measured and quantified using a BioTek® FLx800 plate 
reader and Gen 5® software, respectively. Additionally, fluorescence was visualised and 
imaged using a Nikon inverted fluorescence microscope (Nikon Inc., Tokyo, Japan).  
 
3.2.6 Mitochondrial bioenergetics assessment 
The heart is one of the most metabolically active tissues and therefore relies significantly on 
the role of mitochondria to ensure efficient function (Dott et al., 2014). The oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) of intact H9c2 cells were 
determined in real-time as a direct measurement of mitochondrial dysfunction, using a 
Seahorse XF96 extracellular flux analyser (Seahorse Bioscience, North Billerica, MA, USA). 
The use of this assay not only provides an understanding of the underlying cause of 
mitochondrial dysfunction but also the subsequent role it plays in metabolic pathways 
associated with CVD phenotypes (Brand & Nichollis, 2011). Undifferentiated H9c2 cells 
were cultured and seeded in 24-well XF96 cell culture microplates (Seahorse Bioscience, 
North Billerica, MA, USA) at a density of 1 x 105 cells/well using the above-mentioned growth 
medium. Cells were maintained under standard tissue culture conditions for 48 hours, 
followed by stress induction and treatment as described above. Key parameters of 
mitochondrial function in treated cells were assessed using the gold standard, Seahorse XF 
Mito Stress kit (Seahorse Bioscience, North Billerica, MA, USA), according to the 
manufacturer’s guidelines (Figure 3.1) (Mazibuko-Mbeje et al., 2019). Briefly, cells were 
incubated in an unbuffered Seahorse XF DMEM base assay medium, containing 1 mM 





prior to conducting the extracellular flux assay. Mitochondrial OCR was measured over a 
period of 86 min. During this time, pharmacological modulators of oxidative phosphorylation 
including 1 mM oligomycin, 0.75 mM carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP), and a combination of 0.5 mM rotenone with 0.5 mM antimycin A 
were sequentially added to each well at specified time points (Figure 3.1). The compound 
injections, acting on the various components of the electron transport chain (Figure 3.2), 
were prepared at a concentration 10X higher than the required final concentration. Following 
completion of the assay, the bioenergetic profile is represented by OCR data expressed as 
pmol/min/ and ECAR data as mpH/min.  
 
 
Figure 3.1. A representative of a Seahorse XT Mito Stress profile illustrating key parameters used to assess 
mitochondrial function. The oxygen consumption rate (OCR) is measured before and after the addition of 
several pharmacological modulators of mitochondrial respiration. Baseline respiration is used as a measure of 
the cell’s energy demand under baseline conditions. Following this, oligomycin is added from which derive 
ATP-linked respiration and proton leak respiration can be derived. The addition of carbonyl cyanide-4 





capacity, while the addition of rotenone and antimycin A facilitates the measurement of non-mitochondrial 
respiration driven by alternative processes outside of the mitochondria. Finally, the spare respiratory capacity 
is deduced from basal respiration and maximal respiration, which indicates the cell's ability to respond to 




Figure 3.2. Illustration of inhibitory action resulting from pharmacological modulators on electron transport 
chain (ECT) used during the Seahorse XT Mito Stress assay. Following basal measurements, oligomycin is 
injected which inhibits ATP synthase (complex V). Secondly, the mitochondrial uncoupler, carbonyl cyanide-4 
(trifluoromethoxy) phenylhydrazone (FCCP) is injected which disrupts the mitochondrial membrane and 
subsequently the proton gradient. The third injection is a combination of rotenone (complex I inhibitor) and 
antimycin A (complex III inhibitor) which leads to a complete cessation of mitochondrial respiration. The 
addition of these compounds impacts the flow of electrons through the ECT and either decrease or increase 
mitochondrial respiration, altering the overall OCR profile. 
 
The resulting OCR data was used to calculate assay parameters indicative of mitochondrial 
function namely: non-mitochondrial OCR, basal OCR, ATP production, proton leak, 
maximum respiration, and spare respiratory capacity according to guidelines stipulated in 
the Wave software version 2.61 (Agilent Technologies, Inc., Santa Clara, CA, USA). These 
parameters were then subsequently utilised to derive respiratory flux ratios including 
Stateapparent, respiratory control ratio (RCR), phosphorylating respiration as well as, coupling 
efficiency as described by Dott et al., 2014. As the conventional respiratory state observed 
in isolated mitochondria (state 3 or state 4) is unlikely translated directly to intact cells, an 





respiratory state of the H9c2 cells using Equation 3.1 (Dranka et al., 2010; Brand & Nicholls, 
2011; Dott et al., 2014). Similarly, the RCR, representing the relationship between 
respiration and oxidative phosphorylation was calculated using Equation 3.2 (Brand & 
Nicholls, 2011; Dott et al., 2014). While the proportion of respiration used to produce ATP 
under standard conditions was estimated as the phosphorylating respiration (Equation 3.3); 
the ratio of oxygen utilised for ATP synthesis compared to that driving the proton link was 
indicated by the coupling efficiency (equation 3.4) (Brand & Nicholls, 2011; Domenis et al., 
2012; Dott et al., 2014). Taken together the determined assay parameters and flux ratios 
provide a comprehensive overview of the alteration of mitochondrial function following stress 
induction and/or treatment with the polyphenolic compounds of interest.  
 
Equation 3.1 
𝑆𝑡𝑎𝑡𝑒𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 = 4 − [
𝐵𝑎𝑠𝑎𝑙 𝑂𝐶𝑅 − 𝑃𝑟𝑜𝑡𝑜𝑛 𝑙𝑒𝑎𝑘





















3.2.7 Cellular apoptosis 
A widely used combinatory staining process involving Annexin V-FITC (Invitrogen, Carlsbad, 





evaluate viable, apoptotic, and necrotic cell profiles. Briefly, the combined cell suspension 
of H9c2 cells treated in 24-well plates (1 x 105 cells/mL), containing both detached cells 
present in the supernatant and cells attached the surface area of the plate, was collected. 
Following centrifugation at 390 rpm for 5 minutes, the cell pellet was retained and 
resuspended in 150 µL staining buffer (DPBS supplemented with 10% FBS) prior to the 
addition of 1.5 µL Annexin V and 1 µL PI (2 µg/mL) staining solution. The staining reaction 
was allowed to occur for 10 min, in the absence of light, after which the cells were assessed 
on a BD Accuri™ C6 flow cytometer using the accompanying BD Accuri C6 Annexin V-
FITC/PI template. Quantification of distinct cell populations (i.e live, apoptotic, or necrotic) 
was conducted with the BD Accuri™ C6 software (BD Biosciences, Franklin Lakes, New 
Jersey, USA) using the FITC signal detector FL1 (Ex 488 nm, Em 530 nm) for Annexin V 
positive cells and FL3 detector (Ex 488 nm, Em 670/LP) for PI-positive cells. 
 
3.2.8 Gene expression analysis 
3.2.8.1 RNA isolation and purification  
Confluent H9c2 cells were seeded in 6-well plates at a density of 2 x 105 cells/mL. After 
completing the above-described stress induction and treatment exposure time, experiments 
were terminated by washing H9c2 cells with 1 mL DPBS. Total RNA was extracted from 3 
wells per condition (n = 4 experiments) using Trizol lysis reagent (Invitrogen, Carlsbad, CA, 
USA) and treated with the Ambion Turbo DNase kit (Applied Biosystems, Foster City, CA, 
USA) according to the manufacturer’s instructions to remove genomic DNA. In brief, H9c2 
cells were dissociated with 1 mL lysis reagent, and homogenised using a TissueLyser 
(Qiagen, Hilden, Germany) to further promote cellular disruption. The resulting lysates were 
then subjected to centrifugation at 13 000 rpm for 10 min to remove cell debris. Phase 
separation of the previously retained supernatant was performed through the addition of 200 
µL chloroform (Sigma-Aldrich Corp., St. Louis, MO, USA), followed by vigorous shaking (~15 
seconds) and subsequent incubation at RT for 3 min. Following centrifugation, the clear, 
upper aqueous layer was attained and combined with 500 µL isopropanol (Sigma-Aldrich 
Corp., St. Louis, MO, USA) and incubated overnight at -20°C to enable the precipitation of 
RNA. The RNA was then pelleted with centrifugation at 13 000 rpm for 30 min and subjected 
to a series of wash steps using 70% ethanol, prior to air drying and resuspension in 60 µL 
nuclease-free water. All the steps involved in RNA extraction, including centrifugation, were 





quantified using fluorometric (Qubit™ RNA HS Assay kit) and spectrophotometric 
(Nanodrop) techniques, respectively. Furthermore, RNA integrity was assessed using the 
LabChip® GX Touch (PerkinElmer, Hopkinton, USA) and recommended RNA Assay, 
according to the guidelines provided by the manufacturer.  
 
3.2.8.2 Real-time quantitative PCR (RT-qPCR) to confirm oxidative stress 
A total of 1 μg total RNA was reversed transcribed to synthesise copy DNA (cDNA) using 
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems™, Foster City, CA, 
USA) as described by the manufacturers. Thereafter, real-time quantitative PCR (RT-qPCR) 
analysis was performed using 5 µL TaqMan Universal PCR master mix, 0.5 µL predesigned 
TaqMan gene expression assays (GPX2, NOX4, NRF2 and SOD2), 1 µL cDNA and RNase-
free water to a final volume of 10 µL per reaction. All PCR reactions were carried out on a 
7500 Real-Time PCR System (Applied Biosystems™, Foster City, CA, USA) using the 
following cycling conditions: 50°C for 1 min and 95°C for 10 min, followed by 40 cycles of 
95°C for 15 sec and 60°C for 30 sec. The combination of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and actin-β (ACT-β) was used as endogenous controls and 
employed in the normalisation of expression levels of the genes of interest using the relative 
curve method. 
 
3.2.8.3 RT2 Profiler PCR Array analysis 
The extracted RNA (400 ng) was reversed transcribed to generate cDNA with the RT2 First 
Strand kit according to the manufacturer’s protocol to subsequently employ in the RT2 
Profiler PCR Array system (Qiagen, Hilden, Germany). Accordingly, rat specific 
Atherosclerosis (PARN-038Z) and Skeletal Muscle Myogenesis and Myopathy (PARN-
099Z) RT2 Profiler PCR Arrays that evaluates the expression of 84 genes (including 
housekeeping genes and internal controls) were used. Contrary to pathway-specific arrays, 
disease-specific arrays were selected to analyse the differential expression of genes 
involved in multiple pathways such as apoptosis, remodelling, as well as stress and immune 
response, ultimately providing a more extensive overview of gene transcription. A master 
mix containing 20 µL cDNA; 650 µL RT2 SYBR Green qPCR Master Mix and 639 µL 
nuclease-free water (NF-H2O) was prepared for each sample (n = 4 per condition) and 





QuantStudio™ Flex 7 Real-Time PCR instrument (ThermoFisher Scientific, Inc., Waltham, 
MA, USA) was used for mRNA quantification using the following cycling conditions: 50oC for 
1 min; 1 cycle of 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec; 60°C for 1 min 
and a 4°C infinite hold cycle. The best combination of endogenous controls was selected 
from the housekeeping gene panel included using geometric means. The geometric mean 
was selected as opposed to the arithmetic mean to account for the confounding effect. 
Relative expression levels were normalised to these controls using the delta-delta (2-
(ΔΔCt)) method. Analysis of PCR array data was done using a Microsoft Excel sheet with 
macros and the Gene Globe Data Analysis Centre (Qiagen, Hilden, Germany) made 
available by the manufacturer. Differentially expressed genes (DEG’s) identified from the 
PCR array were selected based on statistical significance with a p-value less than or equal 
to 0.05 considered to be significant. The candidate list was further extended to additionally 
include genes displaying a fold regulation difference higher than or equal to 2, irrespective 
of the p-value and employed in further downstream analyses. 
 
3.2.8.4 Gene ontology (GO) and pathway enrichment analysis 
The candidate lists obtained from the two respective arrays were subjected to Kyoto 
Encyclopedia of Genes and Genomes (KEGG, www.genome.jp/kegg/pathway.html) 
mapper analysis to cluster DEG’s on a biological function level (Kanehisa et al., 2017). 
Furthermore, the relationship between gene functions and biochemical processes was 
integrated using the Database for Annotation, Visualisation, and Integrated Discovery 
(DAVID, david.abcc.ncifcrf.gov) version 6.8 (Huang et al., 2009).  
 
3.2.9 Statistical analysis 
Data sets resulting from in vitro and gene expression experiments were analysed using a 
combination of Microsoft Excel and GraphPad Prism version 7.0 software (GraphPad 
Software, Inc., La Jolla, CA). The distribution of the groups was evaluated for normality and 
differences in variance, before performing any statistical comparisons. Differences between 
the means of groups were assessed for statistical significance using parametric tests 
(ANOVA and student t-tests) followed by a Bonferroni post hoc test, or non-parametric 
(Kruskal-Wallis) tests followed by a Dunn’s post hoc test where applicable. In all instances, 
data is represented as the mean ± standard error of the mean (SEM), and a statistical 






3.3 Results and Discussion 
3.3.1 Cell viability  
The availability of ATP has been known to drastically decrease upon cellular damage and 
has additionally, amongst other intracellular substances, been associated with the mode of 
resulting cell death (Atlante et al., 2005; Garcia and Massieu, 2003; Ulukaya et al., 2008). 
In this study, the ViaLight™ plus ATP kit was used to quantify light emission occurring from 
the chemical conversion of luciferin to oxyluciferin, catalysed by the luciferase enzyme. As 
ATP is present in all metabolically active cells, a linear relationship between the emitted 
luminescent signal and ATP concentration or effectively cell number can be observed 
(Crouch et al., 1993; Mueller et al., 2004). Cardiomyoblasts exposed to HG + Pal media for 
24 hours displayed a significant decrease in cytoplasmic ATP levels compared to the NG 
control (49.29 ± 2.65 vs 100.80 ± 2.93; p = 0.0047) (Figure 3.3). Chronic exposure to glucose 
and saturated free fatty acids such as palmitic acid has previously been associated with 
detrimental effects on cell function through glucotoxicity and lipid toxicity (Dyntar et al., 2001; 
Guan et al., 2019; Mangali et al., 2019; Sears & Perry, 2015). Similarly, in vitro studies 
involving the use of H9c2 cells demonstrated that exposure to either palmitate or high 
glucose decreased intracellular ATP production, resulting in alterations in energy demands 
of H9c2 cells by decreasing major ATP consuming processes (Dludla, 2016; Okatan et al. 
2019). Thus, the decreased cell viability in cells treated with HG + Pal stress induction media 
observed in this study is anticipated and confirmed previous findings of either Pal or HG 
exposure (Davargaon et al., 2019; Johnson et al., 2016; Nobuhara et al., 2013). Although 
the underlying mechanisms involved are not yet fully understood, recent evidence 
implicating the involvement of protein kinase R (PKR) mediated activation of c-Jun N-
terminal kinase (JNK), nuclear factor kappa B (NF‐kB), and NOD-, LRR- and pyrin domain-
containing protein 3 (NLRP3) pathways provide a possible mechanistic approach (Mangali 
et al., 2019). While treatment with Asp was able to slightly increase the metabolic activity of 
HG + Pal exposed cells (57.30 ± 2.92 vs 49.29 ± 2.65), the opposite was observed with 
Afriplex GRT™ treatment (39.16 ± 1.77 vs 49.29 ± 2.65) (Figure 3.3). Therefore, neither 
treatment with Asp nor Afriplex GRT™ was able to significantly improve the cytotoxic effects 
brought on by the combinatory insult of HG + Pal on cardiomyoblasts. The latter was 





green rooibos extract was capable of increasing ATP production in skeletal muscle cells 
under hyperglycaemic conditions. 
 
Figure 3.3. The effect of hyperglycaemic and hyperlipidaemic conditions on metabolic activity. 
Cardiomyoblasts were cultured in normal glucose (NG) (5 mM) or high glucose (HG) (33 mM) plus palmitate 
(Pal) (0.5 mM) for 24 hours. Thereafter, cells were treated with either Aspalathin (Asp) (1 µM) or Afriplex 
GRT™ (10 µg/mL) for 6 hours. Data are presented as the mean ± SEM of 3 separate biological experiments, 
with each experiment having 3 technical repeats (n = 9). Significance is depicted as ** p < 0.005 and **** p < 
0.0001 versus NG control. 
 
3.3.2 Oxidative stress 
The ability of oxidative stress resulting from either high glucose- or palmitate-induced ROS 
accretion to damage DNA, and its involvement in numerous diseases such as diabetes, 
CVD and cancer has been well established (Görlach et al., 2015; Marnett, 2002; Togo et al., 
2018; Wiseman & Halliwell, 1996). In this study, a cell-based assay using the DCFCH-DA 
fluorescent probe was used to measure hydroxyl, peroxyl, or other reactive oxygen species 
activity within the cytosol. In theory, DCFH-DA is rapidly oxidised by ROS to highly 





proportional to levels of ROS within the cell. In this study, HG + Pal stimulation resulted in a 
substantial shift in the fluorescent peak (Figure 3.4) and a significant decrease in the 
intracellular ROS levels in comparison to the NG control (108159 ± 5723 vs 361425 ± 3251) 
(Figure 3.5). Subsequent treatment with Asp (99107 ± 4763 vs 108159 ± 5723), as well as 
Afriplex GRT™ (96614 ± 3648 vs 108159 ± 5723), had no significant effect on the mean 
fluorescence and accumulation of ROS when compared with non-treated cells exposed to 
HG + Pal (Figure 3.4 and 3.5). 
 
 
Figure 3.4. Flow cytometric depiction of fluorescent peak shifts obtained from DCFA-DA assay. In all 






Figure 3.5. The effect of hyperglycaemic and hyperlipidaemic conditions on ROS production. Cardiomyoblasts 
were cultured in normal glucose (NG) (5 mM) or high glucose (HG) (33 mM) plus palmitate (Pal) (0.5 mM) for 
24 hours. Thereafter, cells were treated with either Aspalathin (Asp) (1 µM) or Afriplex GRT™ (10 µg/mL) for 
6 hours. Data are presented as the mean ± SEM of 3 separate biological experiments with each experiment 
having 3 technical repeats (n = 9). Significance is depicted as **** p < 0.0001 versus NG control. 
 
Data obtained from pre-clinical and human studies demonstrate that the excess intake of 
carbohydrates and saturated fat, associated with most western diets, often lead to an 
elevation of ROS and oxidative stress, and the occurrence of insulin resistance (Basciano 
et al., 2005; Daly et al., 1997; Tan & Norhaizan, 2019; Vial et al., 2011). Furthermore, several 
studies, including previously conducted in-house studies by the current research group, 
have shown that exposure of H9c2 cells to either Pal or HG for 24 hours increases oxidative 
stress (Davargoan et al., 2019; Okatan et al., 2019; Wei et al., 2013). The results obtained 
from the current DCFH-DA assay therefore contradicts the bulk of scientific knowledge 
available with regards to cardiomyoblasts undergoing oxidative stress after chronic Pal or 
HG exposure. One possible explanation for this observation could be attributed to the large 
number of cells undergoing apoptosis following HG + Pal stress induction. With most of the 
cells in the suspension undergoing late-stage apoptosis (Figure 3.10), the incorporation of 
the DCFH-DA probe is severely diminished, ultimately resulting in a decrease in 





and other oxidative species has been debated, the enquiry of performing this assay over a 
period, at set intervals, also arises (Kalyanaraman et al., 2012). A plausible alternative 
resolution could be a lack of protein kinase C (PKC) and NADPH oxidase (NOX) activation, 
previously demonstrated to potentially be required for palmitate-induced increased ROS 
production (Kuroda et al., 2010). A previous study conducted by Joseph et al (2016) 
indicated the inhibition of palmitate-induced ROS production in a genetic cardiomyocyte 
mice model through the obstruction of PKC or NOX expression. Additionally, Joseph et al 
(2016) reported that cardiomyocytes have several ROS sources, including NAPDH and nitric 
oxide synthase (NOS).  
Considering this, total RNA extracted from untreated as well as treated cardiomyoblasts 
were used to evaluate the mRNA expression of pro-oxidant and antioxidant genes, to 
provide a more comprehensive view regarding the influence of HG + Pal treatment on the 
oxidative state. Although not significant, exposure of H9c2 cells to HG + Pal decreased the 
expression of glutathione peroxidase 2 (GPX2) (p = 0.435) and nuclear factor erythroid 2 
related factor 2 (NRF2) (p = 0.260) by 1.5-fold relative to the NG control (Figure 3.5). 
Moreover, the mRNA expression of superoxide dismutase 2 (SOD2) and NADPH oxidase 4 
(NOX4) was significantly decreased by 2.1-fold (p = 0.0002) and 1.8-fold (p = 0.0047), 
respectively following HG + Pal treatment when compared to the NG control. Palmitate is a 
known activator of PKC, which leads to an increase NOX4. Although the current study did 
not investigate PKC expression, the decreased mRNA expression of NOX4 (Figure 3.6), 
could suggest that treatment with HG + Pal may have been insufficient to promote an 
augmented ROS production, however, this requires further investigation (Joseph et al., 
2016; Thallas-Bonke et al., 2014). While post-treatment with Asp and Afriplex GRT™ was 
not able to ameliorate the previously described reduction in expression of the evaluated 
genes when compared to the HG + Pal treated cells, treatment with Asp significantly lowered 
the expression of NRF2 (p = 0.043) when compared to the NG control (Figure 3.6). 
Furthermore, post-treatment with Asp and Afriplex GRT™ exacerbated the significant 
decrease of both NOX4 and SOD2 when compared to the NG control (Figure 3.6). 
Conversely, previous findings from Mazibuko et al (2013) using C2C12 muscle cells and 
Dludla et al (2017) using H9c2 cells, reported on the ability of a green rooibos extract (GRE) 
and Asp to ameliorate either HG- or Pal-induced oxidative stress. However, these studies 
involved the individual use of either HG or Pal as a stress, with none evaluating the 
combined effect of HG + Pal as assessed in the current study (Dludla et al., 2017; Mazibuko 






Figure 3.6. The effect of hyperglycaemic and hyperlipidaemic conditions on pro-oxidant and antioxidant mRNA expression. Cardiomyoblasts were cultured in normal 
glucose (NG) (5 mM) or high glucose (HG) (33 mM) plus palmitate (Pal) (0.5 mM) for 24 hours. Thereafter, cells were treated with either Aspalathin (Asp) (1 µM) or 
Afriplex GRT™ (10 µg/mL) for 6 hours. Data are presented as the mean ± SEM of 3 separate biological experiments, with each experiment having 3 technical repeats 





The master regulator, NRF2, is responsible for regulating the expression of numerous genes 
with antioxidant activity involved in an inflammatory response and free radical production. 
Previous studies have demonstrated both GPX2 and SOD2 expression are regulated 
through NRF2-mediated pathways (Banning et al., 2005; Dong et al., 2008; Krehl et al., 
2012; Ma, 2013; Sun et al., 2015; Tonelli et al., 2018). Furthermore, NRF2 exhibits an 
indirect effect on NOX4 expression, which is regulated more prominently by the level of ROS 
as opposed to binding of NRF2 to the NOX4 promoter region (Bernard et al., 2017; Brewer 
et al., 2011; Kovac et al., 2015; Pendyala et al., 2011). The reduction of NRF2 expression 
observed in H9c2 cells treated with HG + Pal, therefore, resulted in impaired GPX2 and 
SOD2 expression, ultimately leading to increased levels of hydroperoxides and a possible 
decline in antioxidant defence (Liu et al., 2017; Margis et al., 2008; Naiki et al., 2014; Toppo 
et al., 2009). As previously discussed, the unexpected decrease of the pro-oxidant gene, 
NOX4, following HG + Pal treatment could either suggest the possible occurrence of a 
counter-regulatory mechanism or be related to the low levels of viable cells present due to 
the severity of the stress conditions (Bernard et al., 2017). While NOX4 is known to play an 
important role in cardiovascular pathophysiology, with its overexpression being directly 
linked to the exacerbation of mitochondrial oxidative stress, the present study was unable 
to demonstrate this. Therefore, further investigation is warranted to ascertaining the exact 
functional significance of this phenomenon (Kuroda et al., 2010).  
 
3.3.3 Mitochondrial bioenergetics  
Similarly, to previous studies, the effect of HG + Pal treatment on the bioenergetic profile of 
H9c2 cells was evaluated with the Seahorse XF96 extracellular flux analyser. The oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) of the cardiomyoblasts 
were used as a measurement of oxidative phosphorylation and glycolysis respectively. 
While cells treated with NG media were able to derive ATP from both oxidative 
phosphorylation and glycolysis, exposure of H9c2 to HG + Pal resulted in an increase in 
basal ECAR and a decreased oxidative phosphorylation (Figure 3.6). Under standard 
conditions, oxidative phosphorylation is the preferred method of ATP production in the heart. 
However, chronic exposure to elevated glucose and free fatty acids brings about a shift in 
substrate preference favouring glycolysis (Ait-Aissa et al., 2019; Rosca et al., 2008; Torsten 
et al., 2013). Treatment with neither Asp nor Afriplex GRT™ was able to alter the 
bioenergetic profile, with cells treated with these compounds displaying similar OCR and 






Figure 3.7. The effect of hyperglycaemic and hyperlipidaemic conditions on the bioenergetic profile as 
illustrated by raw A) oxygen consumption rate (OCR) and B) extracellular acidification rate (ECAR) 
measurements. Cardiomyoblasts were cultured in normal glucose (NG) (5 mM) or high glucose (HG) (33 mM) 
plus palmitate (Pal) (0.5 mM) for 24 hours. Thereafter, cells were treated with either Aspalathin (Asp) (1 µM) 
or Afriplex GRT™ (10 µg/mL) for 6 hours. Data are presented as the mean ± SEM of 3 separate biological 






Figure 3.8. The effect of hyperglycaemic and hyperlipidaemic conditions on mitochondrial function assay 
parameters. Cardiomyoblasts were cultured in normal glucose (NG) (5 mM) or high glucose (HG) (33 mM) 
plus palmitate (Pal) (0.5 mM) for 24 hours. Thereafter, cells were treated with either Aspalathin (Asp) (1 µM) 
or Afriplex GRT™ (10 µg/mL) for 6 hours. Data are presented as the mean ± SEM of 3 separate biological 
experiments with each experiment having 3 technical repeats (n = 9). Significance is depicted as * p < 0.05, 






For efficient energy production in the form of ATP, optimally maintained myocardial 
mitochondrial bioenergetics is required. To this end, the mitochondrial function of H9c2 
cardiomyoblasts was measured through the sequential addition of inhibitors of the 
respiratory chain. In the current study, HG + Pal treatment was able to significantly decrease 
basal oxygen consumption (p < 0.0001); maximal respiration (p < 0.0001); ATP production 
(p = 0.047); as well as non-mitochondrial OCR (p = 0.002) compared to the NG control 
(Figure 3.8). Additionally, there was a tendency towards a decrease in the proton leak 
following HG + Pal treatment. Treatment with Asp as well as Afriplex GRT™ further 
suppressed all assay parameters of mitochondrial function to a similar degree than HG + 
Pal treatment, relative to the NG control (Figure 3.8). The resulting assay parameters were 
used to calculate internally normalised flux ratios to facilitate more accurate comparisons 
between the respective treatment groups.  
 
Table 3.1. Respiratory flux ratios derived from mitochondrial parameters of cultured H9c2 cardiomyoblasts. 
 NG HG + Pal Asp Afriplex GRT™ 
Stateapparent 3.73 ± 0.03 3.40 ± 0.04 3.34 ± 0.05** 3.44 ± 0.03 
Respiratory control ratio 
(RCR) 
5.86 ± 1.22 3.55 ± 0.48 4.52 ± 0.35 5.02 ± 0.75 
Phosphorylating respiration 0.24 ± 0.04 0.41 ± 0.03* 0.50 ± 0.03*** 0.43 ± 0.02** 
Coupling efficiency 0.63 ± 0.12 0.57 ± 0.04 0.69 ± 0.02 0.66 ± 0.03 
Values are expressed as mean ± SEM. Each group consists of n = 6 independent replicates. Bold entries 
represent instances where a significant difference was observed. Stateapparent: HG + Pal + Asp vs NG, ** p < 
0.005. Phosphorylating respiration: HG + Pal vs NG, * p < 0.05; HG + Pal + Asp vs NG, *** p < 0.001 and HG 
+ Pal + Afriplex GRT™ vs NG, ** p < 0.005. 
 
Exposure of H9c2 cardiomyoblasts to HG + Pal decreased the Stateapparent, respiratory 
control ratio (RCR) and coupling efficiency while increasing phosphorylation respiration. The 
Stateapparent value provides an estimation of the relative mitochondrial workload under basal 
conditions, and it can therefore be concluded that cells treated with HG + Pal displayed 
decreased mitochondrial workload (3.40 ± 0.04), which was significantly worsened by Asp 
treatment (3.34 ± 0.05, p < 0.005 compared to the NG control (Table 3.1). Likewise, the 
phosphorylating respiration following HG + Pal treatment (0.41 ± 0.03, p < 0.05) was 
significantly higher relative to the NG control (0.24 ± 0.04), demonstrating that a greater 
proportion of the maximal respiratory capacity (maximal OCR) was used for ATP production 





0.03, p < 0.001) and Afriplex GRT™ (0.43 ± 0.02, p < 0.005) when compared to the cells 
treated with normal glucose media (Table 3.1). Following the hypothesis that increased free 
fatty acid (FFA) uptake and oxidation associated with hypoglycaemic conditions, hinder the 
capabilities of the electron transport chain, several studies have targeted the improvement 
of mitochondrial function to alleviate cardiovascular complications (Bugger & Abel, 2010; 
Wu et al, 2018). In agreement, the present study thus demonstrated that the combination of 
elevated glucose and palmitate severely impaired mitochondrial bioenergetics, resulting in 
mitochondrial dysfunction. Treatment with neither Asp nor Afriplex GRT™ showed any 
promising results in attenuating these detrimental effects.  
 
3.3.4 Membrane potential (ΔΨM) 
The JC-1 dye exhibits potential-dependent accumulation in mitochondria, indicated by green 
fluorescence emission at (~529 nm) for the monomeric form of the probe, which shifts to red 
(~590 nm) with a concentration-dependent formation of red fluorescent J-aggregates. In 
healthy cells, with normal mitochondrial membrane potential, JC-1 forms complexes known 
as J-aggregates producing an orange/red fluorescence. In cells with mitochondrial 
dysfunction, JC-1 remains in the monomeric form and exhibits a green fluorescence. 
Consequently, mitochondrial depolarisation is indicated by a decrease in the red/green 
fluorescence intensity ratio. In this study exposure of H9c2 cardiomyoblasts to HG + Pal 
resulted in significant depolarisation of the membrane, indicated by an in an increase in the 
accumulation of JC-1 monomers and a subsequent decrease in the ΔΨM when compared 
to the NG control (4.27 ± 0.11 vs 6.09 ± 0.27; p < 0.0001). Post-treatment with Asp did not 
affect the extent to which HG plus Pal altered the integrity of the mitochondrial membrane. 
Interestingly, post-treatment with Afriplex GRT™ further exacerbated mitochondrial 
depolarisation when compared with non-treated cells exposed to HG + Pal (2.83 ± 0.20 vs 
4.27 ± 0.11; p = 0.0001) (Figure 3.9). During apoptosis, a significant loss in the permeability 
of the mitochondrial membrane and electron gradient is observed (Sivandzade et al., 2019; 
Zorova et al., 2018) Thus suggesting that the depolarisation of the mitochondrial membrane 






Figure 3.9. The effect of hyperglycaemic and hyperlipidaemic conditions on the mitochondrial potential. 
Cardiomyoblasts were cultured in normal glucose (NG) (5 mM) or high glucose (HG) (33 mM) and palmitate 
(Pal) (0.5 mM) for 24 hours. Thereafter, cells were treated with either Aspalathin (Asp) (1 µM) or Afriplex 
GRT™ (10 µg/mL) for 6 hours. Data are presented as the mean ± SEM of 3 separate biological experiments, 
with each experiment having 3 technical repeats (n = 9). Significance is depicted as **** p < 0.0001 versus NG 





3.3.5 Cell death 
In this study, the effect of hyperglycaemia plus hyperlipidaemia on the apoptotic state of 
cardiomyoblasts was evaluated with the commonly used combination of annexin V and PI 
fluorescent stains. In theory, annexin V is an apoptotic specific marker that binds to 
phosphatidylserine located on the outer membrane of apoptotic cells. The counterstain, PI, 
used for its ability to not bind to living cells, enters the cell, and intercalates to DNA only 
when the membrane has been disrupted. To this end, cells that are negative for both stains 
are considered “live”; annexin V-positive cells are specified as “early apoptotic”; PI-positive 
cells are denoted as “necrotic", and cells positive for both stains are symbolised as “late 
apoptotic” in the cell population being analysed (Figure 3.10 and 3.11). Flow cytometric 
analysis revealed a significant decrease in the percentage of live cardiomyoblasts after 
exposure to HG + Pal, compared to the NG control (41.66% ± 1.41 vs 78.31% ± 1.61; p = 
0.0009). This finding is further supported by a significant increase in cells experiencing late 
cell death (annexin V and PI positive) (30.70 ± 1.10 vs 6.46 ± 0.70; p < 0.0001), as well as 
necrotic cell death (PI-positive only) (14.52 ± 1.63 vs 5.99 ± 0.29; p = 0.0012) following HG 
+ Pal treatment. The increase in PI-positive cells is consistent with the results observed from 
the JC-1 staining experiments and can in part be attributed to the decrease in membrane 
potential and increased membrane permeability observed above (Figure 3.9). Although a 
slight increase in annexin V only positive cells (undergoing early apoptosis) were detected 
in cardiomyoblasts exposed to HG + Pal, this increase was non-significant compared to the 
NG control (13.13% ± 0.85 vs 9.24% ± 0.89). In all instances, secondary treatment with 
either Afriplex GRT™ or Asp had no significant effect on alleviating the degree of apoptosis 
or necrosis resulting from HG and Pal treatment (Figure 3.11). As the effect of HG + Pal was 
more prominent and consistent with late-stage cell damage, it could be speculated that 
simultaneous treatment with Afriplex GRT™ or Asp during the initial HG + Pal exposure as 







Figure 3.10. Flow cytometric depiction of the clustering of cells into four quadrants based on their apoptotic 
status. In all instances, “live” cells are depicted as blue; green cells are specified as “early apoptotic” (annexin 
V-positive); red cells are symbolised as “late apoptotic” (positive for both stains) while black cells represent 






Figure 3.11. The effect of hyperglycaemic and hyperlipidaemic conditions on apoptotic profiles of the cell population. Cardiomyoblasts were cultured in normal glucose 
(NG) (5 mM) or high glucose (HG) (33 mM) and palimitate (Pal) (0.5 mM) for 24 hours. Thereafter, cells were treated with either Aspalathin (Asp) (1 µM) or Afriplex 
GRT™ (10 µg/mL) for 6 hours. Data are presented as the mean ± SEM of 3 separate biological experiments with each experiment having 3 technical repeats (n = 9). 





3.3.6 Transcriptional profiling 
In this study, the cardiac gene regulatory network that is activated under hyperglycaemic 
and hyperlipidaemic conditions on H9c2 cells was evaluated to better understand the 
pathophysiology that drives diabetes-induced cardiac dysfunction. To this end, gene 
expression profiling was employed using rat specific RT2 Profiler PCR Arrays and differential 
gene expression analysis was performed using the Gene Globe Data Analysis Centre. 
Following normalisation to internal housekeeping genes and subsequent statistical 
analyses, 58 out of the 166 genes profiled were identified as differentially expressed (p ≤ 
0.05 or fold change  2) in HG + Pal treated group when compared to the NG control 
(Supplementary Table 1). Amongst these, 39 genes were upregulated (33%), and the 
remaining 19 genes (77%) were downregulated following HG + Pal exposure. Furthermore, 
evaluation of the 58 DEGs in cells treated with either Afriplex GRT™ or Asp revealed a 
similar trend in expression in terms of fold regulation, with neither being able to significantly 
alter mRNA expression when compared to HG + Pal treated cardiomyoblasts 
(Supplementary Table 1).  
To provide biological significance, the DEGs were mapped onto key metabolic pathways 
involved in both disease and normal conditions using KEGG Mapper. Pathway enrichment 
analysis resulted in a total 213 pathway hits, identifying fluid shear and atherosclerosis (21 
out of 58), and hypertrophic cardiomyopathy (18 out of 58) as the top two enriched pathways 
(Figure 3.12). In addition, the pathway enrichment of insulin resistance and immune-related 
terms such as TNF-, IL17- and NF-κB signalling, is of particular interest to the present study 
(Figure 3.12). Collectively, these results illustrate the association between the previously 
described changes in antioxidant capacity, mitochondria depolarization and apoptosis 
following HG + Pal exposure with underlying molecular mechanisms involved in the 







Figure 3.12. The top ten KEGG pathway enrichment terms associated with differentially expressed genes 
(DEGs).  
 
3.3.6.1 Glucolipotoxicity alters shear stress and promotes atherosclerosis 
Mechanistically, shear stress, which is representative of the frictional force of blood flow at 
the endothelial surface of the vessel wall, plays a central role in vascular function (Heo et 
al., 2014; Resnick et al., 2003; Souilhol et al., 2020; Wentzel et al., 2012; Zarins et al., 1983). 
While physiological high shear stress increases the expression of atherosclerotic-protective 
genes, disturbed or low oscillatory shear stress often localised to arterial bends and 
branches, promotes atherosclerosis in collaboration with several other risk factors 
(Cunnigham & Gotlieb, 2005; Garin et al., 2007; Heo et al., 2011; Koskinas et al., 2012; 
Reinhart-King et al., 2008; Won et al., 2007). However, the exact mechanisms through which 
various shear stress environments determine whether to regulate physiological or 
pathological responses remain to be fully elucidated. In this study, KEGG mapper analysis 
identified 21 of 58 (36%) DEGs to be involved in fluid shear stress and atherosclerosis, 
including tumor necrosis factor alpha (TNF-α), nitric oxide synthase 3 (NOS3) and vascular 
endothelial growth factor A (VEGFA) amongst others (Table 3.2). Furthermore, instances, 
where alterations in fluid shear stress are observed have been linked to alterations in the 
expression of genes and signalling proteins involved in antioxidant activity, inflammation, 
thrombosis, and endothelial dysfunction (Garin et al., 2007; Heo et al., 2011; Koskinas et 





Table 3.2. Condensed list of differentially expressed genes (DEGs) associated with shear stress and 
atherosclerosis pathway enrichment in treated H9c2 cardiomyoblasts.  
Gene name Symbol 
Fold regulation 
HG + Pal Asp Afriplex GRT™ 
Inflammation     
Interleukin 6 IL6 1.64 1.73 1.47 
Chemokine (C-C motif) ligand 5 CCL5 -2.55 -2.20 -2.76 
Tumor necrosis factor alpha TNF-α 4.72 4.21 4.78 
Colony stimulating factor 1  CSF1 2.83 2.56 2.10 
Colony stimulating factor 2 CSF2 3.94 3.30 3.64 
Early growth response 1 EGR1 3.10 3.52 3.60 
Fibroblast growth factor 2 FGF2 2.51 2.23 2.67 
Interferon gamma IFNG 2.30 2.42 2.06 
Interleukin 1 beta IL1B 2.09 2.22 2.17 
Vascular cell adhesion molecule 1 VCAM1 -3.24 -3.32 -3.01 
Nitric oxide synthase 2 NOS2 4.87 5.01 4.93 
Nitric oxide synthase 3 NOS3 2.53 2.00 2.10 
Leukemia inhibitory factor LIF 3.63 3.05 3.58 
Titin TTN 1.57 1.44 1.73 
Troponin I type 2 TNNI2 1.58 1.26 1.84 
Troponin T type 3  TNNT3 1.61 1.95 1.89 
Nebulin NEB 1.65 1.33 1.82 
Platelet derived growth factor receptor beta PDGFRB -1.94 -1.44 -1.22 
C-X-C motif chemokine ligand CXCL1 2.29 2.53 2.62 
Insulin resistance     
Serpin peptidase inhibitor, clade E, 1 SERPINE1 1.37 1.48 1.77 
Vascular endothelial growth factor A VEGFA 1.19 1.61 1.77 
Protein kinase, AMP-activated, gamma 3  PRKAG3 7.06 7.53 7.18 
Insulin-like growth factor binding protein 3 IGFBP3 2.91 2.87 2.45 
Neuropeptide Y NPY 6.42 6.61 6.06 
Insulin-like growth factor binding protein 5 IGFBP5 1.84 1.36 1.94 
This table represents a subsection of the complete differentially expressed gene (DEG) table provided as 
supplementary information. All DEGs associated with HG + Pal were either statistically significant (p  0.05) 
or displayed a fold change  2 in either positive or negative direction. In all instances post-treatment with 






• Inflammation  
Numerous studies have provided evidence supporting the role of low shear stress in 
vascular inflammation and plaque formation through the modification of gene expression in 
favour of atherosclerosis (Brooks et al., 2004; Cheng et al., 2007; Cunnigham & Gotlieb, 
2005; Libby et al., 2002; Orr et al., 2005; Seo et al., 2003). This study demonstrated that 
treatment with HG + Pal increased the expression of mRNA encoding the multifunctional 
cytokine TNF-α (4.72-fold change, p = 0.002), which in turn triggered the activation of 
proinflammatory cytokines interleukin 6 (IL6) and interleukin 1 beta (IL1B) by 1.64-fold (p < 
0.001) and 2.09-fold (p = 0.064), respectively (Table 3.2). This study also demonstrated the 
significant upregulation of the chemokine ligand 1 (CXCL1) (2.29-fold change, p < 0.00001), 
which is known to be indirectly induced by IL6 or TNF-α via the activation of the NF-κB 
signalling pathway (Ma et al., 2018). The HG + Pal caused an increase in inflammatory 
cytokines, chemokines and growth factors subsequently promoted the expression of 
proliferative transcription factors VEGFA (1.91-fold change, p < 0.015), resulting in 
atherogenesis (Shaik-Dasthagirisaheb et al., 2013). Interestingly, the vascular adhesion 
molecule, VCAM-1 (-3.24-fold change, p < 0.000097), demonstrated contradictory 
decreased expression compared to related pro-inflammatory molecules. Overall, the results 
obtained illustrate the ability of HG + Pal to activate an inflammatory response and act in 
synergy with low oscillatory shear stress to alter transcriptional changes associated with the 
progression of atherosclerosis, however, post-treatment with neither Afriplex GRT™ or Asp 
was able to attenuate this effect (Table 3.2).  
• Nitric oxide (NO) and ROS 
The vascular wall redox state is modulated by shear stress, partially through the regulation 
of the expression of several oxidases. To this end, vascular endothelial cells displaying low 
oscillatory shear stress, demonstrate increased NAD(P)H activity and ROS production 
(Cunnigham & Gotlieb, 2005; Heo et al., 2014; McNally et al., 2003). The previously 
mentioned increased expression of NAD(P)H oxidase 4 (NOX4) specifically, was also 
associated with an increase in low density lipoprotein cholesterol (LDL-C) oxidation, 
promoting atherosclerosis (Hwang et al., 2003; Matsuura et al., 2008). Although this study 
observed a decrease in ROS production and NOX4 expression following HG + Pal 
exposure, this was accompanied by a reduction in antioxidant gene expression, including 
SOD2 and GPX2 (Figure 3.6). Interestingly, a study conducted by McSweeney et al (2016) 





NRF2 can negatively regulate the expression of NOX4, decreasing ROS. However, this 
requires further investigation 
Furthermore, this study provides evidence that HG + Pal increases the mRNA expression 
of both nitric oxide synthase 2 and 3 (NOS2 and NOS3), by 4.87-fold (p < 0.001) and 2.53-
fold (p = 0.191), respectively (Table 3.2). While increased NOS expression has been 
traditionally considered to be athero-protective, evidence exists supporting its significant 
contribution to ROS production should uncoupling of the electron transfer within the enzyme 
occur (Castier et al., 2005; Cunnigham & Gotlieb, 2005; Forstermann & Munzel, 2006; Heo 
et al., 2014; Verhaar et al., 2004). Accordingly, current study results allow for the speculation 
that HG + Pal exposure increased the bioavailability of NO (possible compensatory 
mechanism), forming reactive nitrogen species that could explain the suppressed ROS 
accumulation and subsequent NOX4 suppression. Nonetheless, because NRF2 expression 
was also decreased following HG + Pal exposure, it was thus unable to diminish the 
suppression of antioxidant activity, that resulted in a loss of mitochondrial activity and 
subsequent myocardial apoptosis. Therefore, further studies are required to fully elucidate 
the signalling mechanisms by which decreased ROS and enhanced NO synthesis is coupled 
with the dysregulation of NRF2-mediated transcription of antioxidant genes, such as SOD2 
and GPX2.  
 
3.3.6.2 Glucolipotoxicity promotes hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy (HCM) is a myocardial disorder that is characterised by 
hypertrophy of myocytes of the left ventricle, myofibrillar disarray, and interstitial fibrosis, 
ultimately contributing towards the development of cardiac dysfunction (Kimura, 2016; 
Marian, 2010; Marian & Braunwald, 2017; Richard et al., 2003). To this end, numerous 
genetic mutations in genes that encode protein constituents of the sarcomere have also 
been associated with HCM (Kaski et al., 2009; Niimura et al., 2002). The asymptomatic 
nature of early onset HCM, along with the concomitant presence of other cardiovascular 
conditions such as hypertension, complicates the implementation of effective diagnostic and 
therapeutic interventions (Chimenti et al., 2004; Sachdev et al., 2002; Seo et al., 2016). In 
this study, pathway analysis revealed 18 out of the 58 (31%) identified DEGs to be 
associated with HCM, including desmin (DES), myosin heavy chain 2 (MYH2), ATP-binding 
cassette transporter A1 (ABCA1), protein kinase AMP-activated non-catalytic subunit 





Table 3.3. Condensed list of differentially expressed genes (DEGs) associated with hypertrophic 
cardiomyopathy pathway enrichment in treated H9c2 cardiomyoblasts. 
Gene name Symbol 
Fold regulation 
HG + Pal Asp Afriplex GRT™ 
Lipid transport and metabolism     
ATP-binding cassette transporter A1 ABCA1 -3.44 -3.34 -3.75 
Low-density lipoprotein receptor LDLR 2.40 2.16 2.67 
Nuclear receptor 1H3 NR1H3 -1.53 -1.22 -1.17 
Prostaglandin-endoperoxide synthase 1 PTGS1 1.53 1.62 1.44 
Perilipin 2 PLIN2 2.23 2.59 2.46 
Retinoid X receptor alpha RXRA -6.01 -6.66 -6.48 
Peroxisome proliferator-activated receptor 
gamma, coactivator 1 alpha 
PPARGC1A 2.20 2.15 2.87 
Hypertrophy     
Actin alpha 1 ACTA1 -1.34 -1.66 -1.73 
Activin A receptor type IIB ACVR2B 1.51 1.22 1.19 
Adrenergic beta 2 ADRB2 3.24 3.08 3.61 
Agrin AGRN -1.54 -1.82 -1.39 
Emerin EMD -1.49 -1.93 -1.84 
Myosin heavy polypeptide 1 MYH1 1.62 1.78 1.99 
Myosin heavy chain 2 MYH2 -5.39 -5.02 -5.85 
Tripartite motif-containing 63 TRIM63 1.40 1.59 1.97 
Desmin DES 1.50 1.30 1.94 
Elastin ELN -4.25 -4.56 -4.30 
Catenin beta 1 CTNNB1 -1.27 -1.29 -1.47 
This table represents a subsection of the complete differentially expressed gene (DEG) table provided as 
supplementary information. All DEGs associated with HG + Pal were either statistically significant (p  0.05) 
or displayed a fold change  2 in either positive or negative direction. In all instances post-treatment with 







• Lipid transport and metabolism 
Scientific research suggests that increased cardiac lipid accretion often leads to fibrosis and 
ventricular stiffness, advancing HCM and cardiac dysfunction (Goldberg et al., 2012; 
Johnson et al., 2016; Sharma et al., 2004; Silver et al., 1999; Smit, 2016). Within the 
myocardium specifically, diabetes-induced lipid toxicity has been associated with left 
ventricular dysfunction, accompanied by increased mRNA expression of sterol regulatory 
element-binding protein (SREBF) and peroxisome proliferator-activated receptor gamma 
(PPARG) (Drosatos et al., 2013; Marfella et al., 2009). In the present study, the evaluation 
of gene expression following HG + Pal exposure revealed elevated mRNA levels of the 
transcriptional coactivator, PPARGC1A (2.04-fold change, p = 0.211), which interacts with 
PPARG to regulate energy metabolism (Table 3.3) (Dorn et al., 2015; Sanchis-Gomar et al., 
2014; Valero, 2014).  
Moreover, combined treatment with HG + Pal also resulted in the significant downregulation 
of mRNA encoding the membrane protein, ATP-binding cassette transporter A1 (ABCA1) (-
3.44-fold change, p < 0.001). The latter is known to regulate cholesterol efflux and prohibit 
inflammation, by binding to apolipoproteins and activating several signalling pathways, 
ultimately exerting a cardioprotective effect (Liu & Tang, 2012; Tian et al., 2019). While this 
study confirms previous findings reporting on the ability of excess glucose to reduce both 
mRNA and protein ABCA1 levels, conflicting evidence exists for the effect of saturated fatty 
acids (SFAs) such as palmitate on ABCA1 expression, with the majority of studies lacking 
the use of HG + Pal as a combined stress (Albrecht et al., 2004; Cuffe et al., 2018; Hodson 
et al., 2001; Lewington et al., 2007; Mauerer et al., 2009; Mauldin et al., 2006; Passarelli et 
al., 2005; Uehara et al., 2007). Overall, the results obtained illustrate the ability of HG + Pal 
to alter lipid metabolism and cholesterol flux by increasing the expression of PPARGC1A 
and decreasing ABCA1 expression, unable of being ameliorated by Afriplex GRT™ or Asp 
treatment (Table 3.3). The observed disordered lipid metabolism combined with the 
upregulation of low-density lipoprotein receptor (LDLR) (2.40-fold change, p = 0.006) 
potentially resulted in the development of atherogenic apolipoprotein and insulin resistance 
profiles, distinctive of HCM (Table 3.3) (Chan & Watts, 2006; DeFronza, 2010; Lee et al., 






• Cardiac muscle contraction and assembly 
During instances of chronic overload such as aging, exercise and metabolic insults the heart 
undergoes multiple changes in myocardial gene expression, influencing cardiogenesis and 
muscle contractability, ultimately promoting the development of HCM (Aoyama & Shibata, 
2017; Barth et al., 2012; Lindskog et al., 2015; Nakao et al., 1997). In the current study, the 
expression of DES (1.50-fold change, p = 0.022) was increased to produce desmin, which 
is a protein required for muscle contraction within the sarcomere (Table 3.3) (Brodehl et al., 
2018; McCormick et al., 2015). Dysregulation of DES results in an elevation of calcium 
sensitivity, possibly altering energy supply and demand withing in the heart under HG + Pal 
stress. In agreement, the present study previously demonstrated that the combination of HG 
+ Pal, decreased cellular ATP content (Figure 3.3, **** p < 0.0001 versus NG control), 
severely impairing mitochondrial bioenergetics (Figure 3.7 and 3.8) and resulting in 
mitochondrial dysfunction unable of being attenuated with Afriplex GRT™ or Asp treatment. 
Furthermore, chronic exposure of H9c2 cells to HG + Pal significantly decreased the 
expression of myosin heavy chain 2 (MYH2) (-5.39-fold change, p < 0.00001), a crucial 
determinant of cardiac muscle contractile performance and fibre arrangement, irreversible 
by Afriplex GRT™ or Asp treatment (Table 3.3) (Allen et al., 2000; Allen et al., 2001; England 
& Loughna, 2013; Tajsharghi et al., 2010). Due to possible circadian regulation of myosin 
heavy chain isoforms, the significant association between decreased expression MYH2 and 
cardiac dysfunction warrants further investigation to exploit its role as a potential prediction 
or therapeutic biomarker (Aoyama & Shibata, 2017; Shavlakadze et al., 2013). The results 
of this study thus collectively illustrate the ability of HG + Pal to modify cardiac muscle gene 
expression signalling pathways, in favour of ventricular hypertrophy, altered muscle 
contraction and assembly, contributing towards the development of HCM and heart failure 
(Table 3.3).  
 
3.4 Conclusions 
The use of in vitro models to simulate disease phenotypes has been widely accepted 
throughout the scientific community as a preliminary strategy to aid in elucidating underlying 
mechanisms. One such model is the use of the clonal cell-line, H9c2, displaying the 
characteristics of primary cardiomyocytes, which renders it extremely valuable in the 
analyses of cardiotoxicity, myocardial injury, as well as hypertrophy (Cai et al., 2002; Hu et 





scientific evidence exists supporting the ability of excess glucose as well as high 
concentrations of the circulating saturated fatty acid, palmitate, to exert detrimental effects 
on cardiomyocytes (Davargaon et al., 2019; Johnson et al., 2017; Kayama et al., 2015; 
Thomas et al., 2014; Wang et al., 2017). However, limited information exists regarding the 
combinatory effect of high glucose plus palmitate (HG + Pal) on cardiovascular function and 
the transcriptional regulatory mechanism activated upon induction of a disease phenotype, 
using an in vitro H9c2 model.  
Furthermore, this study is one of the first studies to investigate metabolic derangements 
induced under HG + Pal stress, and whether Afriplex GRTTM and Asp have the potential to 
reverse the observed effects using undifferentiated H9c2 cells. The data obtained indicate 
that HG + Pal treatment was significantly associated with membrane depolarisation and 
impaired mitochondrial bioenergetics, ultimately resulting in mitochondrial dysfunction and 
a subsequent increase in the number of cells undergoing necrosis and apoptosis. Although 
conflicting results were obtained suggesting the inability of HG + Pal to increase ROS 
production, this study confirmed previous findings that either HG or Pal exposure modulates 
the antioxidant defence system, observed by a decrease in GPX2, SOD2 and NRF2 
expression. The suppression of HG + Pal-induced ROS through increased NOS availability 
provides one possible explanation for the previously mentioned phenomenon; however, 
further studies are required in order to confirm this (McSweeney et al., 2015). Interestingly, 
this study also showed that post-treatment with Asp or Afriplex GRTTM, had no significant 
beneficial effect on the parameters assessed and further exacerbated HG + Pal-induced 
mitochondrial dysfunction and apoptosis. While previous studies have demonstrated the 
ability of both Asp and rooibos extracts to ameliorate metabolic stress in vitro, these studies 
differ from the current study either in terms of the cell line-, the stress inducer-, or the specific 
rooibos extract used (Dludla et al., 2014; Dludla et al., 2017; Johnson et al., 2016; Kroukamp 
et al., 2018; Millar et al., 2020; Mazibuko et al., 2019; Mazibuko-Mbeje et al., 2019). Thus, 
allowing for the speculation that the combinatory insult of both high glucose and palmitate 
used in the current study, strongly contributed to the inability of Asp or Afriplex GRT™ to 
influence the metabolic perturbations evaluated. 
Additionally, this study aimed to provide a better understanding of the cardiac gene 
regulatory network activated under high fat, high sugar (HG + Pal) conditions. Gene 
expression and functional enrichment analyses revealed that HG + Pal treatment was able 
to increase NOS and activate an inflammatory response which in combination with low 





development of atherosclerosis. Exposure to HG + Pal was also able to alter lipid 
metabolism and increase contractile dysfunction, thus promoting the development of 
hypertrophic cardiomyopathy (HCM). Along with shear stress, atherosclerosis and HCM; the 
transcriptional enrichment of insulin resistance, fibrosis and apoptosis was further observed 
following HG + Pal exposure. Treatment with Asp or Afriplex GRTTM was once again unable 
to ameliorate the HG + Pal-induced transcriptional changes, possibly suggesting that the 
combined insult used in the current study may have resulted in a severe cardiac dysfunction 
phenotype unable of being remediated by the particular polyphenols. Future studies 
involving the treatment with Asp and Afriplex GRTTM prior to stress induction, as well as 
combined therapy of the polyphenolic compounds with HG + Pal are advised to fully 
characterise the findings of the present study. To further characterise the role of an 
obesogenic diet in CVD risk development, the following chapters focus on the use of a Wistar 
rats maintained either on a high fat, high sugar (HFHS) or standard (STD) rodent diet, 
supplemented with or without Afriplex GRTTM. 
 
3.5 Supplementary data 
Supplementary Table 1. Complete list of differentially expressed genes (DEGs) identified 
from RT2 Profiler PCR Arrays.  
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Chapter 4: A high fat, high sugar model to investigate diet-
induced CVD in Wistar rats 
4.1 Introduction 
Cardiovascular disease (CVD), collectively referring to conditions that affect the heart tissue 
or involve the obstruction of blood vessels, is the leading cause of mortality worldwide. 
Annually, CVD claims approximately 17.9 million lives, accounting for almost a third of all 
global deaths (WHO, 2021). Over the past decade, there has been an exponential increase 
in the occurrence of CVD in low- and middle-income countries, transferring its historical 
association with affluent economies to underdeveloped countries (Yusuf et al., 2014; WHO, 
2021). This increase is concomitant with a substantial increase in the prevalence of major 
CVD risk factors, including obesity, insulin resistance (IR), and type 2 diabetes mellitus 
(T2DM) (Cavan et al., 2016; Humphries et al., 2010; Yusuf et al., 2004). This can, in part be 
attributed to urbanisation and sedentary lifestyles accompanied by increased dietary fat 
intake and over nutrition (Cavan et al., 2016; Humphries et al., 2010; Kruger et al. 2005; 
Micklesfield et al. 2013).  
Per the American Heart Association, diabetic adults are two to four times more likely to die 
from cardiovascular complications, making it the primary cause of diabetic-related deaths 
(Zhou et al., 2009). While the mechanisms whereby chronically elevated blood glucose 
levels, resulting from T2DM, elicits detrimental effects on the heart have not been fully 
elucidated, increased intracellular flux of free fatty acids (FFAs) have been widely implicated 
(Dyntar, 2003; Giacco & Brownlee, 2010; Kapur & De Palma, 2007; Opie, 2008; Schrieks et 
al., 2018). The excess availability of FFAs alters substrate preference in the heart, during 
which myocardial FFA uptake exceeds the rate of β-oxidation, which in addition to 
hyperglycaemia, further augments myocardial injury (Bugger & Abel, 2010; Schulze et al., 
2016). The increased lipid storage within the diabetic heart correlates with the development 
of coronary artery disease (CAD) and diabetic cardiomyopathy, ultimately leading to 
diabetes-induced cardiac dysfunction (Borghetti et al., 2018). Currently, there are no 
prognostic markers or pharmacological drugs to prevent or treat diabetes-related cardiac 
complications. Furthermore, the asymptomatic nature of early onset CVD complicates the 
successful implementation of preventative and therapeutic strategies (Borghetti et al., 2018). 
Thus, as the burden of CVD continues to increase and the long-term prognosis remains 





investigate novel and more effective therapies to efficiently manage and ultimately alleviate 
the weight of this chronic disease. 
Several clinical and epidemiological studies support the concept that a diet rich in 
polyphenols is associated with anti-diabetic and cardioprotective properties (Aryaeian et al., 
2017; Chellan et al., 2004; Pan et al., 2013; Pandey & Rizvi, 2009; Parks & Booyse, 2002; 
Sun et al., 2020). These polyphenols are present in dietary components such as green tea, 
red wine and cocoa, and their beneficial effects have been attributed to their antioxidant 
capacity (Crescenti et al., 2013; Feil & Fraga, 2012). One such polyphenol, Aspalathin, 
which is unique to rooibos (a fynbos plant indigenous to South Africa), has been shown to 
exert protective effects against metabolic disorders such as insulin resistance (IR) and 
T2DM, both risk factors of CVD (Dludla et al., 2014; Mazibuko et al., 2013; Muller et al., 
2013; Son et al., 2013). Additionally, the effectivity of Aspalathin in attenuating doxorubicin-
induced cardiotoxicity through increased autophagy, while simultaneously increasing the 
expression of the anti-apoptotic BCL2 was also reported (Johnson et al., 2017).  
This study aimed to establish a high fat, high sugar (HFHS) rodent model to allow for the 
investigation of metabolic factors contributing towards the clinical manifestation of diet-
induced CVD. In addition, to ascertain whether an Aspalathin-rich green rooibos extract, 
Afriplex GRT™, could ameliorate the induced metabolic complications and infer 
cardioprotective effects. This animal model and resulting isolated samples will serve as the 
input for all subsequent chapters.  
 
4.2 Materials and Methods 
4.2.1 Study design 
Three-week-old, male (n=40) and female (n=40) Wistar rats (Rattus norvegicuss) were 
caged in pairs according to gender and housed in a controlled animal facility at the Primate 
Unit and Delft Animal Centre (PUDAC) of the South African Medical Research Council 
(SAMRC). Rats of both genders were randomised into two main groups: 1) the control group 
which received a standard (STD) maintenance rodent diet, and 2) the diet-induced insulin-
resistant group fed a high fat, high sugar (HFHS) cafeteria diet for a period of nine months. 
The STD diet consisted of patties formulated to comply with standard nutrient requirements, 
as well as tap water while the HFHS diet consisted of patties with increased fat content, plus 





Both diets were formulated at the PUDAC (SAMRC) and animals in all groups received food 
and water ad libitum for the entire duration of the study. To evaluate the potential of an 
Afriplex GRT™ extract to modulate diet-induced alterations, each group was further divided 
into two subgroups (n=10) receiving daily treatment with either a placebo or the Afriplex 
GRT™ extract throughout the study (Figure 4.1). Feed intake and water consumption was 
monitored two times a week, while body weight was assessed on a weekly basis. Ethical 
clearance for the use of animals in this study was granted by the SAMRC Ethics Committee 
for Research on Animals (ECRA no. 10/17), and the Ethics Committee: Animal Care and 
Use of Stellenbosch University (reference number AUC-2020-14614). 
 
Table 4.1. Diet compositions as determined by Microchem Specialized Lab Services (Pty) Ltd. 
Component STD diet HFHS diet 
Carbohydrates % 24.2 22.3 
Fat % 4.37 10.61 
 Saturated Fat (g/100g)  1.58 5.73 
 Mono-Unsaturated Fat (g/100g)  2.11 3.63 
 Poly-Unsaturated Fat (g/100g) 0.69 1.25 
 Omega 3 Fatty Acids (g/100g) 0.087 0.111 
 Omega 6 Fatty acids (g/100g) 0.60 1.1 
 Cholesterol (mg/100g) 35 88 
Protein %  7.7 9.1 
Dietary Fibre % 5.9 5.3 








Figure 4.1. Experimental design for animal study. A total of 80 Wistar rats (n = 40 males and n = 40 females) were randomised into appropriate groups to evaluate 
the use of Afriplex GRT™ extract as a preventative for diet-induced CVD. Rats were either fed a standard maintenance rodent diet (STD) or a high fat, high sugar 
cafeteria diet (HFHS), with or without Afriplex GRT™ treatment throughout the study. Upon termination at 9 months, blood and heart tissue samples were collected to 





4.2.2 Treatment  
The Aspalathin-rich green rooibos extract, Afriplex GRT™, was prepared according to good 
manufacturing practices and obtained from Afriplex® Pharmaceuticals (Paarl, South Africa). 
This solvent-based extract has previously been shown to have anti-diabetic and cardio-
protective properties (Mazibuko et al., 2013; Muller et al., 2012). As the stability of 
Aspalathin, a major phenolic compound in the extract (Table 4.2), decreases after 12 hours 
in an aqueous solution, working stock solutions of the extract were prepared on the day of 
administration and subsequently added to jelly cubes (de Beer et al., 2015). The rats 
received a jelly cube containing the Afriplex GRT™ extract (60 mg/kg BW) or the vehicle 
only (jelly cubes without the Afriplex GRT™), once a day throughout the treatment period 
(nine months). In all instances, jelly cubes were fed to rats individually using a sterile 
laboratory spatula and observation was made to ensure the complete consumption of the 
entire jelly cube. 
 
Table 4.2. Active phenolic compounds present in the Afriplex GRT™ extract as determined by the SAMRC. 
Compound g/100g Soluble solids 
Aspalathin  12.78 
Nothofagin 1.97 
Isoorientin  1.43 
Orientin 1.26 
Q-3-ROB  1.04 
Isoquercitrin 0.57 
Rutin  0.50 
PPAG 0.42 
Hyperoside 0.40 0.40 
Vitexin 0.39 
Isovitexin  0.30 
 
4.2.3 Fasting blood glucose (FBG) measurements and oral glucose tolerance tests 
(OGTTs) 
Along with the assessment of the general well-being of the animals as well as phenotypic 
traits, fasting blood glucose (FBG) concentrations were measured monthly by tail prick after 
a 16 hour, overnight fast. Furthermore, oral glucose tolerance tests (OGTTs) were 





rats were subjected to a 16 hour fast and plasma glucose levels were determined by tail 
prick at time intervals of 0, 30, 60, and 120 min following the administration of glucose (2 
g/kg BW) by oral gavage according to the SOPs of PUDAC (SAMRC). To maintain a 
constant treatment period between animals in all groups, experiments were staggered to 
facilitate logistics when conducting OGTTs. Relative glucose tolerance was determined by 
comparing the difference in blood glucose for each time point between groups, and by 
comparing the area under curve (AUC) of each individual rat tolerance test between groups. 
 
4.2.4 Harvesting biological samples 
At the completion of the study, all animals were anaesthetised with an Oxygen flowmeter (± 
0.9 L/min) and Isoflurane vaporizer (approximately 3.5-5% for induction and 2% for 
maintenance) followed by termination by exsanguination. Blood samples were collected 
from the vena cava into SST gel tubes as well as EDTA tubes, post-mortem. The hearts 
were excised and subsequently cut into pieces using transverse sections along the 
horizontal plane and immersed in formalin for histological analysis, snap-frozen in liquid 
nitrogen for methylation profiling, and stored in 1 ml of RNAlaterTM for expression analysis. 
All samples were stored at either -20°C or room temperature (RT) depending on the 
downstream applications.  
 
4.2.5 Blood biochemistry analysis 
Serum was isolated from peripheral blood collected into the SST gel tubes and used to 
assess metabolic marker concentrations in order to confirm the disease phenotype. To this 
end, one half of the isolated serum was used for lipid profiling (total cholesterol, triglycerides, 
low-density lipoprotein (LDL) and high-density lipoprotein (HDL)) and liver enzyme (Alanine 
Aminotransferase (ALT) and Aspartate Aminotransferase (AST)) analysis at PathCare 
Medical Diagnostic Laboratories (Cape Town, RSA); while the other half was stored at -80ºC 
for subsequent serum insulin analysis. Rat insulin levels were determined post termination 
using the Rat/Mouse Insulin ELISA from Millipore® according to the manufacturer’s 
instructions (Cat. # EZRMI-13K, Merck KGaA, Darmstadt, Germany). This ELISA based 
assay relies on the combinatory use of monoclonal anti-rat insulin and biotinylated polyclonal 
antibodies, followed by the enzymatic action of horseradish peroxidase (HRP) to 
fluorometrically determine insulin concentrations using a series of standards. To this end, 





duplicate into the respective wells of the coated 96-well microtiter plate. The assay buffer 
supplied was used as the blank, while the standards used represented 0.2, 0.5, 1, 2, 5 and 
10 ng/mL insulin. All reagents and samples were allowed to equilibrate to room temperature 
prior to performing the assay. Following completion of the assay, the absorbance at 450 nm 
and 590 nm was read within 5 min using a BioTek® FLx800 plate reader and Gen 5® 
software (BioTek Instruments Inc., Winooski, VT, USA). Insulin concentrations for all 
samples were inferred using the relative curve method and converted to pmol/L using 
1 μIU/mL = 6.00 pmol/L (Knopp, Holder-Pearson, & Chase, 2019). The homeostasis model 
assessment for insulin resistance (HOMA-IR) index was calculated using the formula: 
HOMA-IR = glucose concentration (mmol/L) X insulin concentration (U/mL) / 22.5, using 
fasting values (Matthews et al., 1985; Salgado et al., 2010).  
 
4.2.6 Histology  
The cardiac tissues collected in formalin were examined for indicators of cardiovascular 
disease such as structural changes in the nuclei of cardiomyocytes, the arrangement of 
cardio myofibers, as well as the collagen content. For this purpose, cardiac tissues were 
embedded in paraffin wax, dissected longitudinally, and stained with Haematoxylin and 
Eosin (H&E), and Mayson’s Trichome (MT) using optimised in-house protocols (Page et al., 
2004; Thent et al., 2012). Stained sections were visualized using an Olympus BX50 light 
microscope (Olympus Optical Co., LTD, Tokyo, Japan), and indications of cardiac structural 
abnormalities were evaluated with the NIS-Elements BR imaging software version 3.0 
(Nikon Inc., Tokyo, Japan). As an additional assessment of the effect of diet on 
glucolipotoxicity, liver tissues were stained using H&E, as previously described.  
 
4.2.7 Statistical analysis 
Data is expressed as either the geometric mean ± standard deviation (SD) or the mean ± 
standard error of the mean (SEM), where appropriate. The geometric mean was selected 
as opposed to the arithmetic mean to take into account the confounding effect. For each 
group, a total of 10 samples were used as independent biological replicates. The distribution 
of the groups was evaluated for normality and differences in variance with Shapiro-Wilk tests 
prior to performing any statistical comparisons. In the instances where data sets were 
normally distributed, they were assessed for statistical significance using ANOVA and 





deviating from normal distribution. To allow for the direct comparison of significance, multiple 
testing correction was performed using either a Bonferroni or Dunn’s post-hoc test, 
depending on the distribution of the data. Statistical analyses were performed using 
Microsoft Excel and GraphPad Prism software version 7.00 (GraphPad Software, Inc., La 
Jolla, CA, USA). In all instances, a statistical significance was inferred for a p-value less 
than, or equal to 0.05. Additionally, regression analysis was conducted, where applicable, 
to explore the relationship between independent and dependent variables, and account for 
time effects.  
 
4.3 Results and Discussion 
4.3.1 Physiological parameters 
4.3.1.1 Food and water consumption 
To evaluate the potential contribution of diet on weight gain, feed intake of all the animals in 
the different diet groups was assessed twice a week, from the start of diet and/or treatment 
administration, until termination of the study (Figure 4.2). Overall, both male (33.42 ± 1.47 
vs 20.15 ± 0.35; p < 0.0001) and female (26.03 ± 1.31 vs 13.96 ± 0.43; p < 0.0001) animals 
in the HFHS groups, consumed significantly more food throughout the study when compared 
to animals maintained on the STD diet (Figure 4.2). This finding is concurrent with previous 
in-house and external studies reporting increased food consumption in Wistar rats fed a 
similar high fed diet, ultimately leading to an increase in body mass, as well as serum insulin 
and lipid levels (Kamau, 2018; Nduhirabandi et al., 2017; Roux, 2011). Treatment with 
Afriplex GRT™ did not significantly influence the average daily food consumption when 
compared to animals in untreated groups maintained on either diet, regardless of the sex 
(Figure 4.2). Several studies have implicated contradictory evidence regarding the ability of 
rooibos to both increase as well as have an inhibitory effect on appetite (Morton, 1983; 
Schloms et al., 2014; Yau & Potenza, 2013). However, these previously described effects 
were not observed in the current study with respect to the Afriplex GRT™.  
Furthermore, no significant differences were observed regarding water intake for rodents 
fed the HFHS diet when compared to their control counterparts, for both male (28.37 ± 1.26 
vs 27.68 ± 0.76) and female (26.02 ± 0.88 vs 24.05 ± 0.70) animals throughout the study 
(Figure 4.3). Although a slight increase in the amount of water consumed daily by animals 





when compared to the untreated control group. At termination of the study (9 months), 
females in the HFHS + Afriplex GRT™ group drank significantly more water than those in 
the STD group (30.03 ± 1.23; p = 0.0004) (Figure 4.3). As this phenomenon was not a 
constant occurrence throughout the study, it is uncertain whether this can be attributed to 
effects introduced by the obesogenic diet; the Afriplex GRT™ extract; or a combination 
between the two variables. Moreover, this study does not provide any substantial evidence 
of the HFHS diet or the Afriplex GRT™ extract having a negative effect on hydration. 
 
 
Figure 4.2. Average daily food consumption per rat for males (A) and females (B) throughout the study. 
Values are expressed as mean ± SEM. A) Food consumption at 3, 6 and 9 months: HFHS vs STD, ***** p < 
0.0001 and HFHS diet + Afriplex GRT™ vs STD diet, ***** p < 0.0001. B) Food consumption at 3, 6 and 9 






Figure 4.3. Average daily water intake per rat for males (A) and females (B) throughout the study. Values are 







4.3.1.2 Body weight (BW) gain and obesity 
As obesity negatively affects multiple systems of the body and remains one of the major risk 
factors of diabetes and its associated cardiovascular complications, the body weight of the 
animals was monitored on a weekly basis throughout the study. Male Wistar rats in all four 
groups gained weight at a steady pace throughout the study, with rats in the HFHS diet fed 
group being significantly heavier than those in the STD diet fed group after 9 months of 
feeding (Table 4.3). This significant increase was maintained for rats on the HFHS diet, in 
the experimental group receiving Afriplex GRT™ when compared to those on the STD diet 
(Table 4.3).  
 
Table 4.3. Comparison between body weight (g) of male rats throughout the study. 
 STD diet 
STD + Afriplex 
GRT™ 
HFHS diet 
HFHS + Afriplex 
GRT™ 
3 months 304.05 ± 7.07 304.32 ± 6.97 327.97 ± 6.24 324.97 ± 10.51 
6 months 401.99 ± 9.48 391.15 ± 10.72 444.90 ± 11.17 440.92 ± 15.46 
9 months 443.50 ± 9.49 429.81 ± 11.23 509.40 ± 13.28* 509.01 ± 16.47* 
Values are expressed as mean ± SEM. Each group consists of n = 10 Wistar rats as independent biological 
replicates. Bold entries represent instances where a significant difference was observed. Body weight at 9 
months: HFHS diet vs STD diet, * p = 0.0141 and HFHS diet + Afriplex GRT™ vs STD diet, * p = 0.0193. 
 
Table 4.4. Comparison between body weight (g) of female rats throughout the study 
 
STD diet 
STD + Afriplex 
GRT™ 
HFHS diet 
HFHS + Afriplex 
GRT™ 
3 months 193.51 ± 4.39 196.25 ± 3.41 206.45 ± 6.77 207.13 ± 2.38* 
6 months 237.01 ± 5.24 237.22 ± 4.87 255.25 ± 9.62 257.88 ± 4.48* 
9 months 255.38 ± 5.43 254.26 ± 6.01 280.18 ± 11.73 284.17 ± 5.47* 
Values are expressed as mean ± SEM. Each group consists of n = 10 Wistar rats as independent biological 
replicates. Bold entries represent instances where a significant difference was observed. Body weight at 3 
months: HFHS diet + Afriplex GRT™ vs STD diet, * p = 0.0232; at 6 months:  HFHS diet + Afriplex GRT™ vs 






Although not significant, a similar trend of increase in BW was observed for female rats 
receiving the HFHS diet compared to those on the STD diet, throughout the study. 
Interestingly, female rats in the HFHS treatment group (HFHS diet + Afriplex GRT™) 
weighed significantly more than their control counterparts receiving the STD diet, which 
equates to an average gain of approximately 9% body weight (Table 4.4). Treatment with 
Afriplex GRT™ had no significant effect on the BW of control rats maintained on the STD 
diet in both male and female groups, suggesting the possibility of the absence of toxic 
effects. Furthermore, no significant differences were observed between groups on the same 
diet, with or without Afriplex GRT™. 
In the past, there has been a general trend of over-reliance on male rodents in diet-induced 
physiological studies however, several studies have highlighted the significance of including 
female animals in preclinical research, especially in the instances of non-communicable 
diseases (Pektaş et al., 2015). One such study by Taraschenko et al. (2011) found a similar 
trend in weight gain between male and female Sprague-Dawley rats maintained on a high 
sucrose diet. However, when fed a high fat diet, male rats were able to gain weight 
excessively while female rats did not. Suggesting a differential response to high fat induced 
obesity between the two different genders (Taraschenko et al., 2011). In the present study 
male rats in all groups appeared almost twice as heavy as the female rats, which can in part 
be attributed to their increased food and water consumption, resulting in increased energy 
intake (Figure 4.4). However, even though male rats (STD diet: 36.01 ± 0.62; HFHS diet: 
93.80 ± 3.27) consumed 1.5 times more calories per day than female rats (STD diet: 24.95 
± 0.78; HFHS diet: 75.34 ± 3.25), the greater intake does not explain the variance in body 
weight gain in its entirety (Figure 4.4). Therefore, the possible influence of female cyclic 







Figure 4.4. Average daily caloric intake for male (A) and female (B) rats throughout the study. Calories from 
both food and water intake for HFHS diet fed animals were taken into consideration. Based on nutritional 
analysis conducted, the STD diet comprised of 1.79 kcal/g while the HFHS diet contained 2.32 kcal/g 
supplemented with an additional 0.58 kcal/g from the water. Values are expressed as mean ± SEM. A) Caloric 
intake at 3, 6 and 9 months: HFHS vs STD, ***** p < 0.0001 and HFHS + Afriplex GRT™ vs STD, ***** p < 
0.0001. B) Caloric intake at 3, 6 and 9 months: HFHS vs STD, ***** p < 0.0001 and HFHS + Afriplex GRT™ 







The inferences made through BW or excessive weight gain alone cannot be used as an 
indication of the occurrence of obesity. As such, this study utilised retroperitoneal fat (RF) 
as a measurement of adiposity, and to estimate the degree of obesity (de Freitas Marthias 
et al., 2007; Tekus et al., 2018). The measurement of visceral adipose tissue such as RF 
has previously been found to be significantly correlated with the occurrence of metabolic 
syndrome and proves to be a valuable addition in cardio-metabolic studies (Hung et al., 
2014; Yano et al., 2016). During terminations, the RF pad was excised, weighed, and 
normalised to the body weight of the animal. After 9 months, both male (104%) and female 
(100%) rats in the HFHS group displayed a significant increase in RF mass relative to body 
weight when compared to their gender matched controls on the STD diet (Table 4.5). For 
male rats specifically, the previously described weight gain observed with the administration 
of HFHS diet feeding directly translates into to an increase in body fat however, this was not 
observed for the female animals. Treatment with Afriplex GRT™ did not significantly affect 
the accumulation of body fat between groups on the same diet, irrespective of the gender. 
However, male (80%) and female (123%) rats in the HFHS + Afriplex GRT™ groups also 
presented with a significant increase in RF weight/body weight ratio when compared to those 
in the STD group (Table 4.5). This result contradicts the finding of a previous study 
conducted by Sanderson et al. (2014), demonstrating the ability of rooibos extracts 
(approximately 7 times less potent than the dose used in the present study) to significantly 
inhibit adipogenesis and confer potential weight loss benefits. However, as this was an in 
vitro study, these findings cannot be directly compared to the current study findings.  
 
Table 4.5. Comparison of RF weight relative to body weight (mg/g) for both male and female animals.  
 STD diet STD + Afriplex 
GRT™ 
HFHS diet HFHS + Afriplex 
GRT™ 
Males 16.24 ± 1.50 14.31 ± 1.50 33.14 ± 3.85** 29.31 ± 2.12*** 
Females 8.10 ± 0.73 8.35 ± 0.72 16.17 ± 1.53** 18.09 ± 1.53*** 
Values are expressed as mean ± SEM. Each group consists of n = 10 Wistar rats as independent biological 
replicates. Bold entries represent instances where a significant difference was observed. Males: HFHS diet vs 
STD diet, ** p = 0.0085 and HFHS diet + Afriplex GRT™ vs STD diet, *** p = 0.0007. Females: HFHS diet vs 






4.3.1.3 Heart weight 
Evaluating the effect of diet or treatments on cardiac remodelling often presenting as 
alterations in heart mass and function provides valuable insight into disease development 
and progression (Azevedo et al., 2016; Kumar et al., 2014). Upon completion of the study, 
the hearts of all animals were removed, and the weights were assessed prior to dissection 
and storage of the tissue for respective downstream analyses. The average absolute heart 
weight remained relatively uniform between male animals in all the respective groups 
(Figure 4.5. A), with no significant differences being observed between HFHS and STD 
animals (1.08 ± 0.04 vs 1.12 ± 0.04). As expected, this lack of variation was further 
maintained when normalising heart weight to body weight with the heart weight of all males 
remaining directly proportional to total body weight (Figure 4.5. B). The aforementioned 
trend also applied to females, with no differences being observed between absolute heart 
weight (HFHS vs STD: 0.74 ± 0.01 vs 0.75 ± 0.02) or the relative heart weight/body weight 
ratio (Figure 4.6. A and B). Moreover, the administration of Afriplex GRT™ had no impact 
on heart mass in male, as well as female animals. While these findings conform with what 
has previously been reported for diets with the same composition, increased caloric intake 
associated with high fat diets consisting of elevated palmitate and oleate content specifically 
have been associated with increased cardiac mass (Ouwens et al., 2005; Salie et al., 2014; 
Smit, 2019). This further supports the multifarious metabolic outcomes observed with the 
different types of fat used in high fat diets.  
 
 
Figure 4.5. Overall distribution of absolute heart weight (A) and normalised heart weight relative to body weight 
(B) for male animals at termination. Scatter dot plots representing individual values accompanied with solid 






Figure 4.6. Overall distribution of absolute heart weight (A) and normalised heart weight relative to body weight 
(B) for females at termination. Scatter dot plots representing individual values accompanied with solid lines 
expressing the mean ± SEM.  
 
4.3.1.4 Hyperglycaemia  
During the development of metabolic syndrome and the onset of insulin resistance (IR), the 
body’s ability to regulate and maintain blood glucose concentrations within the 
physiologically accepted range, becomes severely diminished (Norris & Rich, 2012). In the 
current study, this phenomenon was evaluated by measuring fasting blood glucose (FBG) 
concentrations and conducting OGTTs throughout the study. Male rats maintained on the 
HFHS diet were able to compensate for the diabetogenic effects of the diet throughout the 
study, as there were no significant differences in FBG concentrations between the groups 
(Figure 4.7 A). Although a general trend of increase in FBG concentration was observed for 
rats in the HFHS groups, this was only significant for the HFHS diet fed animals receiving 
Afriplex GRT™ treatment when compared to those in the STD group at 9 months (5.27 ± 
0.15 vs 4.75 ± 0.11; p = 0.0198). Similarly, no significant differences, as well as no consistent 
trends were observed between FBG concentrations of female rodents maintained on the 
HFHFs diet when compared to their control counter parts throughout the study (Figure 4.7 
B). As is the case with weight gain, no differences were observed between animals receiving 
the vehicle and those receiving treatment with Afriplex GRT™ for both male and female, 
irrespective of the diet (Figure 4.7 A and B). The ability to maintain normoglycemia, while 
exhibiting a mildly obese phenotype is not uncommon and can be as a result of excessive 







Figure 4.7. Fasting blood glucose (FBG) concentrations of male (A) and female (B) rats throughout the study. 
Values are expressed as mean ± SE. A) FBG at 9 months: HFHS + GRT vs STD, *** p<0.001. 
 
Furthermore, as is convention with animal studies, OGTT’s were performed on these 
animals to assess glucose concentrations in the blood after its administration. At three 
months, a significant difference was observed in the glucose concentration, 15 min after oral 
glucose stimulation between the male HFHS rats and those on the STD diet (9.03 ± 0.66 vs 
7.63 ± 0.28; p = 0.0343) (Figure 4.8 A). Significant differences were also observed between 
male rats in the HFHS + Afriplex GRT™ group when compared to those in the STD group 





p = 0.0218) time points (Figure 4.8 A). However, this result was not maintained, and blood 
glucose returned to baseline levels at the clinically relevant two-hour assessment time point. 
At six months, HFHS diet fed male rats displayed a significant increase in glucose 
concentrations, 15- (8.61 ± 0.35 vs 6.67 ± 0.14; p < 0.0001) and 30 min (7.47 ± 0.25 vs 5.95 
± 0.21; p = 0.0021) after oral stimulation when compared to those on the STD diet (Figure 
4.8 B). A similar increase was displayed by male rats in the HFHS + Afriplex GRT™ group 
at the 15- (7.82 ± 0.32 vs 6.67 ± 0.14; p = 0.0387) and 30 min (7.99 ± 0.46 vs 5.95 ± 0.21; 
p < 0.0001) interval when compared to the STD group. These results translated to that 
obtained from OGTTs performed at nine months (Figure 4.8 C). Interestingly, a significant 
increase was also observed in male rats in the STD + Afriplex GRT™ group when compared 
to those in the STD group at six months (8.39 ± 0.36 vs 6.67 ± 0.14; p = 0.0003) (Figure 4.8 
B). This increase, however, did not occur at nine months (Figure 4.8 C). Moreover, AUC 
analysis of each individual OGTT using the trapezoidal rule, revealed significantly increased 
AUC in HFHS (927.20 ± 9.68 vs 787.40 ± 14.12; p = 0.0009) and HFHS + Afriplex GRT™ 
(923.30 ± 16.34 vs 787.40 ± 14.12; p = 0.0012) groups compared to the STD group (Figure 
4.8 D). Overall, male rats in the HFHS groups, displayed signs of diminished ability to clear 
glucose from the blood after its administration after nine months of feeding/treatment.  
Similarly, female rats maintained on the HFHS diet displayed similar significant differences 
in glucose concentrations, 15 min after oral glucose stimulation when compared to those on 
the STD diet at three months (10.65 ± 0.79 vs 8.43 ± 0.92; p = 0.0024) (Figure 4.9 A). While 
this increase was observed 15 (8.28 ± 0.52 vs 6.46 ± 0.23; p = 0.0003) and 30 min (8.08 ± 
0.51 vs 6.87 ± 0.30; p = 0.0384) six months after feeding, it was not maintained throughout 
the remainder of the study, with no significant differences being observed between the 
respective groups at completion of the study (9 months) (Figure 4.9 B and C). Additionally, 
treatment with Afriplex GRT™ had no significant effect on the glucose clearance ability of 
female rats however, a significant difference in glucose levels was observed between HFHS 
+ GRT and STD animals, 30 min after administration following six months of feeding (8.79 
± 0.39 vs 6.87 ± 0.30; p = 0.0001). Overall, female rats in the HFHS group, did not display 
significant signs of diminished ability to clear glucose from the blood following its 
administration after nine months of feeding, and instances of increase can be considered as 
contingent. This is further supported by the absence of differences observed in AUC analysis 
of each individual OGTT throughout the study (Figure 4.9 D). Possibly suggesting that 
females are better equipped able to handle the dietary insult, as could also be observed in 






Figure 4.8. Oral glucose tolerance tests (OGTT’s) at three (A), six (B) and nine (C) months for male rats. Values are expressed as mean ± SE. A) 15 min: HFHS vs 
STD, * p = 0.0343 and Afriplex GRT™ vs STD, * p = 0.0112. 30 min: HFHS + Afriplex GRT™ vs STD, * p = 0.0218. B) 15 min: HFHS vs STD, **** p < 0.0001 and 
HFHS + Afriplex GRT™ vs STD, * p = 0.0387. 30 min: HFHS vs STD, ** p = 0.0021 and HFHS + Afriplex GRT™ vs STD, **** p < 0.0001. C) 15 min: HFHS vs STD, 
**** p < 0.0001 and HFHS + Afriplex GRT™ vs STD, **** p < 0.0001. 30 min: HFHS vs STD, *** p = 0.0001 and HFHS + Afriplex GRT™ vs STD, *** p = 0.0009. 60 
min: HFHS vs STD, ** p = 0.0089 and HFHS + Afriplex GRT™ vs STD, ** p = 0,0013. D) Area under the curve (AUC) analysis of individual OGTT tests: HFHS vs 






Figure 4.9. Oral glucose tolerance tests (OGTT’s) at three (A), six (B) and nine (C) months for female rats. Values are expressed as mean ± SE. A) 15 min: HFHS 
vs STD, ** p = 0.0024. B) 15 min: HFHS vs STD, *** p = 0.0003. 30 min: HFHS vs STD, * p = 0.0384 and HFHS + Afriplex GRT™ vs STD, *** p = 0.0001. D) Area 





4.3.2 CVD risk predictors 
Insulin resistance (IR), often considered as the driving force behind T2DM, results in the 
activation of damaging pathways, ultimately leading to diabetes-induced CVD (Bian et al., 
2008; Frankel et al., 2008; Laakso, 2010; Soinio et al., 2006; Voelter-Maholknecht, 2016). 
Furthermore, IR has also been shown to be independently associated with increased CVD 
risk, even in non-diabetic subjects, and therefore remains a valuable predictor (Grant, 2007; 
Laakso, 2010; Libman et al., 2010; Natali et al., 2006). Considering this, serum insulin 
concentrations were measured upon termination of the study, accompanied by the 
application of the HOMA-IR model for the assessment of IR. The previously mentioned 
model has been widely used and validated for inferences in Wistar rats (Antunes et al., 
2016). No significant differences, as well as no consistent trends in serum insulin 
concentrations were observed for both male and female rats after nine months of HFHS diet 
feeding when compared to their STD diet-fed counterparts (Table 4.6 and 4.7).  
 
Table 4.6. Summary of serum insulin, lipid profiling and liver enzyme analyses for male animals. 
 STD diet STD diet + GRT HFHS diet HFHS diet + GRT 
Insulin (pmol/L) 5.84 ± 1.63 8.61 ± 1.65 4.20 ± 0.73 9.15 ± 2.32 
HOMA-IR index 0.21 ± 0.06 0.30 ± 0.06 0.16 ± 0.03 0.35 ± 0.09 
Cholesterol     
 Total (mmol/L) 1.54 ± 0.10 1.43 ± 0.09  1.63 ± 0.10 2.07 ± 0.14 
 LDL (mmol/L) 0.28 ± 0.00 0.28 ± 0.00 0.31 ± 0.02 0.31 ± 0.02 
 HDL (mmol/L) 0.97 ± 0.05 1.00 ± 0.06 0.80 ± 0.03 0.85 ± 0.04 
Triglycerides (mmol/L) 1.23 ± 0.11 1.13 ± 0.13 3.10 ± 0.34** 3.55 ± 0.38*** 
TG:HDL ratio 2.95 ± 0.29 2.54 ± 0.23 9.02 ± 1.08** 9.65 ± 0.10*** 
Liver enzymes     
 ALT (IU/L) 37.30 ± 4.08  28.60 ± 2.03 24.10 ± 1.88 34.00 ± 2.31# 
 AST (IU/L) 58.56 ± 2.98 53.10 ± 3.50  46.40 ± 3.65 59.33 ± 3.06# 
 AST:ALT ratio 1.94 ± 0.18 1.91 ± 0.11 1.97 ± 0.15 1.78 ± 0.08 
Values are expressed as mean ± SEM. Each group consists of n = 10 Wistar rats as independent biological 
replicates. Bold entries represent instances where a significant difference was observed. Triglycerides: HFHS 
diet vs STD diet, ** p = 0.0015 and HFHS diet + Afriplex GRT™ vs STD diet, *** p = 0.0007. TG:HDL ratio: 
HFHS diet vs STD diet, ** p = 0.0017 and HFHS diet + GRT vs STD diet, *** p = 0.0004. Liver enzymes ALT: 
HFHS diet + Afriplex GRT™ vs HFHS diet, # p = 0.0231 and AST: HFHS diet + Afriplex GRT™ vs HFHS diet, 






As expected, this equated to no significant differences in HOMA-IR values between the 
respective groups for both male and female rats, indicating the absence of an IR phenotype 
(Table 4.6 and 4.7). Previous studies using similar diets reported on increased serum insulin 
and HOMA-IR values after three and 12 months of feeding (Huisamen et al., 2011; 
Nduhirabandi et al., 2017; Roux, 2011; Smit et al., 2018). However, these studies also 
reported significantly increased FBG levels, which was not observed in the present study. 
During the establishment of a pre-diabetic model, the absence of increased FBG levels 
could be a result of hyperinsulinemia. However, as this is not the case in the present study, 
the contribution of environmental or genetic predispositions towards the lack of IR 
phenotype cannot be excluded. Supplementation with Afriplex GRT™ had no significant 
effect on insulin serum levels or IR in both male and female rodents, irrespective of the diet 
(Table 4.6 and 4.7). Although an increase in serum insulin concentrations and HOMA-IR 
values were observed for male rodents in the STD + Afriplex GRT™ and HFHS + Afriplex 
GRT™ groups when compared to their placebo receiving counterparts, this increase was 
not significant (Table 4.6). This was unexpected as both rooibos and its major polyphenolic 
compound, Aspalathin, have been implicated to play a role in insulin sensitization (Kawano 
et al., 2009; Mazibuko et al., 2013; Smit et al., 2018). 
 
Table 4.7. Summary of serum insulin, lipid profiling and liver enzyme analyses for female animals. 
 STD diet STD diet + GRT HFHS diet HFHS diet + GRT 
Insulin (pmol/L) 2.06 ± 0.27 2.36 ± 0.48 2.36 ± 0.23 2.77 ± 0.64 
HOMA-IR index 0.07 ± 0.01 0.06 ± 0.01 0.08 ± 0.00 0.10 ± 0.03 
Cholesterol     
 Total (mmol/L) 1.57 ± 0.08 1.49 ± 0.09 1.90 ± 0.12 1.98 ± 0.10* 
 LDL (mmol/L) 0.28 ± 0.01 0.28 ± 0.01 0.28 ± 0.01 0.28 ± 0.01 
 HDL (mmol/L) 1.12 ± 0.06 1.07 ± 0.07 1.19 ± 0.06 1.24 ± 0.06 
Triglycerides (mmol/L) 0.72 ± 0.12 0.77 ± 0.09 1.81 ± 0.29* 2.05 ± 0.22** 
TG:HDL ratio 1.73 ± 0.30 1.67 ± 0.20 3.48 ± 0.62 3.86 ± 0.48** 
Liver enzymes     
 ALT (IU/L) 41.30 ± 5.02 35.40 ± 2.93 24.80 ± 11.51* 28.80 ± 1.47 
 AST (IU/L) 80.10 ± 9.20 73.80 ± 4.74  56.30 ± 3.24 53.80 ± 4.98 
 AST:ALT ratio 1.86 ± 0.08 2.17 ± 0.15 2.33 ± 0.18 1.89 ± 0.17 
Values are expressed as mean ± SEM. Each group consists of n = 10 Wistar rats as independent biological 
replicates. Bold entries represent instances where a significant difference was observed. Total cholesterol: 
HFHS diet + Afriplex GRT™ vs STD diet, * p = 0.0375. Triglycerides: HFHS diet vs STD diet, * p = 0.0132 
and HFHS diet + Afriplex GRT™ vs STD diet, ** p = 0.0012. TG:HDL ratio: HFHS diet + GRT vs STD diet, ** 





Amongst the pathological mechanisms proposed to underline T2D and its associated 
cardiovascular complications, lipid toxicity has been frequently implicated (Duncan, 2011; 
Goldberg et al., 2012; Marnewick et al., 2011; Sharma et al., 2004). This study therefore 
utilised serum isolated from peripheral blood, to perform total lipid profiling in order to provide 
a comprehensive overview of CVD risk in male (Table 4.6) and female (Table 4.7) Wistar 
rats maintained on the obesogenic diet. While no differences were observed in total 
cholesterol, HDL and LDL levels for both male and female rats in the HFHS group, 
triglyceride levels were significantly elevated compared to their control counterparts (STD). 
Interestingly, this increase in triglycerides was maintained for male and female rats on the 
HFHS diet, in the experimental group receiving the extract (HFHS + Afriplex GRT™) when 
compared to those on the STD diet (Table 4.6 and 4.7). Additionally, total cholesterol was 
significantly increased for HFHS diet fed female rats receiving GRT treatment, compared to 
those in the STD group (Table 4.7). Interestingly, the ability of rodents to regulate cholesterol 
transport differs from humans due to the diminished activity of cholesteryl ester transport 
protein (CETP), an enzyme responsible for facilitating the transfer of cholesteryl ester from 
HDL to LDL and very-low-density lipoprotein (VLDL) (Russell & Proctor, 2006; Tsutsumi et 
al., 2001; Yin et al., 2011). The characteristically increased HDL and decreased LDL levels 
often observed in rats with a moderate disease phenotype could be explained by the 
diminished activity of CETP. However, this was not displayed in the present study in both 
male and female animals. 
Though the independent evaluation of HDL is indicative of the liver’s ability to produce 
beneficial HDL cholesterol, decreased HDL levels are often accompanied with an increase 
in triglyceride levels during a state of metabolic stress (Bang et al., 2008; Cordero et al., 
2008). Conversely, when transitioning towards a healthier metabolism, triglyceride levels 
generally tend to decrease while HDL cholesterol levels increase substantially. Given this 
apparent indirect proportionality observed between TG and HDL cholesterol levels, it is not 
unexpected that several studies have provided evidence supporting the use of the TG/HDL 
ratio as a powerful predictor of metabolic syndrome and numerous forms of CVD, such as 
atherosclerosis and coronary artery disease (CAD) (Boizel et al., 2000; Cordero & Alegria-
Ezquerra, 2009; da Luz et al., 2008; Kim-Domer et al., 2009; Nam et al., 2019). This ratio is 
specifically used as an estimator of LDL particle size, which is closely associated with 
vascular diseases and remains unfeasible to analyse in clinical practice (Boizel et al., 2000; 
Cordero et al., 2009; da Luz et al., 2008). Furthermore, normal HDL cholesterol levels in 





of this prediction ratio particularly useful. Evaluation of the TG/HDL ratio in this study 
revealed a significant increase in male rodents receiving the HFHS diet, and once more, this 
increase was maintained for male rats in the HFHS + Afriplex GRT™ group compared to 
rats in the control group (Table 4.6). Female rodents on the other hand, displayed a 
significant increase in TG/HDL ratio for rats in the HFHS group, receiving Afriplex GRT™ 
treatment only, when compared to those in the STD group (Table 4.7). However, despite 
the occurrence of significant increase, both male and female rats in the HFHS group 
displayed an TG/HDL ratio higher than 3.0, indicating atherogenic lipid profiles and 
significant IR and CVD risk (da Luz et al., 2008; Li et al., 2016).  
In addition to the assessment of metabolic marker concentrations, liver enzymes ALT and 
AST were also evaluated due to its association with an increased risk of developing T2DM 
and liver damage. While male rats maintained on the obesogenic diet (HFHS) displayed no 
differences in both ALT and AST levels (Table 4.6), female rats in the HFHS group 
demonstrated significantly reduced ALT levels when compared to the control counterparts 
(Table 4.7). Intriguingly, both ALT and AST levels were increased in the male rats on the 
HFHS diet + Afriplex GRT™ compared to those on the HFHS diet treated with the vehicle 
control (Table 4.6). While this suggests a possible damaging effect on the liver introduced 
by GRT administration, this phenomenon was not consistent in the assessment of other 







4.3.3 Histological assessments of cardiac tissue 
Microscopic structural changes in the nuclei of cardiomyocytes were visualised using H&E 
staining of heart tissue collected for both male (Figure 4.10) and female rats (Figure 4.11), 
at termination of the study. To this end, nuclei are visible in blue while the cytoplasm and 
myofibres are depicted in various degrees of pink/red (Wick, 2019). Overall, single, oval, 
prominent and centrally located nuclei in cardiomyocytes can be observed under the light 
microscope for animals in all the respective groups. Comparing the experimental group 
(HFHS) to the control animals (STD), no significant signs of injuries, including 
disarrangement of cardiac myofibres and deformation in size and shape of nuclei, could be 
identified for both male (Figure 4.10) and female (Figure 4.11) rodents. Treatment with 
Afriplex GRT™ in neither the STD diet fed or HFHS diet fed animals had any effect on 
cardiac muscle fibres or myocyte structure (Figure 4.10 and 4.11).  
 
 
Figure 4.10. Photomicrograph showing longitudinal sections of cardiac tissue from a representative male 
animal in each group. Where N: nuclei of cardiomyocytes, MF: myofibres under Haematoxylin and Eosin (H&E) 








Figure 4.11. Photomicrograph showing longitudinal sections of cardiac tissue from a representative female 
animal in each group. Where N: nuclei of cardiomyocytes, MF: myofibres under Haematoxylin and Eosin (H&E) 








Additionally, MT staining was used to observe the occurrence of connective tissue deposits 
with light microscopy. Contradictory to H&E staining, MT staining allows for the 
differentiation of morphological changes associated with injury and regeneration (Assaw, 
2012). Briefly, heart tissue obtained from male (Figure 4.12) and female rodents (Figure 
4.13) were stained with a combination of three dyes during which the cell nuclei can be 
observed in black, collagen fibre in blue while cardio myofibres and cytoplasm is stained in 
red (Assaw, 2012; Flint et al., 1975; Rieppo et al., 2019). Taken together, a similar amount 
of collagen fibres can be observed between animals in all the respective groups. No signs 
of reactive interstitial fibrosis in the form of connective tissue deposits can be observed in 
the animals fed the HFHS diet when compared to their control counterparts for both male 
(Figure 4.12) and female (Figure 4.13) Wistar rats. The administration of Afriplex GRT™ 
had no effect on the overall structure of cardio myofibres, collagen content, or connective 
tissue deposition (Figure 4.12 and 4.13).  
 
 
Figure 4.12. Photomicrograph showing longitudinal sections of cardiac tissue from a representative male 
animal in each group. Where N: nuclei of cardiomyocytes, MF: myofibres, and C: collagen under Masson’s 









Figure 4.13. Photomicrograph showing longitudinal sections of cardiac tissue from a representative female 
animal in each group. Where N: nuclei of cardiomyocytes, MF: myofibres, and C: collagen under Masson’s 









4.3.4 Histological assessment of liver tissue 
Similar to cardiac tissue, liver specimens from both male and female rodents were stained 
with H&E. Accordingly, the nuclei can therefore be visualised in dark blue, while the 
cytoplasm and extracellular matrix can be observed in different shades of pink. Under light 
microscopy, hepatic steatosis can be identified by either the presence of large fat droplets, 
together with dislocation of the nuclei to the periphery of the cell (macro vesicular steatosis); 
or small lipid droplets and the absence of nuclei displacement (micro vesicular steatosis). 
Male rats maintained on the STD diet, receiving treatment with either the placebo or the 
Afriplex GRT™ extract, displayed normal liver architecture and cellular integrity, 
characterised by the presence of centrally situated nuclei and intact cell walls (Figure 4.14). 
Complementary findings were observed for the female STD diet fed rats in both the 
experimental (STD + Afriplex GRT™) and control groups (Figure 4.15).  
 
 
Figure 4.14. Photomicrograph showing longitudinal sections of liver tissue from a representative male animal 
in each group. Where N: nuclei of hepatocytes, M: Macro vesicular dislocation of nuclei to the periphery, and 









Liver samples obtained from male rats in the HFHS group revealed increased signs of 
steatosis in 30% of the animals, when compared to their control counter parts (Figure 4.14). 
Overall, a substantial increase in lipid accumulation and minor indication of nuclei 
displacement can be observed in the HFHS animals. Micro vesicular complications were 
also detected in a similar percentage (30%) of female rats receiving the HFHS diet, 
compared to those maintained on the STD diet (Figure 4.15). Interestingly, although the 
administration of GRT for both male and female animals on the HFHS diet had no significant 
effect in reducing the degree of fat accumulation in the liver, it also did not exacerbate the 
existing signs of lipo-toxicity (Figure 4.14 and Figure 4.15).  
 
 
Figure 4.15. Photomicrograph showing longitudinal sections of liver tissue from a representative female 
animal in each group. Where N: nuclei of hepatocytes, M: Macro vesicular dislocation of nuclei to the periphery, 










While the use of male rats has been favoured in biomedical research predominantly due to 
intrinsic variabilities associated with female cyclical reproductive hormones, the relevance 
of including female animals in pre-clinical models cannot be overstated in the instance of 
metabolic syndromes. Furthermore, meta-analysis of population data revealed that the rate 
of obesity in South African women are amongst the highest worldwide and as this trajectory 
continues to escalate, so too does the prevalence of obesity-related diseases such as T2D 
and CVD, despite the protective effects of oestrogen prior to menopause (Damasceno, et 
al., 2007; Joubert et al., 2007; Kucharska-Newton et al., 2010; Ng et al., 2014; Zhou, 2017). 
Thus, the inclusion of female rodents in this model enables extrapolation of the current study 
findings to the clinic.  
This study demonstrated that high fat, high sugar diet feeding for a period of 9 months 
introduced increased food and water consumption, significant weight gain as well as 
elevated body mass indicative of a significant increase in RF weight in both male and female 
animals. Furthermore, the OGTTs performed demonstrated diminished glucose clearance 
ability of rodents maintained on the obesogenic diet, even in the absence of increased 
fasting serum insulin levels and HOMA-IR values. Taken together with the elevated 
triglyceride levels and TG/HDL ratio, these results confirm that the HFHS diet was 
successful in establishing a pre-clinical, risk prediction model of capable of being used to 
assess molecular mechanisms underlying CVD pathophysiology. Of interest to this study is 
the ability of the HFHS diet to introduce more prominent effects on the biometric parameters 
assessed in male Wistar rats, compared to females. Interestingly, GRT supplementation in 
the present study, had no significant beneficial or negative effect on the parameters 
assessed in both male and female animals. 
Histological findings of the cardiac tissue in the present study showed no disturbances in 
the structural organisation of cardiac tissues or inflammation indicated by myocardial injury. 
However, histological assessment of the liver tissue showed significant increase in lipid 
droplet accumulation and mild displacement of nuclei in lipocytes towards the cell’s 
periphery resulting from HFHS feeding. The absence of a structural phenotype in 
cardiomyocytes does not demolish the existing severe CVD risk demonstrated from serum 
biomarker analysis, further supporting the notion that the onset of CVD is acute and 
asymptomatic in nature. Although functional assessment of the heart was not conducted in 





demonstrated the ability of a diet high in fat and sugar to introduce functional abnormalities 
in the heart in the form of reduced ejection fraction and left ventricular dysfunction, even in 
the absence of molecular and structural differences (Smit, 2019; Johnson et al., 2020).  
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Chapter 5: Transcriptome profiling of diet-induced CVD in 
Wistar rats through high-throughput mRNA sequencing  
5.1 Introduction 
For years, cardiovascular disease (CVD) has been recognised as the primary cause of 
premature death, claiming more lives globally than all the different forms of cancer combined 
(GBD, 2018; WHO, 2021). Although scientific research has made significant contributions 
towards understanding CVDs, its diverse nature complicates the elucidation of the 
underlying mechanisms involved in disease development and progression (Kim et al., 2010; 
Ramos et al., 2016). Despite endorsed lifestyle interventions aimed at the prevention and 
treatment of CVD, the associated deaths continue to escalate at an alarming rate (Roth et 
al., 2017). Thus, driving the need for continued research towards understanding CVD 
pathophysiology to potentially aid in identifying novel therapeutic and prognostic targets 
(Chamnan et al., 2009; Ruwanpathirana et al, 2015; Voelter-Mahlknecht, 2016).  
The ability to accurately identify individuals at risk of developing a cardiac event allows for 
the implementation of early intervention therapies, while simultaneously increasing life 
expectancy (Bovet et al., 2015; Damen et al., 2016). Numerous mathematical prediction 
models such as Framingham, SCORE, and QRISK have been developed to estimate 
cardiovascular risk based on existing risk factors including diabetes, hypertension, and 
smoking (Antman et al., 2000; Chamnan et al., 2009; Frankel et al., 2008). Furthermore, 
molecular markers such c-reactive protein (CRP), glycated haemoglobin (HbA1c), N-
terminal pro b-type natriuretic peptide (NT-pro-BNP) and serum inflammation markers have 
been extensively used in the exploration of disease pathology (Arnold et al., 2016; Bay et 
al., 2003; Miller et al., 2007; Panagopoulou et al., 2015; Yang et al., 2016). However, as 
these tools remain limited in their early onset CVD prediction ability and differentiate 
between stages of disease progression, the identification of biomarkers and the molecular 
mechanism involved is strongly encouraged (Ge & Wang, 2012; Khot et al., 2003; van 
Holten et al., 2013).  
Moreover, the use of plant-derived polyphenols as an adjuvant to current pharmaceutical 
treatment options for CVD has gained considerable interest in the last decade (Bahadoran 
et al., 2013; Chellan et al., 2014; Gollucke et al., 2013; Pandey & Rizvi, 2009; Parks & 
Booyse, 2002). Of interest to the current study is the Afriplex GRT™ extract derived from 





health promoting and cardio-protective properties. Both in vitro and in vivo studies have 
demonstrated the ability of rooibos extracts and its polyphenolic compounds to beneficially 
impact functional cardiac injury as well as reduce metabolic risk factors associated with the 
development of diabetes induced cardiovascular complications (Dludla et al., 2014; Johnson 
et al., 2016; Kawano et al., 2009; Marnewick et al., 2011; Mazibuko et al., 2015; Muller et 
al., 2012; Pantsi et al., 2011; Smit, 2016; Ulicná et al., 2006). However, to characterise plant 
polyphenols such as the Afriplex GRT™ extract regarding CVD prevention, research 
providing a better understanding of the disease pathophysiology and the molecular 
mechanisms involved in the previously observed cardio-protective effects of Afriplex GRT™ 
is necessary.  
Recent advances in genomics and transcriptomics over the past decade have aided in 
identifying the biological and pathological processes involved in disease development. 
Several studies have utilised microarray profiling and next generation sequencing (NGS) 
technologies to screen and identify altered gene expression associated with CVD. 
Exploration of mRNA expression and the correlation with CVD not only adds to an 
understanding of CVD pathology, but also provides possible new therapeutic targets. This 
study aims to profile differential gene expression associated with the development of diet-
induced CVD using transcriptome sequencing and to ascertain whether treatment with the 







5.2 Materials and Methods 
5.2.1 Study design and sample selection 
A total of 30 male and 30 female Wistar rat (Rattus norvegicuss) cardiac tissue samples 
from the animal study described in Chapter 3 were used in the present study. The sample 
selection criteria were based on the above-mentioned objectives and involved the inclusion 
of both male and female rats from three groups namely: 1) the control group which received 
a standard (STD) maintenance rodent diet (n=10), 2) the high fat, high sugar (HFHS) group 
receiving a cafeteria diet (n=10), and 3) the HFHS group receiving treatment with the Afriplex 
GRT™ extract (n=10).  
 
5.2.2 RNA extraction, assessment, and pooling 
Total RNA was isolated from the cardiac tissues stored in RNAlater using the RNeasy® 
Fibrous Tissue Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions and treated with the TURBO DNA-free kit (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA) to eliminate genomic DNA contamination. Briefly, approximately 25 – 
30 mg of tissue was submerged in a lysis buffer supplemented with β-mercaptoethanol (β-
ME) and homogenised using a TissueLyser (Qiagen, Hilden, Germany). The resulting 
lysates were then subjected to enzymatic digestion using proteinase K to facilitate the 
removal of contractile proteins, connective tissue, and collagen. Following centrifugation, 
the supernatant was attained and combined with 0.5 volumes absolute ethanol to enable 
the precipitation of RNA. The solution was then subjected to a series of column-based wash 
steps, prior to elution of RNA with 60 µL nuclease-free water as per the manufacturer's 
guidelines. The yield and purity of the RNA was determined using fluorometry (Qubit™ RNA 
HS Assay Kit, Thermo Fisher Scientific, Waltham, MA, USA) and spectrophotometry 
(Nanodrop, Thermo Fisher Scientific, Waltham, MA, USA), while the Agilent 2100 
bioanalyser (Agilent Technologies, CA, USA) was used to assess the RNA integrity. Upon 
completion of quality control (QC) assessment, highly intact RNA from individual samples 
with a RIN value ≥ 7 were pooled in duplicate to generate 5 biological replicates of each 
group (Figure 5.1). To this end each pooled sample consisted of an equal amount of DNase 







Figure 5.1. RNA pooling of A) male (n = 30) and B) female (n = 30) samples to generate five biological 





5.2.3 RNA library preparation and sequencing 
The pooled RNA samples (200 ng) were subjected to magnetic bead-based mRNA 
enrichment using the Dynabeads™ mRNA Purification Kit (Invitrogen™, Thermo Fisher 
Scientific, Waltham, MA, USA), according to the protocol described in the MGIEasy RNA 
Library Prep Set User Manual prior to proceeding with library construction. Library 
preparation was performed with the entire component of mRNA for each sample using the 
MGIEasy RNA Library Prep Kit (MGI, Shenzhen, China), according to the manufacturer’s 
instructions. Concisely, mRNA was fragmented to obtain 250 base pair (bp) inserts using a 
highly concentrated buffer at 87°C and subsequently reverse transcribed to generate copy 
DNA (cDNA) products. The cDNA product of each sample was purified using MGIEasy DNA 
Clean Beads (MGI, Shenzhen, China) and subjected to an end-repair and a-tailing (ERAT) 
reaction. The end-repaired products were ligated to 10 X diluted MGIEasy DNA Adapters 
as per the manufacturer’s guidelines, purified using the previously described magnetic 
beads, and amplified. Following purification, the PCR products were quantified with 
fluorometry using the Qubit dsDNA HS Assay kit according to the manufacturer’s 
instructions. Furthermore, the fragment size distribution of purified PCR products was 
assessed using gel electrophoresis.  
To allow for the generation of a minimum of 30 million reads per transcriptome, samples 
were combined in an equal molar manner to allow for the pooling of eight uniquely labelled 
samples per lane. Single-stranded circular DNA libraries were generated from 1 pmol of 
pooled PCR products, followed by purification and quantification with MGIEasy DNA Clean 
Beads and the ssDNA HS Assay kit (Qubit), respectively. The MGILD-200 automatic loader 
was used to load pooled libraries onto the MGISEQ-2000 FCL flow cells. Massively parallel 
sequencing was performed using DNA nanoball-based technology on the MGISEQ-2000 
(BGI, Shenzhen China) with the appropriate reagents supplied in the MGISeq-2000RS High-
Throughput Sequencing Kit. A paired-end sequencing strategy was employed, with a read 






5.2.4 Bioinformatic analysis 
 
Figure 5.2. Schematic workflow describing the bioinformatic pipeline used for the analysis of RNA sequencing data. The workflow steps until the completion of “gene 
count estimation” was implemented for the 30 sequence datasets individually, while differential expression (DEG) analysis was performed separately for male (n = 15) 






The raw transcriptome sequence reads were obtained from the MGISEQ-2000 in the 
universal FASTQ format and processed using the computational infrastructure available at 
the Centre for High Performance Computing (CHPC). Measurements of quality control and 
sample complexity were assessed and visualised using FastQC version 0.11.5 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Read files were processed 
individually to identify and remove possible unwanted contaminants, while retaining high 
quality bases to improve downstream analyses. In brief, hts_SeqScreener from the 
HTStream suite version 1.3.1 was used to count the level of ribosomal RNA (rRNA) present 
in the samples using default parameters and the collection of all rRNA FASTA files for Rattus 
norvegicus available on NCBI (Street, 2017). Subsequently, Trimmomatic version 0.36 was 
used to remove MGI adapter sequences, bases with a Phred quality score below Q20 from 
the 5' end of the sequence reads using a sliding window of 3 nucleotides (nts), as well as 
reads with a minimum length less than 20 nts (Bolger et al., 2014). Following completion of 
all pre-processing steps, comparisons between trimmed and raw read files were conducted 
in the context of the previously described QC metrices using FastQC.  
 
5.2.4.2 Alignment and count estimation 
Gene- or transcript-level counts were generated as a proxy for gene expression by 
employing a conventional alignment-based strategy. To this end, “cleaned” reads from each 
pooled sample were aligned to the Rattus norvegicus reference genome version 6.0 
(ftp://ftp.ensembl.org/pub/release-
100/fasta/rattus_norvegicus/dna/Rattus_norvegicus.Rnor_6.0.dna.toplevel.fa.gz) using the 
“splice-aware” aligner, STAR version 2.5.3a (Dobin et al., 2013). The latter was selected 
based on its ability to compensate for aligning intron-spanning reads. The alignment was 
further coordinated with the corresponding reference annotation 
(ftp://ftp.ensembl.org/pub/release-
100/gtf/rattus_norvegicus/Rattus_norvegicus.Rnor_6.0.100.gtf.gz) and executed using 
default parameters, with the addition of the --quantmode GeneCounts function in order to 
compute the number of reads associated with host genes. Additionally, the summary 
statistics obtained upon completion of alignment steps were assessed using SAMtools 
version 1.10 and collated with MultiQC version 1.10.1 for quality assurance purposes (Li et 





5.2.4.3 Differential expression (DE) analysis  
Differential gene expression analysis has been shown to be predominantly influenced by 
the methodology of identifying differentially expressed genes (DEGs) as opposed to the 
adopted method of mapping or quantification of reads (Costa Silva et al., 2017). In light of 
this, DE analysis was performed in R version 4.0.3, in combination with a variety of add-on 
packages from Bioconductor (Figure 5.4) (Gentleman et al., 2004; R Core Team, 2020). 
Briefly, raw counts data were adjusted for differences in sequencing depth between libraries 
using the calcNormFactors function from the edgeR package. The latter employs a weighted 
trimmed means of M-values (TMM) scaling method for normalisation (Robinson et al., 2010; 
McCarthy et al., 2012). Following the removal of genes with a normalised read count below 
3 counts per million (CPM), log transformed normalised data (log2 CPM) and mean-variance 
estimates were obtained using the voom function from the limma package, to determine the 
weight of each observation made initially by a linear model (Ritchie et al., 2015).  
The lmFIT function from the previously mentioned package, was then used to fit a linear 
model to the voom transformed data using the weighted least squares (WLS) for each gene. 
The log2 fold changes for all the genes in the reference annotation were obtained as 
contrasts of the fitted models between two distinct comparisons for male and female animals 
respectively namely: 1) the HFHS diet fed group versus the STD diet fed control group and 
2) the HFHS group receiving treatment with Afriplex GRT™ versus the HFHS diet fed group. 
Due to the large number of genes being analysed simultaneously, Empirical Bayes (EB) 
smoothing of standard errors, as well as multiple testing correction using the False 
Discovery Rate (FDR) method were applied (Benjamini & Hochberg, 1995). In all instances, 
a gene was considered to be significantly differentially expressed between the respective 
groups if it had an adjusted p-value ≤ 0.05. The information of significantly DEGs resulting 
from each comparison, for male and female animals respectively, was exported and used 





5.2.4.4 Functional annotation 
To perform biological functional enrichment of the DEGs, the R Bioconductor tool was used 
to identify enriched gene ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes 
(KEGG) pathways (Ashburner et al., 2000; Kanehisa & Goto, 2000; Yu et al., 2012). Briefly, 
GO terms were retrieved from the Bioconductor database org.Rn.eg.db and assigned to up- 
and down-regulated DEGs obtained from the previously described comparisons using the 
topGO package. The Kolmogorov-Smirnov test was used to identify significantly enriched 
terms due to its application of a weighted algorithm and subsequent usefulness in datasets 
with varying number of significant genes. In all instances, an adjusted probability value of 
less than, or equal to 0.05 was deemed biologically significant. Significant GO enrichments 
identified in up- and down-regulated mRNAs were categorised in to the three controlled 
vocabularies namely: biological processes (BP), cellular components (CC) and molecular 
function (MF). Furthermore, KEGG pathway enrichment testing was conducted for the 
identified DEGs using the KEGGREST package and subsequent rat specific (rno) pathway 
assignments. Significant pathways were identified using the Wilcoxon rank-sum test, which 
is the nonparametric analogue of the two-sample t-test.  
 
5.3 Results and Discussion 
5.3.1 RNA isolation and library preparation 
The isolation of total RNA from male (n = 30) and female (n = 30) cardiac tissue resulted in 
concentrations ranging from 336 to 1218 and 324 to 1302 ng/µL, respectively. Further 
assessment of the RNA quality using a bioanalyzer computed average RIN values of 9.2 
and 9.6 for RNA isolated from male and female samples. Both male and female samples 
yielded RNA of sufficient quantity (> 200 ng) and quality (RIN value > 7), with no significant 
differences observed between samples from different genders or treatment groups. 
Following the successful completion of library preparation, 15 male and 15 female single 
stranded (ss), circular DNA libraries with an average yield of 6.6 and 5.7 pmol, respectively, 
were utilised for paired-end 100 bp (PE100) sequencing on the MGISEQ-2000. All the 
samples passed in-house quality control measurements throughout the library preparation 





5.3.2 Transcriptome sequencing and pre-processing 
The raw datasets generated through mRNA sequencing (2 x 100 nts) on the MGISEQ-2000 
platform consisted of between 86.31 and 92.64 million read pairs for male libraries while 
female libraries contained between 75.97 and 82.70 million read pairs. Overall, 
approximately 30.66 gigabases (GB) of raw data was obtained per sample, suggesting that 
the pooling strategy employed (i.e., eight per lane) was effective. Initial QC assessment and 
visualisation with FastQC illustrated bases of a Phred quality score > 20 across the read 
length (100 bp), over-represented kmers and an unequal proportion of bases at the 5’ end 
of the reads. The latter is a common occurrence with RNA sequencing experiments that 
utilise random primers during the library preparation protocol, such as the one employed in 
this study (Hansen et al., 2010). Following pre-processing, an average of 0.30% and 10% 
of the total reads were removed because of over-represented kmers and rRNA 
contamination, respectively.  
Additional QC metrices displayed in Table 5.1 and 5.2, revealed that all processed samples 
possessed reads with exceptionally high-quality bases, with approximately 91.40% of 
sequence bases displaying a quality score above 30 (Figure 5.3). Furthermore, the 
considerably low amount of read pairs (between 8.96 and 11.32%) lost during pre-
processing steps can be ascribed to efficacious library preparations and subsequent 
sequencing. In the case of DEG analysis, as this study intends to explore, the influence of 
sufficient biological replicates and read depth (number of reads per samples), outweighs 
that of genome coverage (ENCODE, 2017; Illumina, 2020). Overall, an average of 
approximately 59.66 million “cleaned” read pairs per sample were retained post processing, 
which is in line with majority of published whole transcriptomic experiments and the 






Table 5.1. Read statistics of male sample datasets following pre-processing. 
Group Sample Clean reads Clean bases %GC content Q20% Q30% 
STD 
M1 61 734 249 12 346 849 800 48 98,13 91,85 
M2 64 067 075 12 813 415 000 48 98,09 91,68 
M3 57 597 622 11 519 524 400 47 98,00 91,39 
M4 52 313 659 10 462 731 800 48 98,07 91,65 
M5 56 714 398 11 342 879 600 48 97,54 89,68 
HFHS 
M6 63 696 717 12 739 343 400 47 97,31 89,13 
M7 70 993 790 14 198 758 000 47 97,96 91,15 
M8 66 084 258 13 216 851 600 47 97,93 91,08 
M9 62 306 822 12 461 364 400 47 97,77 90,99 
M10 53 761 537 10 752 307 400 47 97,78 91,11 
HFHS + Afriplex GRT™ 
M11 61 656 846 12 331 369 200 47 97,82 91,21 
M12 58 607 535 11 721 507 000 47 96,45 89,37 
M13 66 246 502 13 249 300 400 48 97,75 90,93 
M14 53 072 740 10 614 548 000 48 97,27 89,55 
M15 61 495 619 12 299 123 800 47 96,79 89,12 
 
Table 5.2. Read statistics of female sample datasets following pre-processing. 
Group Sample Clean reads Clean Bases %GC content Q20% Q30% 
STD 
F1 59 141 630 11 828 326 000 47 98,07 92,12 
F2 57 843 581 11 568 716 200 48 98,00 91,85 
F3 58 139 072 11 627 814 400 47 98,26 92,85 
F4 56 085 888 11 217 177 600 47 98,13 92,36 
F5 61 813 339 12 362 667 800 47 98,05 91,99 
HFHS 
F6 55 970 378 11 194 075 600 46 97,36 89,86 
F7 58 521 066 11 704 213 200 47 98,01 91,86 
F8 57 427 629 11 485 525 800 47 98,21 92,65 
F9 52 614 213 10 522 842 600 47 98,24 92,44 
F10 57 440 705 11 488 141 000 47 98,29 92,64 
HFHS + Afriplex GRT™ 
F11 53 357 559 10 671 511 800 47 98,28 92,60 
F12 57 062 909 11 412 581 800 47 98,33 92,82 
F13 62 704 044 12 540 808 800 47 98,38 92,92 
F14 65 718 748 13 143 749 600 47 97,66 90,57 






Figure 5.3. Per base sequence quality scores obtained from FastQC for a representative sample of A) male 
and B) female processed reads. The BoxWhisker plot represents the range of Phred quality score for each 
base across the read length. Red line: median value; yellow box: inter-quartile range (25-75%); upper and 
lower whiskers: 10% and 90% points; blue line: mean quality. A consistent distribution of quality scores was 
observed for all male and female sequence samples. The higher the quality score, the more reliable the base 





5.3.3 Alignment and gene expression comparison 
Upon completion of alignment of the trimmed and filtered reads to the Rattus norvegicus 
(Rnor6.0) reference using STAR, the resulting alignments was assessed with the bamstats 
command in SAMtools. Overall, an average of 85.41% of the “cleaned” reads mapped 
uniquely to the reference genome across all the samples, with approximately 9.28 to 15.51% 
mapping to multiple loci (Table 5.3 and Table 5.4). Furthermore, an average insert size of 
253 bp and 261 bp was obtained for male and female libraries, respectively. The 
assessment of quality metrices of the individual sample alignments revealed no significant 
differences between or within the different experimental groups for both male and female 
datasets, therefore allowing for the incorporation of all sample datasets in downstream 
analyses. 
 
Table 5.3. Summary of mapping statistics obtained following the alignment of processed male datasets to the 
Rattus norvegicus (Rnor6.0) reference genome. 







M1 87.28 9.94 0.44 
M2 86.17 10.97 0.45 
M3 87.56 9.50 0.47 
M4 87.36 9.80 0.45 
M5 87.04 9.28 0.52 
HFHS 
M6 86.75 10.49 0.52 
M7 85.72 11.28 0.47 
M8 86.66 10.36 0.48 
M9 86.39 10.50 0.51 
M10 86.37 10.51 0.52 
HFHS + Afriplex GRT™ 
M11 86.31 10.83 0.53 
M12 82.58 11.68 0.50 
M13 82.94 13.65 0.54 
M14 82.60 14.21 0.54 





Table 5.4. Summary of mapping statistics obtained following the alignment of processed female datasets to 
the Rattus norvegicus (Rnor6.0) reference genome.  







F1 86.27 10.61 0.49 
F2 80.98 15.51 0.50 
F3 83.62 13.38 0.50 
F4 85.73 11.35 0.50 
F5 85.07 11.78 0.50 
HFHS 
F6 83.84 13.23 0.57 
F7 86.56 10.55 0.50 
F8 86.05 11.21 0.50 
F9 85.11 11.87 0.45 
F10 84.05 13.12 0.46 
HFHS + Afriplex GRT™ 
F11 84.24 12.73 0.48 
F12 84.39 12.74 0.46 
F13 85.67 11.52 0.46 
F14 86.52 10.80 0.49 
F15 86.26 10.95 0.47 
 
Raw count data for all genes was extracted from the alignment outputs and used as a 
measure of gene expression. To determine the appropriate cut-off criteria to be applied for 
the removal of lowly expressed genes, the transcripts were filtered in terms of counts per 
million (CPM) values ranging from 1 to 3 (Figure 5.4). Among the 32 883 transcripts 
annotated in the Rattus norvegicus (Rnor6.0) assembly, 32.09% of the total transcripts were 
covered at a CPM of ≥ 3 in the male datasets, and 32.08% in the female datasets (Figure 
5.4). As no significant differences were observed between the number of transcripts covered 
in male and female datasets at the different CPM thresholds, the more stringent bottom 
threshold value of 3 was deemed biologically significant and the genes meeting this criterion 
were included in DEG analysis. Additionally, as gender is considered a binary characteristic 
in the present study, genes located on the Y chromosomes were excluded to provide a more 






Figure 5.4. Transcript abundance levels covered at a range of 1 to 3 counts per million (CPM) for male and 
female samples. No significant variation was observed in the number of genes remaining after CPM filtering 
between male and female samples, irrespective of the cut-off value. Therefore, lowly expressed genes with a 
normalised read count < 3 CPM were excluded from downstream differential expression analysis.  
 
Normalised read counts (log2CPM) of the filtered datasets were used to identify differences 
in transcript levels between the HFHS group and the STD control group, as well as the 
HFHS + Afriplex GRT™ group and the HFHS group. Initial visualisation of the characteristics 
between biological replicates of the different groups was conducted using the top 1 000 
genes with the highest variation (mean-variance as determined by the voom function) across 
male and female samples, independently. Hierarchical clustering revealed distinct 
expression profiles between the HFHS group and the STD control for both male (Figure 5.5) 
and female datasets (Figure 5.6), with all biological replicates correctly classified to the 
respective groups. While previous pre-clinical and clinical studies have been able to 
demonstrate expression profiles unique to CVD, it is promising to be able to discriminate 
between the present animals in the absence of an extreme disease phenotype (Civelek et 
al., 2011; Heidecker et al., 2008; Liao et al., 2019; Patino et al., 2005; Seo et al., 2004). 
Furthermore, administration of Afriplex GRT™ did not result in a third, distinct expression 
profile, with biological replicates clustering closely together with those in the HFHS group 







Figure 5.5. Heatmap illustrating normalised expression (log2CPM) of the 1 000 most variable genes across 
male mRNA sequencing datasets. The heatmap was constructed using the commonly applied red and blue 
colour scheme, where over expression is indicated in varying shades of blue and decreased expression in red. 
Hierarchical clustering demonstrated that the HFHS and STD biological replicates were categorised into two 
distinct groups based on mRNA expression. Biological replicates in the HFHS + Afriplex GRT™ group 







Figure 5.6. Heatmap illustrating normalised expression (log2CPM) of the 1 000 most variable genes across 
female mRNA sequencing datasets. The heatmap was constructed using the commonly applied red and blue 
colour scheme, where over expression is indicated in varying shades of blue and decreased expression in red. 
Hierarchical clustering demonstrated that the HFHS and STD biological replicates were categorised into two 
distinct groups based on mRNA expression. Biological replicates in the HFHS + Afriplex GRT™ group 






Employing the limma pipeline, including subsequent contrasts and statistical analyses 
described previously, a total of 571 genes were differentially expressed (FDR ≤ 0.05) in 
HFHS diet fed male rats compared to those fed the STD diet. Amongst these, 238 genes 
were upregulated, and the remaining 333 genes were downregulated in the HFHS group 
(Supplementary Data – Table S1). Conversely, 414 differentially expressed genes (DEGs) 
were identified in the HFHS fed female rats, of which 252 genes were over expressed and 
162 genes under expressed in the HFHS group (Supplementary Data – Table S2). 
Evaluation of the DEGs identified in the HFHS group using an in-house developed python 
script revealed that 35 DEGs were shared amongst male and female animals maintained 
on the HFHS diet (Figure 5.7). Furthermore, contrast comparisons between the HFHS + 
Afriplex GRT™ and the HFHS group revealed 120 and 337 DEGs in male and female 
animals receiving treatment with the Afriplex GRT™ extract, respectively (Supplementary 
Data – Table S3 and S4). Interestingly, no common DEGs were observed between male 
and female animals in the HFHS + Afriplex GRT™ group.  
 
 
Figure 5.7. Differentially expressed genes (DEGs) in HFHS diet fed animals compared to those fed the STD 
diet. All DEGs had an adjusted p-value of ≤ 0.05 (with an FDR ≤ 0.05) following the bioinformatical analyses. 
A total of 35 DEGs were shared between male and female animals of which 21 were over expressed and 14 






5.3.4 Functional annotation of DEGs associated with HFHS diet 
To gain further insight into the biological function of the identified DEGs, gene ontology (GO) 
and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analyses 
were performed. To this end, up- and down-regulated mRNA obtained from the separate 
comparisons for both male and female animals were categorised into the three controlled 
GO vocabularies namely: biological processes (BP), cellular components (CC) and 
molecular function (MF) using the R/Bioconductor package topGO. Overall, GO terms were 
assigned to 508 of the 571 DEGs in the HFHS diet fed male Wistar rats. The major GO 
categories in upregulated mRNA included gene products involved in the regulation of 
transcription by RNA polymerase II and positive regulation of gene expression (biological 
processes: GO:0006357; GO:0010628), gene products localised in nuclear chromatin and 
the membrane raft (cellular component: GO:0000790; GO:0045121), as well as gene 
products involved in ATP- and transcription regulatory region sequence-specific DNA 
binding (molecular function: GO:0005524; GO:0000976) (Figure 5.8). On the other hand, 
the top GO enrichment terms in downregulated mRNA were gene products involved in 
protein localisation and vesicle mediated transport (biological processes: GO:0045184; 
GO:0016192), gene products localised in the protein containing complex and the perinuclear 
region of cytoplasm (cellular component: GO:0032991; GO:0048471), as well as gene 
products involved in ATP- and kinase binding (molecular functions: GO:0005524; 
GO:0019900) (Figure 5.9). Aside from the processes required for primary cellular function, 
GO enrichment analysis revealed the involvement of DEGs in cardiac muscle contraction, 
cardiac myofibril assembly, response to oxidative stress, inflammatory response and 
autophagy of the mitochondrion is of particular interest for this study (Figure 5.8 and 5.9). 
Furthermore, the top KEGG pathways enriched in up- and downregulated mRNAs included 
HIF-1 signalling pathway, adrenergic signalling in cardiomyocytes, insulin signalling 
pathway, MAPK signalling pathway, mitophagy, cytokine-cytokine receptor interaction and 
TGF-beta signalling pathway (Figure 5.10). Taken together these results illustrate the 
involvement of DEGs associated with a HFHS diet in molecular mechanisms and biological 








Figure 5.8. Gene ontology (GO) enrichment analysis of upregulated differentially expressed genes (DEGs) in high fat, high sugar (HFHS) diet fed male Wistar rats. 







Figure 5.9. Gene ontology (GO) enrichment analysis of downregulated differentially expressed genes (DEGs) in high fat, high sugar (HFHS) diet fed male Wistar 







Figure 5.10. Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analysis of differentially expressed genes (DEGs) in high fat, high sugar 






Of the 414 DEGs identified in female HFHS fed Wistar rats, 369 were annotated following 
GO enrichment analysis. The top GO terms assigned to upregulated mRNA included 
participation in regulation of cell population proliferation and chaperone-mediated protein 
folding (biological processes: GO:0042127; GO:0061077), gene products that are intrinsic 
components of the plasma membrane and dendrite (cellular component: GO:0031226; 
GO:0030425), as well as those involved in GTP binding and GTPase activity (molecular 
functions: GO:0005525; GO:0003924) (Figure 5.11). Moreover, the leading GO categories 
in downregulated mRNA included gene products implicated in the positive regulation of 
transcription, DNA-templated and regulation of cell population proliferation (biological 
processes: GO:0045893; GO:0042127), genes products that are localised in the 
nucleoplasm and cell junction (cellular component: GO:0005654; GO:0030054), as well as 
gene products involved in enzyme- and RNA polymerase II cis-regulatory region sequence-
specific DNA binding (molecular functions: GO:0019899; GO:0000978) (Figure 5.12). Of 
particular interest to the current study, was the involvement of DEGs in response to insulin, 
response to glucose and Notch signalling, especially in downregulated mRNA (Figure 5.10). 
Additionally, pathway enrichment analysis revealed the major KEGG pathways involved 
were the MAPK signalling pathway, B cell receptor signalling pathway, hypertrophic 
cardiomyopathy, and Adrenergic signalling in cardiomyocytes, exclusively in down-
regulated DEGs (Figure 13). Interestingly both MAPK signalling pathway and adrenergic 
signalling in cardiomyocytes were also enriched in upregulated mRNAs in HFHS males 
(Figure 5.9). Collectively, these results demonstrate the involvement of DEGs identified in 
HFHS diet-fed female rats, in the underlying mechanisms known as risk factors for CVD 
pathophysiology.  
In order to potentially elude the possible role of observed transcriptomic interactions and 
CVD risk or pathophysiology, significant (FDR ≤ 0.05) GO terms were selected and 
discussed further. Expectedly, majority of the significant GO terms linked to CVD were 
identified in the HFHS males following FDR adjustment, with no significant disease related 







Figure 5.11. Gene ontology (GO) enrichment analysis of upregulated differentially expressed genes (DEGs) in high fat, high sugar (HFHS) diet fed female Wistar 







Figure 5.12. Gene ontology (GO) enrichment analysis of downregulated differentially expressed genes (DEGs) in high fat, high sugar (HFHS) diet fed female Wistar 







Figure 5.13. Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analysis of differentially expressed genes (DEGs) in high fat, high sugar 






5.3.4.1 DEGs involved in cardiac muscle contraction and myofibril assembly 
The heart continuously needs to adapt to the body’s demands brought on by either 
physiological or pathological stimuli. These adaptations often include vascular modifications 
associated with cardiac remodelling such as myofibrillar assembly, hypertrophy, 
myopathies, and fibrosis (Machackova et al., 2004; Small et al., 2010; Xiong et al., 2019). 
Although these changes can be acutely beneficial under certain circumstances, they often 
contribute to altered contractile function over time. In this study, 11 DEGs identified in the 
HFHS diet fed males were associated with cardiac muscle contraction and myofibril 
assembly, as is evident from the GO enrichment results (Figure 5.8). In depth analysis 
revealed that two of the DEGs significantly increased following HFHS diet feeding, encoded 
transcription factors (TFs) that drive fetal programming in the heart namely GATA-4 and 
serum response factor (SRF) (Dirkx et al., 2013; Harvey & Leinwand, 2011). The role of 
GATA TFs in the developing heart cannot be understated, with GATA-4 being an important 
regulator of hypertrophic cardiac gene transcription (Liang & Molkentin, 2002; Pikkarainen 
et al., 2004). While overexpression of GATA-4 has been known to increase cardiomyocyte 
differentiation, inhibition of GATA-4 triggers extensive apoptosis and even embryonic fatality 
(Crispino et al., 2001; Garg et al., 2003; Konhilas & Leinwand, 2006; Kuo et al., 1997; 
Latinkic et al., 2003; Pikkarainen et al., 2003).  
The second TF, SRF is widely expressed and unlike majority of TFs, has no known paralogs 
and therefore relies on the use of coactivators to direct cell specific gene expression profiles 
(Miano et al., 2004; Wang et al., 2004). The importance of SRF is highlighted by its ability 
to bind the CArG DNA consensus sequence which numerous cardiac muscle genes require 
for accurate expression (Konhilas & Leinwand, 2006; Reecy et al., 1998; Sprenkle et al., 
1995). Studies involving knockout models of the SRF gene have demonstrated that it is not 
only essential for heart development but also cardiac homeostasis (Dirkx et al., 2013; 
Parlakian et al., 2004; Parlakian et al., 2015). Furthermore, the cardiac overexpression of 
SRF, prevents DNA binding and has been linked to several CVDs in response to cytoskeletal 
stress (Angelini et al., 2015; Xiong et al., 2019; Zhang et al., 2001). As both the abolition 
and overexpression of SRF have been linked to the pathological development of dilated 
cardiomyopathy and hypertrophy, the heart is required to maintain sufficient balance of SRF 
levels during developmental stages and adult life. The activation of SRF is often stimulated 
by the same signalling cascades which induce GATA-4 activation, allowing the TFs to 
interact with each other, possibly cooperatively, to bind DNA of interest (Lin et al., 2002; 





both GATA-4 and SRF are activated through hypertrophic catalysts induced by high fat diet, 
they often require the simultaneous activation of cofactors in order to affect the expression 
of their dependent cardiac genes. One such cofactor capable of conveying signals to the 
rest of the genome, myocardin (MYOCD), has been shown to be a transcriptional coactivator 
of SRF and interestingly, MYOCD expression is also regulated bi-directionally through 
GATA-4 (Figure 5.14) (Aravind & Koonin, 2000; Chen et al., 2002; Oh et al., 2004; Wang et 
al., 2001). It can therefore be hypothesised that MYOCD causes the recurrence of fetal 
cardiac genes under regulation of GATA-4 and SRF in the pathological heart. However, 
since the role of MYOCD in the adult heart has not been fully elucidated, the importance of 
alternative regulatory mechanisms such as posttranslational modifications of the previously 
mentioned TFs and cofactor become apparent in target cardiac gene activation (Li et al., 
2003). Furthermore, the upregulation of GATA-4 and SRF in the absence of a severe 
disease phenotype and structural alterations in the heart, as shown in this study, supports 
the asymptomatic nature of CVD onset. 
Amongst the many SRF target genes, α-cardiac actin (ACTC1), the most abundant isoform 
in the cytoskeleton of mature cardiomyocytes, was also significantly increased in the HFHS 
diet fed males in the current study (Angelini et al., 2020; Boutilier et al., 2017; Ilkovski et al., 
2005; Suurmeijer et al., 2003). Studies involving knockout mouse models revealed that 
disruption of SRF results in drastically decreased expression of ACTC1, ultimately leading 
to severe heart defects (Parlakian et al., 2005; Touvron et al., 2012). Moreover, ACTC1 loss 
of function mutations have been associated with dilated cardiomyopathy and reduced 
protein levels have also been detected during heart failure (Daehmlow et al., 2002; Dirkx et 
al., 2013; Mundia et al., 2012). Although diminished ACTC1 plays a key role during 
cardiomyogenesis, studies have shown that overexpression of ACTC1 mRNA can be 
induced following pathology, especially during regeneration of myofibers (Angelini et al., 
2020; Jiang et al., 2010). Of particular interest to this study is the existing evidence 
supporting modulation of ACTC1 regulatory mechanisms through diet, as well as the 
correlation of variable ACTC1 expression with promoter methylation (Boutilier et al., 2017; 
Wang et al., 2016). Taken together the current study supports the conception of HFHS diet 
acting as a pathological stimulus with the ability to alter the expression of cardiac genes 
such as ACTC1 through the combinatory action of TFs (SRF and GATA-4) and coactivators 
(such as MYOCD), ultimately affecting hypertrophic related functional pathways. Correlation 





especially ACTC1, and differential DNA methylation in Chapter 6 will therefore aid further 
insight into the underlying mechanisms involved.  
 
 
Figure 5.14. Schematic diagram of GATA-4- and serum response factor (SRF) dependent cardiac gene 
regulation adapted from Konhilas & Leinwand, 2006. A signalling cascade that reacts on transcriptional 
regulators of GATA-4 and SRF, is activated through hypertrophic stimuli in the heart. GSK-3β, glycogen 
synthase kinase 3β; HDAC5, histone deacetylase 5; MRTF, myocardin-related transcription factor; MEF2, 





5.3.4.2 DEGs involved in response to oxidative stress  
One of the most widely studied pathological mechanisms underlying the development of 
CVDs is increased oxidative stress. Oxidative stress associated with type 2 diabetes mellitus 
(T2DM) plays a significant role in CVD disease pathogenesis (Guldiken et al, 2009; Lapolla 
et al., 2007; Senoner & Dichtl, 2019; Van Campenhout et al., 2006). While basal levels of 
reactive oxygen species (ROS) are undoubtedly necessary for cellular function, excessive 
amounts have damaging effects on multiple cellular components and may eventually lead 
to mitochondrial dysfunction (Finkel, 2011; Holmström et al., 2014; Padmalayam, 2012). 
Several studies have linked abnormal ROS production to the induction of hypertrophic 
signalling and pro-inflammatory responses, consequently augmenting cardiac remodelling 
and myocardial apoptosis (Dludla et al., 2014; Ingwall, 2009; Kim & Kang, 2010; Soliman et 
al., 2008; Tahhan et al., 2017). These ROS mediated mechanisms have particularly been 
highlighted in the instance of diet induced metabolic syndrome due to the chronic 
hypoglycaemia and altered lipid content conditions (Boudina & Abel, 2010; Dludla et al., 
2014; Ingwall, 2009; Joseph et al., 2014; Kattoor et al., 2017; Kuroda et al., 2010; Mapanga 
& Essop; 2016; Senoner & Dichtl, 2019; Tahhan et al., 2017; Tarquini et al., 2011; Zhou et 
al., 2018). Additionally, ROS have also been associated with the promotion of 
atherosclerotic plaque formation, hypertension, and heart failure (Baradaran et al., 2014; 
Kattoor et al., 2017; Lapolla et al., 2007; Tsutsui et al., 2011).  
Nonetheless, the body is equipped with an endogenous antioxidant defence network, 
comprised of both enzymatic and non-enzymatic compounds with the potential to 
circumvent free radical damage (Balaban et al., 2005; Senoner & Dichtl, 2019). However, 
these protective measures are known to become deficient following chronic exposure to 
pathological stimuli such as hyperglycaemia (Bhatt et al., 2013; Marnewick et al., 2011; 
Padmalayam, 2012). In the present study, genes involved in the response to oxidative stress 
were differentially expressed in males following HFHS diet feeding for 9 months (Figure 5.9). 
A total of 15 genes associated with intracellular antioxidant activity and ROS neutralisation 
were significantly down regulated including LIAS, PCNA, NQO1, PRDX1, OGG1, GPX1, 
SELENOS and RPS3 which may have led to an increase in ROS levels and subsequent 
oxidative stress.  
Amongst the significantly decreased DEGs was lipoic acid synthase (LIAS), a gene 
responsible for the production of α-lipoic acid (LA) in the mitochondria (Parker et al., 1995; 





network through its ability to scavenge several ROS and the regeneration of various other 
antioxidants including vitamin E, coenzyme Q10 and glutathione (Biewenga et al., 1997; 
Konstantinidou et al., 2013; Shay & Hagen, 2009). Furthermore, LA also serves as an 
essential cofactor for the α-ketoglutarate dehydrogenase complex, suggesting its potential 
involvement in mitochondrial energy production (Padmalayam, 2012; Reed, 1998). Due to 
its potent antioxidant capabilities, the efficacy of externally administered LA to improve 
oxidative stress in diabetes and its related complications has gained considerable interest 
in several animal studies and clinical trials (Koh et al., 2008; Parker & Cadenas, 2011; Salehi 
et al., 2019; Shay et al., 2009; Shindyapina et al., 2017; Ziegler, 2009). The reduced 
expression levels of LIAS observed in the current study could imply an overall reduction in 
the antioxidant defence network following HFHS feeding.  
Furthermore, a significant reduction in the expression of genes encoding enzymes involved 
in the dissimilation of ROS including quinone reductase (NQO1), glutathione peroxidase 
(GPX1) and peroxiredoxin (PRDX1), was observed in males receiving the HFHS diet. 
NAD(P)H:quinone oxidoreductase (NQO1), one of the major mammalian two-electron 
reductases, is known to be induced in response to oxidative stress (Mondal et al., 2018; 
Ross & Siegel, 2017). Besides for its role in quinone detoxification, NQO1 has also been 
implicated in the generation of antioxidants (such as vitamin E), as well as the modulation 
of metabolic disorder through interacting with SERPIN1A1 mRNA which encodes a serine 
protease inhibitor α-1-antitrypsin (Di Francesco et al., 2016; Hyun et al., 2006; Siegel et al., 
1997; Siegel et al., 2004). Accordingly, GPX1 and PRDX1 exert their antioxidant capabilities 
by preventing the accumulation of hydrogen peroxide within cells through its reduction to 
water, under numerous physiological conditions (Antunes et al., 2002; Huang et al., 2017; 
Liebthal et al., 2018; Lubos et al., 2011; Rhee et al., 2018). While PRDX1 is more abundantly 
expressed than GPX1 and has been known to attenuate cardiovascular events through 
oxidative stress and apoptosis; certain isoforms are subject to inactivation at low levels of 
hydrogen peroxide (Forman et al., 2010; Jiang et al., 2020; Jing et al., 2011; Martinez-Pinna 
et al., 2011).  
Despite the ongoing debate regarding the effectiveness of GPX1 versus PRDX1 to modulate 
intracellular peroxides, a reduction in the expression of both genes, as seen in this study, 
further supports the cumulative decrease in antioxidant activity associated with HFHS 
feeding. Interestingly, the master transcriptional regulator of antioxidant genes, nuclear 
factor erythroid-2-related factor 2 (NRF2) was also decreased in the HFHS diet-fed males, 





corresponding control group. Substantial evidence exists supporting the role of NRF2 in 
mediating numerous components of the body’s antioxidant response including the 
expression of NQO1 and GPX1, both identified to be significantly reduced following HFHS 
feeding in the present study. The exclusion of NRF2 from the DEGs identified in the present 
study, as well as the inclusion of alternative DEGs not under the regulation of NRF2, 
suggests the potential involvement of alternative mechanisms resulting in an ineffective 
antioxidant defence network following HFHS feeding. 
 
5.3.4.3 DEGs involved in inflammatory response 
The role of inflammation as a first line defence mechanism in the body has been well 
established and is integral in the detection and removal of detrimental stimuli (Fernández & 
Lamkanfi, 2015; Strauss et al., 2018). To this end multiple metabolic risk factors including 
age, obesity, and smoking, have been linked to the onset of inflammation through the 
assembly of inflammasome complexes (Sastre et al., 2011; Yu & Du, 2017). Furthermore, 
several studies have described the inflammatory response as a significant underlying 
mechanism contributing to the development of T2DM and its associated cardiovascular 
complications (Frangogiannis, 2012; Mann, 2015; Montecucco et al., 2017; Ridker & 
Luscher, 2014; Yu & Du, 2017). The chronic hyperglycaemic conditions associated with 
T2DM, activate pro-inflammatory transcription factors such as nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) which subsequently increases pro-inflammatory 
gene expression, ultimately accelerating cardiac fibrosis and apoptosis (Castello et al., 
2010; Esposito et al., 2002; Lorenzo et al., 2011; Miguel-Carrasco et al., 2010). The latter is 
further exacerbated by an increase in the release of inflammatory cytokines and chemokines 
such as tumor necrosis factor alpha (TNF-α) and monocyte chemotactic protein 1 (MCP1), 
respectively (Goyal et al., 2008; Inoue et al., 2008; King, 2008; Melter et al., 2001).  
In the current study, 18 DEGs associated with inflammatory response were significantly 
under expressed in HFHS diet fed male Wistar rats, as evident from the GO enrichment 
results (Figure 5.9). Further analysis revealed the inclusion of mRNA encoding the 
inflammatory caspase, cysteine-dependent aspartate-specific protease 4 (CASP4), as well 
as the chemokine c-c motif ligand 24 (CCL24). Along with several other inflammatory 
caspases, CASP4 has been demonstrated to play a key role in inflammatory signalling 
responsible for the release of extracellular pro-inflammatory cytokines and activation of 





McIlwain et al., 2013; Yin et al., 2008). While little is known regarding decreased expression 
of CASP4 and CVD, as observed in the present study, reduction in CASP4 expression has 
been linked to poor prognosis in cancer (Papoff et al., 2018; Shibamoto et al., 2017). The 
chemokine CCL24 on the other hand, is a member of a group of signalling proteins 
responsible for the induction of migration and activation of immune cells during inflammation 
(Bacon et al., 2002; Griffith et al., 2014; Mor et al., 2019; Sahin & Wasmuth, 2013). Through 
acting on the CCR3 receptor, increased expression of CCL24 has been shown to be 
involved in pro-inflammatory processes including fibrosis (Gaspar et al., 2013; Heiman et 
al., 2005; Kohan et al., 2010). Due to the important role of CCL24 in fibroblast activation and 
the migration of inflammatory cells to the inflamed area, the potential exists that a decrease 
in the expression of mRNA encoding CCL24, as observed in this study, could lead to 
alterations in the overall host immune response to pathological stimuli (Mor et al., 2019).  
The previously mentioned DEGs related to antioxidant activity including LIAS, GPX1 and 
SELENOS were also linked to the inflammatory response enrichment terms. The inevitable 
link between ROS and inflammation cannot be understated, with a decline in antioxidant 
defence extensively implicated in the pathogenesis of vascular inflammation, ultimately 
leading to cardiac dysfunction (Kamata et al., 2005; Kim et al., 2007; Sharma et al., 2016). 
To this end, selenoproteins such as glutathione peroxidase 1 (GPX1) and selenoprotein S 
(SELENOS) have been recognised as key components involved in inflammatory regulation, 
immunity, oxidative stress, and endoplasmic reticulum stress (Christensen et al., 2012; 
Fradejas et al., 2011; Gao et al., 2004; Yu & Du et al., 2017). These pathophysiological 
reactions usually have reciprocal causations, mutually promote one another, and participate 
in the occurrence and development of T2DM and cardiovascular complications (Chistiakov 
et al., 2014; Donath & Shoelson, 2011; Forbes & Cooper, 2013; Rani et al., 2016).  
Furthermore, a study conducted by Sharma et al. (2016) demonstrated that the lack of GPX1 
prolonged correlated with a reduction in nitric oxide (NO) bioavailability and augmented NF-
κB activity, further supporting the critical role of GPX1 in regulating pro-inflammatory 
pathways. Therefore, the decline in antioxidant defences observed in the present study, as 
evident by the decreased expression of LIAS, GPX1 and SELENOS mRNA, could suggest 
the activation of pro-inflammatory pathways such as MAPK and NF-κB, ultimately facilitating 






Figure 5.15. Summary of major functional enrichments involved in disease pathophysiology in HFHS diet fed 
male Wistar rats. Pathways labelled with a red arrow represents functional enrichments where an up-arrow 
indicates overexpression and a down-arrow decreased expression. The number of DEGs associated with the 
enriched terms are indicated in the dark grey boxes. The HFHS diet was capable of transcriptionally decreasing 
antioxidant activity, which could alter ROS neutralisation capabilities and increase oxidative stress, ultimately 
influencing host inflammatory responses. This was further accompanied by an increase hypertrophic gene 





5.3.5 Functional annotation of DEGs associated with Afriplex GRT™ treatment 
Differentially expressed mRNAs obtained from the separate comparisons for both male and 
female animals receiving the HFHS diet + Afriplex GRT™ treatment were subjected to GO 
and KEGG pathway enrichment analysis. Considering this, up- and downregulated DEGs 
were categorised into the three previously mentioned GO vocabularies namely: biological 
processes (BP), cellular components (CC) and molecular function (MF) using the 
R/Bioconductor package topGO. Of the 120 DEGs identified in male HFHS diet + Afriplex 
GRT™ Wistar rats, 101 were annotated following GO enrichment analysis. The top GO 
terms assigned to upregulated mRNA included participation in the regulation of DNA-
templated transcription and brain development (biological processes: GO:0006355; 
GO:0007420), gene products that are intrinsic components of the nucleus and external side 
of the plasma membrane (cellular component: GO:0005634; GO:0009897), as well as those 
involved in DNA- and cytoskeletal protein binding (molecular functions: GO:1990837; 
GO:0008092) (Figure 5.15). Moreover, the leading GO categories in downregulated mRNA 
included gene products implicated in cell migration and the positive regulation of DNA-
binding transcription factor activity (biological processes: GO:0016477; GO:0051091), 
genes products that are located in the mitochondrion and the apical plasma membrane 
(cellular component: GO:0005739; GO:0016324), as well as gene products involved in 
RNA- and lipid binding (molecular functions: GO:0003723; GO:0008289) (Figure 5.16).  
GO terms were assigned to 296 of the 337 DEGs in the HFHS diet + Afriplex GRT™ female 
Wistar rats. The major GO categories in upregulated mRNA, included gene products 
involved in the regulation of cell differentiation and adhesion (biological processes: 
GO:0030154; GO:0007155), genes confined to the cytosol and extracellular space (cellular 
component: GO:0005829; GO:0005615), as well as those involved in cell adhesion 
molecule binding and RNA polymerase II-specific, DNA-binding transcription factor activity 
(molecular function: GO:0050839; GO:0000981) (Figure 5.15). On the other hand, the top 
GO enrichment terms in downregulated mRNA were gene products associated with female 
pregnancy and ribosomal RNA generation (biological processes: GO:0007565; 
GO:0000467), gene products situated in the mitochondrion and cytoplasmic vesicle (cellular 
component: GO:0005739; GO:0031410), as well as gene products involved in signalling 







Figure 5.16. Gene ontology (GO) enrichment analysis of upregulated differentially expressed genes (DEGs) in HFHS + Afriplex GRT™ male Wistar rats. The top 






Figure 5.17. Gene ontology (GO) enrichment analysis of downregulated differentially expressed genes (DEGs) in HFHS + Afriplex GRT™ male Wistar rats. The top 






Figure 5.18. Gene ontology (GO) enrichment analysis of upregulated differentially expressed genes (DEGs) in HFHS + Afriplex GRT™ female Wistar rats. The top 






Figure 5.19. Gene ontology (GO) enrichment analysis of downregulated differentially expressed genes (DEGs) in HFHS + Afriplex GRT™ female Wistar rats. The 






Further analysis of all GO enrichments revealed that majority of the DEGs associated with 
Afriplex GRT™ treatment were involved in processes required for intrinsic cellular and 
molecular function. Due to the lack of significantly enriched, disease related ontologies 
observed in males and females receiving Afriplex GRT™ treatment (Figure 5.15 to 5.18), 
further in-depth discussion of the ontologies identified was not of interest to this study. 
Additionally, pathway analysis revealed that while only one KEGG pathway, cell adhesion 
molecules (rno04514) was significantly enriched for in upregulated mRNAs (p = 0.04) of 
males, no significant KEGG pathways were enriched in the female data set (data not 
shown). Although HFHS diet + Afriplex GRT™ animals appeared to cluster closely together 
to those maintained on the HFHS diet in terms of normalised read counts, the DEGs 
identified do not display a similar coherence in terms of biological and functional assignment. 
This finding further signifies the importance of the pipeline used to identify DEGs between 
groups and the statistical methods used to correct for multiple comparisons on a genome 
wide scale.  
Evaluation of common DEGs shared amongst animals in the HFHS group and those in the 
HFHS diet + Afriplex GRT™ group revealed 5 common DEGs for males and 24 for females, 
respectively (Supplementary Data – Table S5 and S6). Interestingly, albeit it not significant, 
treatment with Afriplex GRT™ was able to reverse the average expression of all common 
DEGs in terms of the logFC values. One of the common DEGs identified in make datasets, 
was the previously described antioxidant, NQO1. Although, Afriplex GRT™ had no 
significant effect on the expression of any other antioxidant genes or those involved in ROS 
production, the modulating effect on NQO1 expression provides a promising avenue for 
further exploration (da Costa et al., 2019; Di Francesco et al., 2020). However, as one of 
the aims of the current study was to evaluate the ability of Afriplex GRT™ to modulate 
transcriptional signatures associated with HFHS diet feeding on a genome wide scale, the 
alteration of the expression of an individual gene of interest does not directly fall within the 
scope. Overall, the lack of relevant enrichments observed in the current study suggest that 
Afriplex GRT™ was unable to significantly ameliorate transcriptional, disease associated 
modifications induced by HFHS diet (Figure 5.15 to 5.18). Therefore, animals from this group 








Non-communicable diseases (NCDs) place a significant burden on the health care systems 
of underdeveloped countries such as South Africa. Considering this, the comprehensive 
application of high throughput sequencing technologies has aided in the profiling and 
discovery of numerous differentially expressed targets involved in NCDs including CVD. 
Studies have demonstrated the aberrant expression of multiple RNA species in left 
ventricular dysfunction, myocardial infarction, and several other cardiovascular events 
(Jneid et al., 2012; Liao et al., 2019; Lundmark et al., 2015).  
This study provides the first large scale RNA sequencing (RNA-Seq) analysis of both male 
and female Wistar rats maintained on this particular diet and treated with the Afriplex GRT™ 
extract. To explore differentially expressed mRNA signatures in the heart, RNA from five 
biological replicates of rodents in the three experimental groups previously described were 
subjected to PE100 transcriptome sequencing. Following an extensive pre-processing 
pipeline, an average of 59.66 million paired-end reads were obtained per sample with 
approximately 85.41% mapping uniquely to the latest version of the annotated reference 
genome. The remaining percentage of unmapped reads could be attributed to the presence 
of PCR duplicates, discrepancies in the reference annotation or the stringency of the 
mapping criteria applied.  
Rigorous bioinformatic analysis revealed that a total of 238 mRNAs were significantly 
upregulated and 333 mRNAs downregulated in the HFHS males, while 252 mRNAs were 
upregulated, and 162 mRNAs downregulated in female rats maintained on the HFHS diet 
when compared to the control. Furthermore, 64 mRNAs were significantly upregulated, and 
56 mRNAs downregulated in the HFHS + Afriplex GRT™ males whereas 221 mRNAs were 
upregulated, and 116 mRNAs downregulated in female rodents in the HFHS + Afriplex 
GRT™ group when compared to the HFHS group. Hierarchical clustering revealed the 
distinct classification of DEGs by treatment groups, with animals in the HFHS + Afriplex 
GRT™ group more closely related to those in HFHS group, suggesting the possible use of 
these mRNA to distinguish the disease group from the control.  
In order to determine the landscape of the molecular functions and associated pathways of 
the identified DEGs, GO enrichment and KEGG pathway analyses were performed for each 
of the separate signatures. Some of the major findings associated with the HFHS group 





myofibril assembly, as well as the decreased expression of DEGs involved in the response 
to oxidative stress. Additionally, the enrichment of immune related terms was observed in 
downregulated mRNAs including inflammatory response, cytokine-cytokine receptor 
interaction and the TGF-beta signalling pathway. Collectively these results demonstrate the 
ability of the HFHS diet to act as a pathological stimulus capable of decreasing antioxidant 
activity, which could alter ROS neutralisation capabilities and increase oxidative stress, 
ultimately activating host inflammatory responses. This is further accompanied by an 
increase hypertrophic gene expression, possibly affecting cardiac muscle functionality. 
Furthermore, albeit the lack of a severe CVD disease phenotype in these animals, the 
enrichment of the pathways involved in disease pathophysiology nonetheless indicates the 
disruption of cardiac tissue homeostasis. As expected, the previously described 
enrichments were more frequent in males than females, with female animals only displaying 
enrichment of one of the underlying pathways involved in hypertrophic signalling. Due to the 
limited changes in the metabolic risk parameters of females assessed in Chapter 4, the 
bases exist for speculating that the insult of the HFHS diet may have been insufficient to 
induce molecular changes in the cardiac tissue of female rodents specifically, further 
supporting the possible protective involvement of female hormones against metabolic 
disorders.  
Functional analyses of DEGs associated with HFHS + Afriplex GRT™ groups yielded no 
significant enrichment of disease or pathology related processes and no high confidence 
results for the amelioration of the transcriptomic signatures resulting from HFHS diet 
feeding. However, this data set still provides a basis for further exploration in terms of 
candidates specifically associated with the Afriplex GRT™ profile that were not focussed on 
in the current study. Transcriptomic signatures associated with the HFHS diet identified will 
be compared comprehensively to the methylation analysis described in Chapter 5 and has 
the potential of providing insight into the underlying mechanisms associated with a HFHS 
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Chapter 6: Whole genome bisulfite sequencing to assess 
aberrant DNA methylation associated with diet-induced CVD in 
Wistar rats 
6.1 Introduction 
The advent of epigenetics, the interplay between genetic components and environmental 
influences, has provided a new dimension to pharmacogenomics (Khalil, 2014; Stenvinkel 
et al., 2007). Epidemiological research has shown that cardiovascular disease (CVD) has 
both a heritable and an environmental component, suggesting that epigenetic mechanisms 
may play a critical role in CVD development (Baccarelli et al., 2010; Meaney, 2014). 
Amongst the numerous forms of epigenetic modifications investigated, DNA methylation 
remains the most widely studied (Michels, 2012; Solomon et al., 2020; Zhong et al., 2016). 
DNA methylation is the addition of a methyl group to the 5th carbon position of the cytosine 
ring, occurring primarily in CpG islands in the promoter regions of genes (Bird, 2002; Deaton 
& Bird, 2011; Du et al., 2015). This process is catalysed by DNA methyltransferases 
(DNMTs) and plays an imperative role in maintaining genomic stability and regulating gene 
expression (Jaenisch & Bird, 2003; Kirchner et al., 2013; Kurdyukov & Bullock, 2016). 
Furthermore, DNA methylation also alters protein binding sites on DNA, often leading to 
transcriptional silencing of genes, which may affect phenotype and lead to disease 
development (Moore et al., 2013). 
Numerous studies have implicated aberrant DNA methylation in the development of obesity, 
T2D, as well as biological processes underlying CVD (Baccarelli et al., 2010; Bansal & 
Pinney, 2017; Friso et al., 2008; Ikram et al., 2009; Muka et al., 2016; Pasquier et al., 2015; 
Ron & Ling, 2015; Turunen et al., 2009). Of particular interest to this study is the role of 
altered DNA methylation associated with hyperglycaemia and glucose intolerance resulting 
from increased dietary fat intake, described in fetal programming human and animal models 
(Cannon et al., 2014; Moody et al., 2017; Seki et al., 2017; Soubry et al., 2015; Zang et al., 
2019). Furthermore, the adverse effects brought on by increased sugar intake, specifically 
fructose, has also been suggested to be mediated by DNA methylation (Davegårdh et al., 
2018; Yamanda et al., 2017). While the previously described metabolic conditions are all 
risk factors contributing to the development and progression of diet-induced CVD, limited 
evidence exists evaluating the combinatory ability of high fat and high sugar to stimulate 





of several pathways involved in cardiac dysfunction such as inflammation and oxidative 
stress.  
The advent and evolution of next generation sequencing (NGS) has considerably impacted 
genomic research. However, until recently, researchers were unable to access platforms 
capable of massive parallel sequencing on a genome-wide scale, locally and at an 
affordable price. Consequently, this study utilised a genome-wide sequencing approach to 
investigate DNA methylation associated with diet-induced CVD in rodents. The reversible 
nature of epigenetic phenomena allows for the modification of the transcription of critical 
genes associated with the development of diet-induced CVD (Crider et al., 2012; 
Jamaluddin et al., 2007; Nazki et al., 2014). Identifying DNA methylation signatures 
associated with CVD on a genome wide scale, as proposed by this study, aids in the 
elucidation of the pathophysiology of diet-induced CVD and the identification of possible 
new targets for epigenetic therapies. 
 
6.2 Materials and Methods 
6.2.1 Study design and sample selection 
A total of 20 male Wistar rat (Rattus norvegicuss) cardiac tissue samples from the animal 
study described in Chapter 3 were used in the study. The sample selection criteria were 
based on the abovementioned objectives and involved the inclusion of male rats from two 
groups namely: 1) the control group which received a standard (STD) maintenance rodent 
diet (n=10), and 2) the high fat, high sugar (HFHS) group receiving a cafeteria diet (n=10). 
As a result of the limited protective metabolic (Chapter 4) and transcriptional (Chapter 5) 
changes previously observed with administration of Afriplex GRT, male rodents treated 
with Afriplex GRT diet were not included in DNA methylation analysis. Similarly, female 
rodents were excluded from this part of the study as observational alterations in 
cardiovascular risk factors including increased body weight, glucose intolerance, as well as 






6.2.2 DNA extraction, assessment and pooling 
Genomic DNA (gDNA) was extracted from snap frozen cardiac tissues with a modified, non-
organic protocol that involved the use of highly concentrated sodium chloride (NaCl). Briefly, 
approximately 25 – 30 mg of tissue was submerged in a 100 μL lysis buffer (400mM NaCl, 
10mM Tris-HCl pH 8, 2mM EDTA pH 8 and 10% [w/v] SDS) supplemented with 5 μL 
proteinase K (20 mg/μL) and homogenised using a TissueLyser (Qiagen, Hilden, Germany). 
The resulting homogenates were then incubated in a water bath for 1 hour at 80°C to 
facilitate sufficient tissue disruption and the removal of proteins. The isolation of DNA was 
promoted by the addition of 1/3 volume of 6 M NaCl, followed by vigorous vortexing (~15 
seconds) and subsequent centrifugation at max speed for 10 min in order to pellet cell 
debris. Following centrifugation, the supernatant was attained and combined with equal 
volume ice cold isopropanol and incubated overnight at -20°C to enable the precipitation of 
DNA. The DNA was then precipitated with centrifugation at 13000 rpm for 10 min and the 
resulting pellet was subjected to a series of wash steps using 70% ethanol, before air drying 
and resuspension in 50 µL TE buffer. All above mentioned centrifugation steps were 
conducted at room temperature (RT) unless otherwise stated.  
The yield and purity of the DNA was determined using fluorometry (Qubit™ DNA HS Assay 
Kit, Thermo Fisher Scientific, Waltham, MA, USA) and spectrophotometry (Nanodrop, 
Thermo Fisher Scientific, Waltham, MA, USA), while the quality was evaluated through 
electrophoresis on a 1% [w/v] TBE agarose gel stained with ethidium bromide. Upon 
completion of quality control (QC) assessment, DNA isolated from individual samples were 
pooled in duplicate to generate 5 biological replicates of each group (Table 6.1). To this end 
each pooled sample consisted of an equal amount of high molecular weight, gDNA (10 μg) 






Table 6.1. DNA pooling of male (n = 20) samples to generate five biological replicates per group, for 
sequencing and subsequent expression analysis. 
Rat IDs Pooled DNA ID Group 
R1 + R2  M1 
STD 
R3 + R4 M2 
R5 + R6 M3 
R7 + R8 M4 
R9 + R10 M5 
R11 + R12 M6 
HFHS 
R13 + R14 M7 
R15 + R16 M8 
R17 + R18 M9 
R19 + R20 M10 
 
6.2.3 DNA library preparation and sequencing 
Pooled gDNA samples (1 g) were fragmented with the M220 Focused-ultrasonicator 
(Covaris, Woburn, MA, USA), followed by size selection using MGIEasy DNA Clean Beads 
(MGI, Shenzhen, China) to obtain an optimal insert size of 250 base pairs (bp). Lambda 
phage DNA (MGI, Shenzhen, China) was used to evaluate the C to T conversion efficiency 
and subjected to the previously described fragmentation and size selection protocol prior to 
library construction. Library preparation was performed with the MGIEasy Whole Genome 
Bisulfite Sequencing (WGBS) Library Prep Kit V2.0 (MGI, Shenzhen, China) according to 
an adapted version of the manufacturer’s protocol. Briefly, 20 ng size selected DNA of each 
sample was combined with 0.4 ng size selected lambda DNA (1:50) and subjected an end 
repair and A-tailing (ERAT) reaction. The end-repaired products were ligated to 5 X diluted 
MGIEasy DNA Adapters and subsequently purified using the QIAquick PCR Purification Kit 
(Qiagen, Hilden, Germany) without the addition of pH Indicator I to Buffer PB. Bisulfite 
treatment and purification was performed with the EZ DNA Methylation-Gold Kit (Zymo 
Research, CA, USA) using the purified adapter-ligated DNA products and 200 ng 





products were purified using previously described magnetic beads, and quantified with 
fluorometry using the Qubit dsDNA HS Assay kit (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA) according to the manufacturer’s instructions. Furthermore, the fragment 
size distribution of purified PCR products was evaluated using gel electrophoresis. 
Double-stranded (ds), circular DNA libraries were generated from 1 pmol of PCR product, 
followed by purification and quantification with MGIEasy DNA Clean Beads and the Qubit 
dsDNA HS Assay kit, respectively. In accordance with the proprietary technology unique to 
the MGI sequencing platform, DNA nanoballs (DNBs) were generated from the ds, circular 
DNA libraries using rolling circle replication (RCR). Considering the imbalanced nucleotide 
composition observed in WGBS libraries, the libraries were combined with whole genome 
sequencing (WGS) libraries constructed from the same samples using the MGIEasy 
Universal DNA Library Prep Kit (MGI, Shenzhen, China). Pooling occurred post DNB 
generation in a 2:1 ratio (300 ng WGBS DNB:150 ng WGS DNB). The MGILD-200 automatic 
loader was used to load pooled DNBs onto MGISEQ-2000 FCL flow cells, following a one 
sample per lane approach. Massively parallel sequencing was then performed on the 
MGISEQ-2000 (MGI, Shenzhen China) with the appropriate reagents supplied in the 
MGISeq-2000RS High-Throughput Sequencing Kit. A paired-end sequencing strategy was 





6.2.4 Bioinformatic analyses 
 
Figure 6.1. Schematic workflow describing the bioinformatic pipeline used for the analysis of whole genome bisulfite sequencing (WGBS) data. The workflow steps 
until the completion of “gene count estimation” was implemented for the 10 sequence datasets individually, while differential methylation analysis was performed 





6.2.4.1 Data pre-processing 
The raw WGBS datasets generated on the MGISEQ-2000 were obtained in FASTQ format 
and processed using the computational resources provided by the Centre for High 
Performance Computing (CHPC). All datasets were first individually evaluated in terms of 
sequencing quality and library composition using FastQC version 0.11.5 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Subsequently, quality trimming 
was performed with Trimmomatic version 0.36 and bases with a Phred quality score below 
Q20 from the 5' end of the sequence reads were removed using a sliding window of 3 
nucleotides (nts) to get rid of potentially incorporated sequencing errors (Bolger et al., 2014). 
This led to a base calling accuracy of 99%, further improving the overall quality of datasets 
for subsequent analyses. Additional Trimmomatic parameters included a minimum read 
length of 20 bp and the removal of possible MGI adapter contamination. Following 
completion of all trimming and filtering steps, read file QC metrices were once again 
assessed with FastQC, to evaluate the efficiency of the pre-processing pipeline.  
 
6.2.4.2 Alignment, methylation calling and conversion rate estimation 
An alignment-based approach was utilised in order to infer the methylation status of every 
cytosine position in the processed WGBS datasets. To this end, “cleaned” reads from each 
sample were aligned to a custom reference genome containing the Rattus norvegicus 
reference genome version 6.0 (ftp://ftp.ensembl.org/pub/release-
100/fasta/rattus_norvegicus/dna/Rattus_norvegicus.Rnor_6.0.dna.toplevel.fa.gz) and the 
Escherichia phage Lambda, complete genome 
(https://www.ncbi.nlm.nih.gov/nuccore/J02459.1?report=fasta) using Bismark version 
0.22.3 (https://www.bioinformatics.babraham.ac.uk/projects/bismark). The selection of this 
three-letter aligner was largely based on flexibility to support the mapping of bisulfite reads 
generated from different sequencing technologies (Krueger & Andrews, 2011). Briefly, 
sequence reads were first temporarily transformed to generate complete bisulfite converted 
versions of the forward (C > T) and reverse (G > A) reads. These in silico generated read 
versions were then subsequently aligned to two, similarly converted versions of the custom 
reference genome (C > T and G > A) (Krueger & Andrews, 2011). The Bismark read 
alignment step was executed using default parameters with the addition of the --bowtie2 and 
--non_directional options to perform mapping with Bowtie 2 (http://bowtie-





constructed WGBS libraries, respectively. Following completion of individual alignments, the 
deduplicate_bismark script was used to remove duplicate alignments from SAM output files 
possibly originating from excessive PCR amplification, prior to executing the supplementary 
bismark_methylation_extractor script with default parameters to obtain base pair 
methylation level measurements. The conversion efficiency (C > T) of the bisulfite treatment 
was further calculated as 100 % minus the methylation level of the lambda DNA spike-in. 
Furthermore, summary statistics obtained from the various alignment steps were assessed 
using SAMtools version 1.10 and collated with MultiQC version 1.10.1 for quality assurance 
purposes (Li et al., 2009; Ewels et al., 2016).  
 
6.2.4.3 Differential methylation (DM) analysis 
To take advantage of the per base resolution provided by WGBS, differential methylation 
was evaluated using the Bioconductor package, methylKit version 1.8.0 in R version 4.0.3 
(Figure 6.1) (kalin et al., 2012; Gentleman et al., 2004; AR Core Team, 2020). Briefly, 
methylRaw objects containing per base methylation calls were generated from SAM output 
files sorted by both chromosome and read position. Following the removal of cytosines with 
sequencing depth < 10 X to account for low-coverage regions and normalisation using the 
normalizeCoverage function, samples were merged to facilitate comparative analysis (Pepin 
et al., 2019). Differentially methylated cytosines (DMCs) were obtained using the 
calculateDifMeth function, which employs a logistic regression test when biological 
replicates are present. The resulting p-values were adjusted to their corresponding q-values 
using the SLIM method (Wang et al., 2011). Additionally, an overdispersion correcting 
Chisq-test was performed to account for increased biological variability and the lack of 
technical replicates (Wreczycka et al., 2017). Due to the large number of cytosines being 
analysed simultaneously, multiple testing correction using the False Discovery Rate (FDR) 
method was applied and an adjusted p-value ≤ 0.05 was used to assign statistical 
significance (Benjamini & Hochberg, 1995). The significant DMCs resulting from the 






6.2.3.4 Annotation and functional analyses 
The Bioconductor package, genomation version 1.24.0 was used to annotate previously 
identified DMCs using the most recent BED file annotation of the Rattus norvegicus genome 
(rno6.0) obtained from the UCSC Genome Browser (Akalin et al., 2014; Kent et al., 2002). 
To this end, regional annotation was conducted in terms of promoters (defined as 1000 bp 
on up- or downstream of the TSS), introns, exons, and intergenic regions as well as CpG 
islands and shores. Transcripts overlapping with DMCs were regarded as differentially 
methylated genes (DMGs), with the mean difference in methylation of all corresponding 
DMCs representing the gene level difference.  
Furthermore, the potential biological significance inferred by the differentially methylated 
genes was investigated with gene ontology (GO) and Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) pathway analyses (Ashburner et al., 2000; Kanehisa & Goto, 2000; Yu 
et al., 2012). Briefly, GO terms were retrieved from the Bioconductor database, 
org.Rn.eg.db, while rat specific (rno) pathway assignments were obtained from the 
KEGGREST package. Statistically significant enrichments were identified using either the 
Kolmogorov-Smirnov or Wilcoxon rank-sum test where applicable, with an adjusted 
probability value of less than, or equal to 0.05 deemed biologically significant. Comparative 
analysis was performed between differentially expressed genes (DEGs) identified in 
Chapter 5 and overlapping DMGs to identify potential associations between methylation 






6.3 Results and Discussion 
6.3.1 DNA isolation and library preparation 
For WGBS specifically, utilising DNA of high quality, purity and quantity are crucial as the 
bisulfite treatment may degrade up to 90% of the input sample (Ehrich et al., 2007; Grunau 
et al., 2001; Kint et al., 2018). While traditional organic, phenol-chloroform protocols yield 
highly concentrated DNA, the presence of impurities such as PCR inhibitors have been 
shown to influence downstream applications (Fan & Gulley, 2001; Gumińska et al., 2018; 
Psifidi et al., 2015). Conversely, commercial tissue extraction kits yield extremely pure DNA 
but less than the required concentration, often requiring repeat extraction in many cases 
(DNA < 50 ng/µL) (Gumińska et al., 2018; Psifidi et al., 2015). In this study, a non-organic, 
highly concentrated NaCl protocol was utilised and optimised to enable the extraction of 
high quantity DNA, with minimal co-purified contaminants, from snap frozen tissue. The 
adapted protocol resulted in highly intact gDNA from male (n = 20) cardiac tissue samples, 
with concentrations ranging between 205 and 621 ng/µL. Further evaluation of potential 
contaminants demonstrated an overall mean A260/280 ratio of 1.98 and an overall mean 
A260/230 ratio of 2.03, collectively considered to be within the acceptable standards for pure 
DNA (Arif et al., 2010; Dauphin et al., 2011; Psifidi et al., 2010). All male samples yielded 
gDNA that met the quantity and quality requirements for WGBS, with no significant 
differences observed between samples from different treatment groups. Following the 
successful completion of WGBS and WGS library preparation, pooled bisulfite and whole-
genome libraries were subjected to paired-end 100 bp (PE100) sequencing on the MGISEQ-
2000. All the samples passed in-house quality control measurements throughout the library 
preparation and sequencing protocols.  
 
6.3.2 Methylation sequencing and pre-processing 
Upon successful completion of WGBS of the 10 libraries on the MGISEQ-2000 platform, an 
average of approximately 39.21 gigabases (GB) of raw data and 200.54 million paired-end 
reads were obtained per sample. Consequently, suggesting that the incorporation of the 
WGBS:WGS pooling strategy allowed for stable base pair calling and the generation of 
sufficient sequencing read depth. Evaluation of the data with FastQC revealed mean Phred 
quality scores above 20 throughout the entire read length (100 bp), indicating accurate 





and uneven per base sequence content distribution across the reads were observed. 
However, due to the chemical modification employed, bisulfite-treated reads are inherently 
different from standard sequencing reads regarding of the QC metrices assessed. To this 
end, forward reads are generally rich in T bases and poor in C bases, whereas the reverse 
reads are rich in A- and poor in G bases (Nair et al., 2018; Sun et al., 2015). This imbalance 
in nucleotide base proportions was observed in the present study and further explains the 
previously mentioned reduction in GC content (Figure 6.2 and Table 6.2).  
The pre-processing of FASTQ reads resulted in the removal of roughly 3.42 million paired 
sequences per sample, with an average of 86.96% of the remaining bases displaying a 
quality score of at least 30 (Table 6.2). Interestingly, the read duplicate rate remained higher 
than 10% after pre-processing. While this is still within the acceptable range, it is higher than 
what has previously been observed with genome sequencing on this platform (Glanzman et 
al., 2020). This high PCR amplification bias remains one of the main areas of concern with 
WGBS library preparation protocols that utilise post-bisulfite PCR amplification, such as the 
one employed in this study, and will be corrected for in the downstream alignment analysis 
(Olova et al., 2018; Walker et al., 2015). Overall, pre-processing resulted in the loss of a 
considerably low amount of read pairs and the retainment of exceptionally high-quality 
bases, with no significant adapter contamination across the read length.  
 
Table 6.2. Read statistics of male sample WGBS datasets following pre-processing. 
Group Sample Clean reads %Duplicate reads %GC content Q20% Q30% 
STD 
M1 209 304 406 16,5 24,0 96,13 88,21 
M2 211 036 748 16,6 24,0 95,32 86,92 
M3 212 577 162 16,6 23,5 95,46 87,28 
M4 200 890 158 18,0 23,5 95,35 86,68 
M5 152 234 820 16,4 24,0 95,55 87,44 
HFHS 
M6 207 592 718 15,0 24,0 93,51 83,80 
M7 221 431 577 14,5 23,5 96,30 88,53 
M8 202 467 829 16,1 23,0 95,47 87,14 
M9 223 075 662 16,5 23,5 95,55 87,06 







Figure 6.2. Graphical output obtained from FastQC processed WGBS data of a representative sample. Distribution of per base Phred quality scores obtained for A) 





6.3.3 Alignment evaluation 
Processed bisulfite treated reads were mapped to the custom reference genome with 
Bismark and the resulting alignments were assessed using a combination of the built-in 
scripts provided by the software. An average alignment efficiency of 70.77% was achieved 
across all samples, which is high for WGBS data considering that the reads are not 
complementary to the reference (Table 6.3) (Chatterjee et al., 2012). Approximately 9.24 to 
10.24% of the reads mapped to multiple locations on the genome, while between 14.75 and 
24.53% were not aligned and subsequently removed from downstream analyses (Table 
6.3). The bisulfite treatment introduces a reduction in sequence complexity from four bases 
to three bases (Nair et al., 2018; Sun et al., 2015). Furthermore, while T nucleotides in reads 
can align to C nucleotides in the reference genome, the reverse is not the case 
(Rauluseviciute et al., 2019; Xi & Li, 2009). The damaging effects associated with bisulfite 
treatment thus support the lower rate of alignment when compared to traditional DNA 
sequencing and increased non-alignments observed in the current study. The assessment 
of quality metrices of the individual sample alignments revealed no statistically significant 
differences between or within the STD and HFHS experimental groups, allowing for the 
incorporation of all sample datasets in downstream analyses (Table 6.3).  
 
Table 6.3. Summary of mapping statistics obtained following the alignment of processed male datasets to the 
custom reference genome.  
Group Sample %Unique alignmentsa %Multiple alignmentsb %No alignmentsc 
STD 
M1 75.00 10.24 14.75 
M2 73.20 9.99 16.83 
M3 69.00 9.82 21.15 
M4 73.20 9.24 17.56 
M5 72.80 10.17 17.02 
HFHS 
M6 68.30 9.62 22.04 
M7 72.70 10.13 17.16 
M8 68.01 10.02 21.97 
M9 69.80 9.92 20.27 
M10 66.30 9.22 24.53 
a Proportion of reads mapping uniquely to reference genome representative of the alignment efficiency. 
b Proportion of reads mapping to multiple positions/loci on the reference genome. 






In addition to efficiently aligning bisulfite treated reads, Bismark also provides CpG-, CHG- 
and CHH-context specific methylation outputs, where H is representative of any non-G base. 
To this end, average methylation levels were extracted from the mapping files after 
performing a mandatory deduplication step. Of the 2318.02 to 5691.13 million Cs covered 
by uniquely mapped reads across all the samples, a mean of 57.4% was methylated in the 
CpG context (Table 6.4). However, it should be emphasised that this percentage methylation 
value is only a rough estimation (Equation 6.1) characterising the methylation profile at the 
mapping step (Krueger & Andrews, 2011). Definite methylation levels will vary after user-
specific filtering and processing steps are completed. DNA methylation at non-CpG sites 
was historically known to be present more abundantly in plants than differentiated, adult 
mammalian cells. However, recent scientific studies have described the occurrence of 
extensive non-CpG methylation in mammalian brain, skeletal muscle, and testis tissue, 
further stimulating the possibility of considering non-CpG methylation as an alternative form 
of DNA methylation capable of influencing disease development (Kinde et al., 2015; Pinney 
et al., 2014; Wang & Kadarmideen, 2019; Yuan et al., 2016; Zhang et al., 2017). The 
methylation proportions determined in CHG and CHH context in the present study were, 
however, negligible (below 1%) in all the samples and therefore excluded from downstream 
differential methylation analysis (Table 6.4) (Deshpande et al., 2020; Tomizawa et al., 2011). 
 
Equation 6.1 
%𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛 = 100 × [
𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑒𝑑 𝐶𝑠 
(𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑒𝑑 𝐶𝑠 + 𝑈𝑛𝑚𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑒𝑑 𝐶𝑠)
] 
 
As a supplementary QC measure, the average percentage methylation for each position 
across the read length was also visualised using the M-bias plot outputs generated by 
Bismark to identify possible biases in methylation calls (Krueger & Andrews, 2011). While 
the theoretical methylation level distribution is expected to be uniform throughout the read, 
deviation from the horizontal line was observed in the first 10 bases of the reverse reads in 
the current study (Supplementary Figure 1). This deviation, observed at either end of the 
read, is in line with previous findings and the bases involved were removed from further 





Table 6.4. Summary of methylation statistics extracted from Bismark alignment files. 
Group Sample 
Total Cs analysed 
(million) 
%Methylation Conversion 
rate%d CpGa CHGb CHHc 
STD 
M1 5586.75 56.7 0.7 0.8 99.52 
M2 5290.10 54.5 0.6 0.7 99.64 
M3 2318.02 60.9 0.6 0.7 99.69 
M4 3989.57 54.6 0.6 0.7 99.67 
M5 3844.49 55.3 0.6 0.6 99.68 
HFHS 
M6 4973.89 56.8 0.6 0.7 99.67 
M7 5691.13 60.6 0.6 0.7 99.65 
M8 4606.58 56.1 0.8 2.9 99.72 
M9 3807.98 60.9 0.6 0.7 99.69 
M10 2516.32 57.1 0.7 0.8 99.68 
a Percentage methylation in terms of the symmetrical CpG dinucleotide context. 
b Percentage methylation in terms of the symmetrical CHG dinucleotide context.  
c Percentage methylation in terms of the asymmetrical CHH dinucleotide context. 
d Bisulfite conversion rate calculated using the lambda phage DNA spike-in.  
 
The accuracy of DNA methylation detection depends on the conversion efficiency (C > T) of 
the bisulfite treatment reaction, and the incomplete transformation of cytosine in sequences 
may lead to false-positive results. In this study, lambda phage DNA was spiked in prior to 
sequencing, as an unmethylated control to calculate the conversion rate using the previously 
described formula. A conversion rate above 99% was obtained for all the samples in this 
study, suggesting that the bisulfite treatment was performed optimally and that any biases 
observed in methylation calls are not due to incomplete bisulfite conversion (Table 6.4). The 
latter was confirmed with M-bias plots illustrating the almost complete conversion of non-
CpG cytosines, enabling the use of all biological replicated in the differential methylation 






6.3.4 Genome-wide DNA methylation patterns 
Given the low levels of CHG and CHH methylation observed in this study, all analyses from 
this point forward were conducted in CpG dinucleotide context only (Jang et a., 2017; 
Laurent et al., 2010; Lindroth et al., 2001; Lister et al., 2009). Initial descriptive statistics 
revealed a mean per base methylation of 72.93 and 71.31% for STD and HFHS samples 
respectively. No samples were flagged for excessive PCR duplication bias in terms of per 
base read coverage, suggesting the effectiveness of the deduplication steps performed. 
Following secondary filtering and normalisation comparative analysis was conducted on 
70 183 sites covered in the 10 samples. Overall, a similar trend was observed in the 
genome-wide methylation status between STD and HFHS samples, with Pearson’s 
correlation scores ranging between 0.58 and 0.98 (Figure 6.3 A). Variable methylation levels 
were observed across the 22 Rattus norvegicus chromosomes.  
While majority of the CpG sites analysed were located on chromosome 1 (21.18%) and 2 
(11.32%), chromosome 10 (0.75%) and Y (0.45%) contained the least amount of CpG sites. 
This variation in CpG site per chromosome could possibly be explained by several factors, 
including stringent coverage filtering methods, genome stability and chromosome size. 
Regional annotation performed on the methylated CpG sites (70 183) revealed the 
distribution of 1.71, 1.51, 10.24 and 86.87% within promoter, exon, intron, and intergenic 
regions, respectively (Figure 6.3 B). The increased methylated CpG dinucleotides located 
within non-coding regions (intergenic) observed in the current study is in line with previous 
findings and supports the essential role of DNA methylation in processes required for normal 
development such as genomic imprinting and transposable element repression (Dahlet et 
al., 2020; Huff & Zilberman, 2014; Tost, 2010). Moreover, 4.31% of the global sites analysed 
were annotated within CpG islands (CpGi), 3.30% in CpG island shores (CpGi shore) and 






Figure 6.3. A) Genome-wide distribution of methylated sites with average STD (green) and average HFHS (red) methylation. The methylation levels of n = 5 samples 
per group are shown by lines in track 1 and 2 from inside to outside. The labels of the outside track represent the chromosomes of the Rattus norvegicus genome. B) 
Regional annotation of global methylated sites in terms of gene parts (promoter, exon, intron and intergenic) and CpG island regions (CpGi = CpG island, CpGi shore 





6.3.5 Differentially methylated cytosines (DMCs) and annotations  
As global methylation status is often insufficient to characterise the biological significance of 
observed changes in DNA methylation levels, differential methylation analysis was 
performed on a per base level using the previously identified 70 183 CpG sites annotated in 
the Rattus norvegicus (rnor6.0) assembly. A total of 5 531 DMCs (FDR  0.05) were 
identified in male Wistar rats maintained on the HFHS diet compared to those in the STD 
diet-fed control group. DMCs located on the Y chromosome were excluded from 
downstream analysis in the present study, thus reducing DMCs by 0.43% (5 508). Among 
these DMCs, 3 047 DMCs were hypomethylated, while the remaining 2 461 were 
hypermethylated in the HFHS group.  
Visualisation of the methylation dynamics between samples was conducted using the 
methylation levels of the most variable DMCs (FDR  0.01). Accordingly, using Ward’s 
method, hierarchical clustering revealed categorical separation between the HFHS and STD 
control samples, with all biological replicates correctly classified to the respective groups 
(Figure 6.4) (Murtagh & Legendre, 2011). While no discernible outliers were detected 
amongst biological replicates, moderate variation within the methylation profiles of STD 
samples was observed (Figure 6.4). Although little is known regarding sources of inter-
individual differences in methylation among control rats, changes in cellular mechanisms 
responsible for maintaining of DNA methylation levels and chromatin homeostasis could 
partially be responsible (Bewick et al., 2016; Niederhuth et al., 2016; Zhang et al., 2020). 
Alternative plausible influences include circadian rhythms, seasonality, and changes in 
temperature (Baccarelli et al., 2009; Pinto et al., 2005; Ricceri et al., 2014; Shi et al., 2013; 
Vollmers et al., 2012; Zhu et al., 2011). While the extent and consequences of these stimuli 
remain to be fully explored, their influence in the current study can be excluded as the 
animals were maintained in a temperature-controlled facility. Nonetheless, the variation 
amongst control samples observed in this study was considered statistically irrelevant and 
could therefore most likely be ascribed to the small sample size used, the pooling of 







Figure 6.4. Heatmap illustrating methylation levels of differentially methylated cytosines (DMCs). DMCs with 
a false discovery rate (FDR)  0.01 in high fat, high sugar (HFHS) diet fed rodents relative to standard (STD) 
diet fed animals, as determined using whole genome bisulfite sequencing (WGBS) datasets. The heatmap 
was constructed using the BrBG RColorBrewer palette, where hypermethylation is indicated in varying shades 
of blue/green and hypomethylation in different degrees of gold/brown. Hierarchical clustering via Euclidean 
distance of DMCs revealed that the HFHS and STD biological replicates were categorised into two groups 





Investigation into the genomic location of the above-mentioned 5 306 DMCs (FDR  0.05) 
across the Rattus norvegicus chromosomes, revealed that majority of the DMCs occupied 
chromosome 1 (29.40%) and 14 (9.77%), while less than 1% of the DMCs were located on 
chromosomes 10, 11 and 18. The extent to which DNA methylation can influence 
transcriptional events is largely dependent on DMC position, relative to established genomic 
features (Jingo et al., 2012; Pepin et al., 2019). Therefore, regional annotation was also 
performed to assess the distribution of the DMCs within annotated genic features such as 
promoter (3.23%), exon (2.52%), intron (17.27%) and intergenic (76.99%) regions (Figure 
6.5 A). In this study, majority of the DMCs in the heart of HFHS rodents mapped in the 
intronic and intergenic regions, both known to contain functionally important elements such 
as enhancers (Jeschke et al., 2015; Qu et al., 2017; Rearick et al., 2011; Takeshi, 2019).  
Though promoter methylation has been the focus of numerous diseases and extensively 
implicated in the regulation of adjacent gene expression, increasing evidence supports the 
ability of methylation in the gene body and intergenic regions to also influence gene 
expression (Aran et al., 2011; Ball et al., 2009; Jeschke et al., 2015; Lu et al., 2012; Rauch 
et al., 2009; Schlesinger, et al., 2013; Shenker & Flanagan, 2012; Thomas et al., 2012). 
Altered methylation levels in these regions have further been associated with modified gene 
expression in cancer and CVD incidence (Fernández-Sanlés et al., 2018; Jeschke et al., 
2015; Muka et al., 2016; Shenker & Flanagan, 2012). Similarly, a recent study conducted 
by Deshpande et al. (2020) demonstrated increased CpG sites located within intronic, and 
intergenic regions resulted in the enrichment of embryonic development signalling pathways 
in spermatozoa of high fat diet fed male rats. While the aforementioned study does not 
compensate for the combinatory effect of high fat and high sugar, as the present study does, 
the confirmation of increased DMCs in non-promoter regions remains a noteworthy 
observation and subsequent functional enrichment analysis should therefore be extended 
to include DMCs beyond the promoter context.  
The percentage of DMCs located in CpG island regions were evaluated in terms of CpGi 
(18.26%), CpGi shores (5.63%) and other (76.11%) regions respectively (Figure 6.5 B). 
Compared to the globally methylated CpG site annotation, the percentage of DMCs 
annotation within both CpGi and CpGi shores increased, while DMCs annotation within other 
CpG islands regions decreased (Figure 6.5 B). As anticipated, further investigation 
regarding the localisation of CpGi to the respective genic features revealed that majority of 
the DMCs associated with both CpGi and CpGi shores were located within intronic (55.92%) 






Figure 6.5. Regional annotation of differentially methylated cytosines (DMCs) in terms of A) gene parts 
(promoter, exon, intron and intergenic) and B) CpG island regions (CpGi = CpG island, CpGi shore = CpG 
island shores).  
 
6.3.6 Functional analysis of genes associated with DMCs 
Transcripts overlapping with DMCs, regarded as differentially methylated genes (DMGs), 
were identified by matching the 5 508 DMCs to the rat RefSeq database (rno6.0) retrieved 
from UCSC. A total of 5 253 DMCs were annotated within gene components of 533 unique 
genes, of which 339 genes were hypermethylated and 194 genes hypomethylated in the 
HFHS group (Supplementary Data - Table S7). Upon cross referencing of DMGs with the 
CTD Gene-Disease Associations dataset, 137 DMGs were found to be significantly 
associated with CVD including very low-density lipoprotein receptor (VLDR), platelet derived 





others (Supplementary Data - Table S8) (Johnson et al., 2020; Rouillard et al., 2016; Zhao 
et al., 2011).  
To gain a holistic view regarding the biological significance of the identified DMGs, hyper- 
and hypomethylated genes were jointly categorised into the three organised GO 
vocabularies namely: biological processes (BP), cellular components (CC) and molecular 
function (MF) using the R/Bioconductor package topGO. Overall, GO terms were assigned 
to 498 of the 533 DMGs in HFHS diet fed male Wistar rats. Evaluation of significant (p  
0.05) ontologies demonstrated that major GO categories included gene products involved 
in intracellular signal transduction and G protein-coupled receptor signalling pathway 
(biological processes: GO:0035556; GO:0007186), gene products localised in the 
cytoplasm and intracellular membrane-bounded organelle (cellular component: 
GO:0005737; GO:0043231), as well as gene products involved in protein- and metal ion 
binding (molecular function: GO:0005515; GO:0046872) (Figure 6.6). Aside from the 
processes relating to cellular development, function and signalling, GO analysis also 
revealed the enrichment of DMGs involved in central nervous system development, immune 
response, negative regulation of apoptotic process and response to drug, which are of 
particular interest to this study (Figure 6.6).  
Additionally, KEGG pathway analysis was conducted using the KEGGREST package and 
subsequent rat specific (rno) pathway assignments. The top 15 significant pathways 
enriched with genes associated with DMCs included phagosome, type I diabetes mellitus, 
platelet activation, steroid hormone biosynthesis, toll-like receptor signalling pathway, cell 
adhesion molecules and diabetic cardiomyopathy (Figure 6.7). Upon further investigation, 
the most significant pathway was the phagosome pathway (p = 1.04 x 10-7) containing 18 
genes including ATP6V1G1, C1R, CD209B, CTSS, DYNC1I1, EEA1, FCGR2A, IMPG1, 
FCGR2B, CD36 antigen-like, SEC61G and TLR4. Phagocytosis, defined as the process of 
particle consumption and removal through the formation of phagosomes, is essential for 
tissue homeostasis and the activation of an immune response (Flannagan et al., 2012; 
Freeman & Grinstein, 2014; Gordon, 2016; Uribe-Querol & Rosales, 2020). The significant 
enrichment of DMGs involved in this pathway could possibly indicate the potential presence 
of pathogenic microorganisms. However, the inclusion DMGs encoding membrane proteins 
such as cluster of differentiation 36 (CD36 antigen-like) and toll-like receptor 4 (TLR4) 
indicates that this pathway may rather have been aimed at the elimination of lipids or 
apoptotic cells instead (de Kleijn & Pasterkamp, 2003; Dirks et al., 2002; Kawai & Akira, 






Figure 6.6. Gene ontology (GO) enrichment analysis of genes associated with differentially methylated cytosines (DMCs) in high fat, high sugar (HFHS) diet fed male 







Figure 6.7. Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analysis of genes 
associated with differentially methylated cytosines (DMCs) in high fat, high sugar (HFHS) diet fed male Wistar 
rats. The top KEGG enrichment items of differentially methylated genes (DMGs) are listed and sorted by 
significance (p  0.05). 
 
Collectively, the demonstrated pathways and gene ontology enrichments suggest that 
differential methylation in HFHS diet fed rodents accompanies inflammation (possibly 
promoted by oxidative stress), altered lipid transport and apoptotic processes, known for 
their underlying role in CVD (Figure 6.6 and 6.7) (Goldberg et al., 2012; Kim & Kang, 2010; 





6.3.6.1 DNA methylation changes in HFHS diet fed rats result in the activation of acute 
inflammatory processes  
In depth analysis revealed a significant overlap of DMGs involved in six of the above-
mentioned enriched pathways namely: phagosome, cell adhesion molecules (cAMS), 
allograft rejection, type 1 diabetes mellitus, toll-like receptor signalling pathway and retinol 
metabolism (Figure 6.7). The involvement of immune-related mechanisms in CVD, 
particularly atherosclerosis, has been supported by a magnitude of scientific evidence 
(Chroni et al., 2010; Husain et al., 2015; McMaster et al., 2015; Montecucco et al., 2017; 
Ridker & Luscher, 2014; Sexena et al., 2015; Stenvinkel et al., 2007; Timmers et al., 2012; 
Zhou et al., 2001). The innate immune system, often considered as the body’s first line 
defence mechanism, is a dynamic complex involving the interaction of numerous signalling 
molecules and pathways (de Kleijn & Pasterkamp, 2003). To this end, toll-like receptors 
(TLRs) have been identified as one of the major receptors capable of recognising exogenous 
pathogen-associated structures and consequently activating a rapid immune response 
(Bijani et al., 2012; Frantz et al., 2007; Takeuchi & Akira, 2010). However, increasing 
evidence suggests that TLRs are also capable of responding to endogenous stimuli 
produced in response to injury and oxidative stress (Bianchi, 2007; Frantz et al., 2007; 
McGuire & Arthur, 2015; Yang et al., 2016).  
In the current study, male Wistar rats fed a HFHS diet displayed TLR4 hypomethylation 
within the gene body when compared to the STD diet fed controls. Amongst all TLRs, TLR4 
displays the highest expression levels in the heart and has consequently been reported to 
play a crucial role in myocardial inflammation associated with atherosclerosis, hypertension, 
and heart failure (Bagheri et al., 2014; Bijani et al., 2012; de Kleijn & Pasterkamp, 2003; Liu 
et al., 2015; Satoh et al., 2014; Yang et al., 2016). Additionally, studies involving TLR4 
knockout mice models identified TLR4 as a key mediator of high fat diet induced cardiac 
complications such as vascular inflammation, ROS, contractility, and myocardial dysfunction 
(Hu & Zhang, 2017; Kim et al., 2007). Evaluation of RNA sequencing analyses conducted 
on the same animals in Chapter 5, revealed that TLR4 mRNA was not amongst the 
significantly differentially expressed genes (DEGs). Possibly suggesting that 
hypomethylation of the specific DMCs located in the intronic region of TLR4 did not affect 
gene expression. Interestingly, TLR4 interactor with leucine-rich repeats (TRIL) mRNA was 
found to be significantly upregulated (p = 0.007) in HFHS diet fed male rodents. 
Furthermore, low density lipoprotein receptor (LDLR) mRNA expression was also 





to elevated LDL levels, which in its oxidised form (OxLDL), is a known ligand recognised by 
TLR4 (de Kleijn & Pasterkamp, 2003; Kruth, 2013; Thirunavukkarasu & Khader, 2019). 
Mechanistically, the stimulation of TLR4 by either exogenous or endogenous factors (such 
as HFHS diet as proposed in the current study) initiates several signalling events that 
ultimately trigger mitogen-activated protein kinase (MAPK) and nuclear factor κB (NF-κB) 
signalling pathways (Arthur & Ley, 2013; Coll & O’Neill, 2010; McGuire & Arthur, 2015; Yang 
et al., 2016). Briefly, TLR4 activation initiates the recruitment of the myeloid-differentiation 
factor 88 (MyD88) adaptor protein, which facilitates the formation of a myddosome structure 
through binding interleukin-1 receptor associated kinases (IRAKs) (Figure 6.8) (Flannery et 
al., 2010; Gay, 2019; Latty et al., 2018; Ve et al., 2017; Yamamoto et al., 2010). In this study, 
IRAK4, a key component of the myddosome was also hypomethylated in HFHS diet fed 
male Wistar rats. The myddosome is required for downstream activation of tumor necrosis 
factor receptor (TNF-R)-associated factor 6 (TRAF6), ultimately leading to the activation of 
transcription factors such as NF-𝜅B and interferon regulatory factors (IRFs), as well as 
MAPK pathways (Balka & De Nardo, 2018; Lopez-Pelaez et al., 2014; McGuire & Arthur, 
2015; Takaoka et al., 2005). Pertinent to the present study, genes encoding MAPK kinases 
responsible for activating MAPKs namely MAP2K and MAP3K7, were hypomethylated in 
the HFHS group. Induction and binding of the previously mentioned transcription factors to 
related gene promoters induces the expression of proinflammatory cytokines and 
chemokines that elicits an inflammatory response (O'Neill & Bowie, 2007; Terrel et al., 2006; 
Vallejo, 2011; Yang et al., 2016). Alternatively, signalling cascades downstream of TLR4 
can also be mediated by the TIR-domain-containing adapter-inducing interferon-β (TRIF) 
adaptor protein (Figure 6.8) (Balka & De Nardo, 2018; Gay et al., 2006; McGuire & Arthur, 
2015; Tatematsu et al., 2010;). The association of TRIF with TLR4 leads to the activation of 
both NF-𝜅B and IRF via TRAF (De Nardo, 2015; Hoebe, et al., 2003; O'Neill, 2006; O'Neill 






Figure 6.8. Schematic diagram to illustrate the proposed involvement of TLR4 and its ligands in underlying 
CVD processes. Downstream signalling of TLR4 is either mediated by the MyD88 or TRIF adaptor proteins, 
ultimately inducing the expression of proinflammatory cytokines and chemokines. The ability of cathepsin to 
mediate TLR4 signalling with the aid of the phagosome pathway is also displayed. Genes labelled with a red 
arrow represents differentially methylated genes identified in the present study where an up-arrow indicates 
hypermethylation and a down-arrow hypomethylation. TLR4, toll-like receptor 4; MyD88, myeloid-
differentiation factor 88; IRAK4, interleukin-1 receptor associated kinases; MAP2K, mitogen-activated protein 
kinase kinase; MAP3K7: mitogen-activated protein kinase kinase kinase 7; TRIF, TIR-domain-containing 
adapter-inducing interferon-; TRAF, tumor necrosis factor receptor-associated factor; NF-κB, nuclear factor 
κB; IRFs, interferon regulatory factors; CTSK, cathepsin K and CTSS, cathepsin S. Adapted from “TLR 






Two additional genes encoding cathepsin, CTSK and CTSS, were also amongst the 
overlapping DMGs in the pathways associated with immune response. These two 
cathepsins, known for their role in protein degradation and cellular turnover, have been 
associated with CVD and were first described in atherosclerotic tissue (Liu et al., 2004; 
Nomura & Katunuma, 2005; Plat et al., 2007). Since then, numerous studies involving in 
vitro, animal, and human models have confirmed the involvement of increased cathepsin 
levels in several CVDs, including myocardial infarction, cardiac hypertrophy, 
cardiomyopathy, hypertension, and atherosclerosis (Chen et al., 2013; Hua et al., 2013; Liu 
et al., 2006; Rodgers et al., 2006; Sharir et al., 2014; Stypmann et al., 2002; Sun et al., 
2010). Of particular interest to the current study, is the regulation of cathepsin expression in 
the heart through stimuli such as cholesterol, ROS, oxLDL, elevated glucose, as well as 
oscillatory shear stress (Liu et al., 2018; Plat er al., 2007). Not only did male rodents on the 
HFHS diet display diminished glucose clearance ability and atherogenic lipid profiles 
(Chapter 4), but genes involved in oxidative stress were also differentially expressed in these 
animals compared to the controls (Chapter 5). Additionally, cathepsins share overlapping 
ligands with TLRs (e.g., oxLDL) and have been shown to indirectly contribute to CVD 
development by regulating the immune response through TLR activation (Liu et al., 2018).  
Taken together the current study supports the concept of a HFHS being able to induce 
aberrant DNA methylation within the gene body of genes associated with a proinflammatory 
response in the heart. The hypomethylation of TLR4 is proposed to have increased TLR 
activation either through ligands associated with ROS or cardiac injury binding directly to 
TLR4 or via the hypomethylation and subsequent increase in cathepsins CTSS and CTSK. 
The activation of TLR4 was accompanied by hypomethylation of genes involved in the 
myddosome structure (IRAK4) and MAPK signalling pathway (MAP2K and MAP3K7), 
possibly affecting gene expression in favour of cytokine and chemokine release via NF-𝜅B 
and IRF.  
 
6.3.7 Correlation analysis 
To explore whether changes in the cardiac methylome corresponded with altered gene 
expression, WGBS analysis was compared to RNA sequencing analysis, described in 
Chapter 5, performed on the same samples. To this end, overlapping targets were identified 
by matching genes identified to be differentially expressed in HFHS vs STD male rats to 





previously mentioned criteria namely: C1D nuclear receptor corepressor (C1D); cathepsin 
K (CTSK); cluster of differentiation 36 (CD36); cyclin G2 (CCNG2); early endosome antigen 
1 (EEA1); eukaryotic translation initiation factor 4A2 (EIF4A2); phosducin like (PDCL); 
peroxiredoxin 4 (PRDX4); SEC61 translocon subunit gamma (SEC61G) and retinitis 
pigmentosa 1 (RP1) (Supplementary Data – Table S9). To enable a more comprehensive 
understanding on the relationship between HFHS diet induced DNA methylation and CVD 
pathophysiology, the 10 genes were subjected to an additional filtering step to include only 
genes with a validated experimental and/or clinical CVD association (Table 6.5). Following 
completion of the correlation and filtering procedures, five eligible genes were identified to 
fulfil all selection criteria (Table 6.5).  
 







%Diff.c P-val Log2FCd P-val 
CCNG2 14 5 Intergenic -18.7 0.004 -0.266 0.007 
CD36 4 2 Intron  -5.6 0.015 -0.451 <0.001 
SEC61G 14 6 Intergenic  -19.3 0.009 -0.895 0.008 
CTSK 2 14 Intergenic  -17.3 0.002 -0.579 0.003 
PRDX4 X 8 Intergenic  -19.9 0.004 -0.832 0.002 
a Differentially methylated cytosines (DMCs) to which target genes have been associated.  
b Genomic region in which DMCs are located following regional annotation analysis. 
c Percentage methylation difference in HFHS group compared to STD group. The mean difference in 
methylation of all corresponding DMCs represents the gene level difference.  
d Log2 fold changes for genes obtained as contrasts between HFHS group and STD group. 
 
Of the six genes fulfilling all three selection criteria, CCNG2 responsible for encoding cyclin 
G2, a protein involved in cell cycle regulation (Bennin et al., 2002; Bernaudo et al., 2016; 
Liu et al., 2004; Xu et al., 2008; Zhang et al., 2021). This unconventional cyclin is expressed 
at high levels in cells experiencing cell cycle arrest and terminal differentiation, conferring a 
potential tumor supressing role in cancer (Adorno et al., 2009; Choi et al., 2009; Gao et al., 
2018; Kim et al., 2004; Li et al., 2019; Nakae et al., 2008; Xu et al., 2008; Zimmermann et 
al., 2012). Cyclin G2 is capable of inhibiting G1/S phase cell cycle progression through 
binding to protein phosphatase 2A (PP2A) and peroxisome proliferator-activated receptor 
(PPARγ) (Aguilar et al., 2010; Bennin et al., 2002; Zhao et al., 2018). Data generated in this 





CCNG2 accompanied by reduced gene expression in HFHS rats compared to STD rats 
(Table 6.5). Similarly, previous studies have demonstrated altered CCNG2 mRNA and 
protein expression levels in adipose tissue, indicating an inverse association between 
CCNG2 expression and obesity and insulin resistance (IR) (Abdalla et al., 2021; Aguilar et 
al., 2010; Garrido-Sánchez et al., 2014; Pivovarova et al., 2015). Additionally, a study by 
Zimmermann et al. (2016) showed that insulin and insulin-like growth factor-1 (IGF-1) was 
able to significantly lower the expression of CCNG2, ultimately promoting cell proliferation. 
Considering that both obesity and IR are major metabolic risk factors of CVD, the reduced 
CCNG2 expression associated with these disorders could be linked to the involvement of 
CCNG2 in underlying CVD pathology (Haywood et al., 2020; Minta et al., 2010; Zhang et 
al., 2021).  
The second gene identified with correlation analysis, CD36 (multifunctional receptor), is 
expressed in various tissues including the vascular system (Couturier et al., 2019; Hou et 
al., 2015; Son et al., 2018; Yang et al., 2018; Yu et al., 2020). In line with its involvement in 
numerous pathological processes including fatty acid (FA) uptake, immune response, 
platelet activation and metabolic regulation, CD36 ligands include both lipid and protein 
molecules such as oxLDL and thrombospondin, respectively (Glatz & Luiken, 2017; 
Magwenzi et al., 2015; Wang & Li, 2019; Zhao et al., 2018). As FAs are considered the 
predominant source of energy (ATP) production in cardiac muscle tissue and approximately 
70% of FA uptake is arbitrated by CD36, CD36 is essential in myocardial lipid metabolism 
(Glatz & Luiken, 2018; Kim & Dyck, 2016; Shu et al. 2020). The DMCs identified in this 
study, located within the intronic region of CD36, were hypomethylated in the HFHS group 
when compared to animals in the control group (Table 6.5). Similarly, CD36 mRNA 
expression levels in HFHS rats were significantly lower than in the STD rats (Table 6.5). 
Decreased CD36 expression has previously been observed in hypertrophy and ischemia, 
resulting in a decreased FA oxidation and impaired contractile function (Abumrad & 
Goldberg, 2016; Dehn & Thorp, 2018; DeLeon-Pennell et al., 2016; He et al., 2019; 
Lesnefsky et al., 2017). Similarly, pressure overload has been shown to inhibit CD36 
synthesis via the downregulation of peroxisome proliferator-activated receptor a (PPARa), 
which subsequently leads to the accumulation of toxic lipids and heart failure (Dobrzynet al., 
2013; Iemitsu et al., 2003; Karam et al., 2017; Madonna et al., 2011; Oka et al., 2015; Sung 
et al., 2017). The hypomethylation and decreased expression of CD36 observed in this 
study, accompanied by increased hypertrophic gene expression (Chapter 5), therefore 





level. Conversely, in CVDs such as diabetic cardiomyopathy and atherosclerosis, increased 
CD36 expression in the sarcolemma facilitates excessive myocardial FA uptake and overall 
disease progression (Ackers et al., 2018; Carley & Severson, 2008; Coort et al., 2004; 
García-Rúa et al., 2012; Li et al., 2020; Ouwens et al., 2007; Sato et al., 2018; Xu et al., 
2019). Interestingly, studies have shown that the inhibition of CD36 can impede lipid 
accumulation and ROS generation in high fat diet-induced cardiomyopathy by promoting 
glycolysis (Angin et al., 2012; Glatz et al., 2021; Yang et al., 2007; Zhang et al., 2015). 
Considering this, the reduction in CD36 expression observed in the current study could also 
be viewed as a possible defence mechanism against the HFHS diet insult aimed at 
decreasing FA uptake and normalisation of cardiac substrate metabolism. Collectively, 
these studies suggest that the role of CD36 in cardiac muscle tissue is mainly dependent on 
the pathological stimuli and how it influences CD36 synthesis and translocation (Shu et al., 
2020). Furthermore, considering the significant role of CD36 in cardiac metabolism, it may 
present as a potential target for metabolic modulation therapy (Glatz et al., 2021; Revenco 
& Morgan, 2009). 
Additional genes meeting the selection criteria utilised in comparative analysis included 
SEC61 translocon gamma subunit (SEC61G), peroxiredoxin 4 (PRDX4) and cathepsin K 
(CTSK) (Table 6.5). While the latter has previously been described for its role in the immune 
response via the TLR signalling pathway (Figure 6.8), SEC61G encodes a subunit of the 
protein translocation complex of the endoplasmic reticulum (ER) and PRDX4 prevents the 
accumulation of hydrogen peroxide within the cell (El Eter & Al-Masri, 2015; Greenfield & 
High, 1999; Liebthal et al., 2018; Linxweller et al., 2017; Nebendahl et al., 2013; Rhee et al., 
2018). This study found that intergenic DNA methylation, as well as expression of SEC61G, 
PRDX4 and CTSK was significantly reduced in HFHS diet fed rats compared to those 
maintained on the STD diet (Table 6.5). While SEC61G expression is induced under 
conditions conducive of ER stress, complete silencing of SEC61G results in cellular 
apoptosis (Li et al., 2020; Liu et al., 2019; Lu et al., 2009; Marslli et al., 2020; Reis-Filho et 
al., 2006; Tsukamoto et al., 2008). Of particular interest to the current study is the 
hypomethylation of SEC61G in skeletal muscle of males clinically diagnosed with T2DM 
demonstrated by Mudry et al. (2017). On the other hand, increased levels of PRDX4 have 
been known to attenuate cardiovascular events through oxidative stress (Forman et al., 
2010; Jiang et al., 2020; Jing et al., 2011; Martinez-Pinna et al., 2011). 
In the current study, the lowered expression and intronic methylation of CD36 indicates the 





with in ischemic and pressure overload conditions. Additionally, the hypomethylation and 
downregulation of SEC61G and PRDX4 suggests the cumulative decrease in antioxidant 
activity and increased apoptosis associated with HFHS feeding. While these hypotheses are 
supported by the GO enrichment of DEGs involved in cardiac muscle contraction, response 
to oxidative stress and hypertrophic gene regulation, demonstrated by RNA sequencing 
analysis conducted on the same animals (Chapter 5), further investigation is required in 
order to confirm this.  
 
6.4 Conclusions 
The exponential increase and availability in high throughput technologies over the past few 
years has facilitated a deeper understanding into the molecular mechanisms underpinning 
multiple diseases including CVD. Despite the efforts to advance precision medicine and 
develop personalised treatments for CVD, the diverse and asymptomatic nature of the 
disease, hinders progress significantly. Therefore, shifting the provisional scientific focus 
from single etiology to converging mechanisms driving CVD pathogenesis. Amongst the 
multiple factors contributing towards CVD development, epigenetics has been suggested to 
provide a mechanistic link between heritable and environmental components. Moreover, 
DNA methylation, the most widely studied epigenetic mechanism, has been extensively 
implicated in CVD development and progression (Baccarelli et al., 2010).   
While there are currently several methods available to evaluate DNA methylation, WGBS 
remains the gold standard and is more comprehensive than targeted approaches. The 
present study is the first study demonstrating the successful application of WGBS 
technology in South Africa and allowed for the comprehensive profiling of DNA methylation 
in male Wistar rats maintained on a HFHS diet and its relation to underlying CVD 
pathophysiology. In order to explore differentially methylated bases in cardiac tissue, DNA 
from five biological replicates in the experimental groups previously described were 
subjected to WGBS using a PE100 strategy. Following QC assessment and trimming, an 
average of 200.54 million paired-end reads were obtained per sample with approximately 
70.77% all remaining reads mapping uniquely to the latest version of the annotated 
reference genome and no samples displaying excessive PCR duplication bias. Furthermore, 
a conversion rate above 99% was obtained for all the samples in this study, indicative of 





Genome wide evaluation of DNA methylation levels revealed a mean CpG methylation of 
57.4%, while non-CpG methylation in the CHG and CHH context was negligible. 
Comparative analysis between groups, conducted in the CpG context, showed a per base 
methylation of 72.93 and 71.31% for STD and HFHS samples respectively. In line with 
previous findings, regional annotation performed on the methylated CpG sites revealed 
increased distribution of methylated bases in intergenic regions compared to promoter 
regions. Differential methylation analysis, performed on a per base level, identified a total of 
5 329 DMCs (FDR  0.05) in male Wistar rats maintained on the HFHS diet compared to 
those in the STD diet-fed control group. The exclusion of DMCs located on the Y 
chromosome further reduced the number of DMCs by 0.43% (5 306), of which 2 936 DMCs 
were hypomethylated and 2 370 hypermethylated in the HFHS group. Hierarchical 
clustering revealed the distinct classification of the most variable DMCs (FDR < 0.01) by 
treatment groups, suggesting the possible use of these DMCs to distinguish between the 
disease and the control groups. In this study, transcripts overlapping with DMCs were 
regarded as DMGs, with a total of 5 254 DMCs annotated within gene components of 533 
unique genes, of which 339 genes were hypermethylated and 194 genes hypomethylated 
in the HFHS group. These DMCs mainly remained in the intergenic and gene body regions 
suggesting the possibility of non-promoter methylation correlating with gene expression 
involved in the pathological processes of HFHS diet feeding and its resulting cardiovascular 
complications.  
Moreover, GO enrichment and KEGG pathway analysis conducted in this study 
demonstrated a distinct link between DMC-related genes and the enrichment of molecular 
functions underlying CVD pathology. Some of the major findings associated with the HFHS 
group included the differential methylation of genes involved in phagosome, type I diabetes 
mellitus, platelet activation, toll-like receptor signalling pathway and diabetic 
cardiomyopathy. The enrichment of immune related terms corresponded with intergenic and 
gene body hypomethylation of several overlapping genes including TLR4, MAP2K, 
MAP3K7, IRAK4, CTSK and CSS. Collectively these results demonstrate the ability of the 
HFHS diet to act as a pathological stimulus capable of inducing altered DNA methylation of 
genes associated with lipid metabolism and proinflammatory responses in the heart. The 
notable changes in cardiac DNA methylation induced by the HFHS diet were further 
associated with increased risk of CVD development and the possible induction of a 
hypertrophic background through comparative analysis of WGBS and RNA sequencing 





biomarkers or targets for diet-induced CVD, which may play significant roles in early 
diagnosis and clinical treatment. However, considering that the epigenome comprises 
numerous additional modifications and that DNA methylation has been shown to accompany 
chromatin remodelling, further investigation aimed at characterising these interactions in this 
particular animal model is required.  
 
6.5 Supplementary Data 
Supplementary Data: Table S7 - List of DMCs and corresponding annotation in HFHS 
males. 
Supplementary Data: Table S8 - List of DMGs associated with CVD according to the CTD 
database. 
Supplementary Data: Table S9 - List of DMGs corresponding with DEGs identified in RNA 
sequencing analysis. 
Supplementary Figure 1. M-bias plots of a representative samples generated with Bismark. 
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Chapter 7: Conclusions, limitations, and prospects   
7.1 Concluding findings 
Unhealthy diets, rich in fat and sugar derivatives, remain one of the major contributors to the 
worldwide increase in cardiovascular disease (CVD) risk factors including dyslipidaemia 
insulin resistance (IR) and type 2 diabetes mellitus (T2DM). In an era where these non-
communicable diseases continue to place a colossal burden on the health system and 
economy of developing countries such as South Africa, research exploring the contributing 
mechanisms is crucial. Recent breakthroughs in omics-based technologies have 
transformed genomic research. Next generation sequencing (NGS) is being utilised to 
decode various diseases including CVD pathophysiology, to develop improved diagnostic, 
prognostic, and therapeutic markers. Furthermore, the limited cardioprotective capacity of 
drugs aimed at treating CVD risk factors such as hyperglycaemia and hyperlipidaemia, 
strongly supports the need to explore alternative therapies. In recent years, studies focused 
on the use of plant derived nutraceuticals as an alternative therapy to alleviate diet induced 
metabolic disarrangements and decrease cardiovascular risk. In this study, a Wistar rat in 
combination with NGS technologies was utilised to explore the influence of nutrition in CVD 
development and the role of AfriplexGRTTM to ameliorate observed alterations.  
The results obtained showed that treatment of cardiomyocytes with high glucose plus 
palmitate (HG + Pal) induced a cardiac insult capable of reducing ATP production and the 
host antioxidant defence system through modulating a key redox regulator, NRF2. 
Additionally, HG + Pal treatment was significantly associated with membrane depolarization 
and impaired mitochondrial bioenergetics, resulting in mitochondrial dysfunction and a 
subsequent increase in apoptosis. Interestingly, this study also showed that post-treatment 
with either Asp or Afriplex GRTTM, had no significant beneficial effect on the parameters 
assessed and further exacerbated HG + Pal-induced mitochondrial dysfunction and 
apoptosis. Gene expression and functional enrichment analyses revealed that HG + Pal 
treatment induced transcriptional changes associated with altered lipid metabolism, 
inflammatory response, and increased contractile dysfunction, promoting the development 
of atherosclerotic and hypertrophic phenotypes, unable of being ameliorated by Asp or 
Afriplex GRTTM treatment. These findings contradict previous findings reporting on the ability 
of Asp to reverse HG-induced stress on cardiomyocytes and possibly suggests that the HG 





To explore whether the previously described findings translated to an obesogenic diet-
induced in vivo model, Wistar rats maintained either on a high fat, high sugar (HFHS) or 
standard (STD) rodent diet. This study demonstrated that HFHS diet feeding resulted in 
increased caloric intake and body weight, corresponding to the augmented retroperitoneal 
fat (RF) weight in both male and female animals. While a definite IR phenotype was not 
induced, rodents maintained on the obesogenic diet displayed diminished glucose clearance 
abilities. Taken together with the elevated serum triglyceride levels and TG/HDL ratio, these 
results confirm that the HFHS diet was successful in establishing a pre-clinical, CVD risk 
prediction model that was used to assess the molecular mechanisms underlying disease 
pathophysiology. In this study, HFHS diet-induced effects on the biometric parameters 
assessed were more prominent in male rats and Afriplex GRTTM supplementation, had no 
significant adverse effect on these parameters. 
Moreover, while this study provided the first large scale, cardiac transcriptomic profiling of 
Wistar rats maintained on this particular diet and treated with the Afriplex GRT™ extract, 
using RNA sequencing (RNA-Seq). In depth bioinformatics analysis allowed for the 
identification of 571 and 414 differentially expressed genes (DEGs) in HFHS diet fed males 
and females, respectively. Furthermore, animals receiving Afriplex GRT™ supplementation 
clustered closely with those in HFHS group, with a total of 120 and 337 DEGs identified in 
males and females in the Afriplex GRT™ group, respectively. The results demonstrated the 
ability of the HFHS diet to act as a pathological stimulus capable of increasing host 
inflammatory response whilst decreasing antioxidant activity, which could increase oxidative 
stress. The decrease in host defence mechanisms is further accompanied by increased 
hypertrophic gene expression, possibly affecting cardiac muscle functionality. As expected, 
the described mRNA enrichments were more prominent in males than females, correlating 
with the limited changes in the metabolic risk parameters of female animals. Functional 
analyses of DEGs associated with Afriplex GRT™ supplementation yielded no significant 
enrichment of disease or pathology related processes and no high confidence results for the 
amelioration of the transcriptomic signatures resulting from HFHS diet feeding.  
The known influence of epigenetic modifications on gene expression and the obesogenic 
diet induced disruption of cardiac gene regulatory network observed in males in the present 
study, supported the complementation of cardiac transcriptomic signatures with 
comprehensive DNA methylation analysis. Whole genome bisulfite sequencing (WGBS), 
successfully employed for the first time in South Africa, identified 5 329 differentially 





compared to those in the STD diet-fed control group. A total of 533 unique transcripts 
overlapped with DMCs located mainly in the intergenic and gene body regions. Interestingly, 
approximately 77% of the DMCs identified in this study were located within intergenic 
regions known to house regulatory elements and non-coding RNA. Considering that the 
degree to which DNA methylation effects the transcriptome significantly depends on the 
genomic location of methylated sites, exploring the functional relevance of intergenic DNA 
methylation in the context of diet induced CVD is an avenue worth exploring. Moreover, this 
study demonstrated a distinct link between DMC-related genes and the enrichment of 
molecular functions underlying CVD pathology. Some of the major findings associated with 
the HFHS group included intergenic and gene body hypomethylation of genes related to 
lipid metabolism and immune related terms in the heart. The notable changes in cardiac 
DNA methylation induced by the HFHS diet were further associated with increased risk of 
CVD development and the possible induction of a hypertrophic background through 
comparative analysis of WGBS and RNA sequencing data.  
Taken together, this study demonstrated that HFHS feeding induced traditional CVD risk 
factors of dyslipidaemia and decrease glucose clearance that may have contributed to the 
observed sex disparities. This study further provides new insight into the deleterious effect 
HFHS feeding has on altered gene expression and overlapping DNA methylation profiles, 
with the underlying molecular mechanism of low-grade inflammation (e.g., TLR4, MAP2K, 
IRAK, CTSK and CSS), oxidative stress (e.g., NRF2, PDX4 and SEC61), lipid metabolisms 
and hypertrophy governing early onset of CVD. 
 
7.2 Study limitations 
As the case with multiple studies, particularly those involving the use of NGS technologies, 
this study was considerably impacted by financial constraints. Additional limitations include:  
• The HG + Pal treatment conditions used in the vitro model resulted in cell viability levels lower 
than 50%, which could have limited the recovering ability of the cells and the action of the 
antioxidant.  
• The inability of the HFHS diet to induce a significant metabolic disorder and CVD phenotype.  
• The lack of cardiac functional parameter assessments due to limited access to 
echocardiogram infrastructure. 





7.3 Future prospects 
This study provided insight into the cardiac transcriptomic and epigenomic alterations in an 
obesogenic diet induced Wistar rat model displaying moderate CVD risk. Furthermore, it 
generated scientific knowledge regarding the molecular mechanisms through which Afriplex 
GRT™ confers its potential cardioprotective effects. The transcriptomic signatures and 
methylation sites identified in this study could potentially serve as novel targets for diet-
induced CVD, ultimately playing a significant role in early diagnosis and clinical treatment.  
Future studies should: 
• Further explore the Afriplex GRT™ datasets explicitly, to provide a better understanding of 
the associated transcriptional signatures, pathway enrichments and possible mode of action. 
• Include gender specific evaluation of the mRNA sequencing data, to elaborate on potential 
gender differences.  
• Aim to characterise alternative epigenetic alterations such as histone modifications in this 
particular animal model.  
• Utilise WGBS to perform DNA methylation analysis on female, as well as Afriplex GRT™ 
samples.  
• Include functional studies involving high priority candidates, to explore signalling cascades 
and downstream targets.  
• Explore the regulatory elements associated with intergenic DMCs and their transcriptional 
relevance in terms of disease pathophysiology.  
• Utilise an alternative diet capable of inducing a severe cardiac disease phenotype, to validate 








Supplementary Table 1. Complete list of differentially expressed genes (DEGs) identified from RT2 Profiler 
PCR Arrays. DEGs categorised in terms of their role in major underlying CVD mechanisms.  




HG + Pal Asp 
Afriplex 
GRT 
Lipid transport and metabolism 
ATP-binding cassette transporter A1 ABCA1 -3.44  -3.34  -3.75 
Low-density lipoprotein receptor LDLR 2.40 2.16 2.67 
Nuclear receptor 1H3 NR1H3 -1.53  -1.22  -1.17 
Prostaglandin-endoperoxide synthase 1 PTGS1 1.53 1.62 1.44 
Perilipin 2 PLIN2 2.23 2.59 2.46 
Retinoid X receptor alpha RXRA -6.01  -6.66  -6.48 
Peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha PPARGC1A 2.20 2.15 2.87 
Insulin resistance 
Serpin peptidase inhibitor, clade E, 1 SERPINE1 1.37 1.48 1.77 
Vascular endothelial growth factor A VEGFA 1.19 1.61 1.77 
Protein kinase, AMP-activated, gamma 3  PRKAG3 7.06 7.53 7.18 
Insulin-like growth factor binding protein 3 IGFBP3 2.91 2.87 2.45 
Neuropeptide Y NPY 6.42 6.61 6.06 
Insulin-like growth factor binding protein 5 IGFBP5 1.84 1.36 1.94 
Inflammation 
Interleukin 6 IL6 1.64 1.73 1.47 
Chemokine (C-C motif) ligand 5 CCL5 -2.55  -2.20  -2.76 
Tumor necrosis factor TNF 4.72 4.21 4.78 
Colony stimulating factor 1  CSF1 2.83 2.56 2.10 
Colony stimulating factor 2 CSF2 3.94 3.30 3.64 
Early growth response 1 EGR1 3.10 3.52 3.60 
Fibroblast growth factor 2 FGF2 2.51 2.23 2.67 
Interferon gamma IFNG 2.30 2.42 2.06 
Interleukin 1 beta IL1B 2.09 2.22 2.17 
Vascular cell adhesion molecule 1 VCAM1 -3.24  -3.32  -3.01 
Nitric oxide synthase 2 NOS2 4.87 5.01 4.93 
Nitric oxide synthase 3 NOS3 2.53 2.00 2.10 
Leukemia inhibitory factor LIF 3.63 3.05 3.58 
Titin TTN 1.57 1.44 1.73 
Troponin I type 2 TNNI2 1.58 1.26 1.84 
Troponin T type 3  TNNT3 1.61 1.95 1.89 
Nebulin NEB 1.65 1.33 1.82 
Platelet derived growth factor receptor 
beta PDGFRB -1.94  -1.44  -1.22 







Collagen type 3 alpha 1 COL3A1 -1.44  -1.27  -1.25 
Connective tissue growth factor CTGF -1.39  -1.84  -1.40 
Transforming growth factor beta 2 TGFB2 -2.10  -2.26  -2.19 
Matrix metallopeptidase 3 MMP9 1.80 1.14 1.38 
Endoglin ENG -1.56  -1.09  -1.65 
Integrin alpha 2 ITGA2 2.97 2.24 2.36 
Apoptosis 
B-cell leukemia/lymphoma 2 related 
protein A1d BCL2A1 2.04 2.59 2.88 
Baculoviral IAP repeat-containing 3 BIRC3 2.87 2.91 2.18 
Secreted phosphoprotein 1 SPP1 3.80 3.32 3.27 
CASP8 and FADD-like apoptosis 
regulator CFLAR 1.61 1.83 1.94 
Paired box 3 PAX3 1.45 1.68 1.36 
Myogenic differentiation 1 MYOD1 -1.21  -1.80  -1.06 
Tenascin C TNC -2.53  -2.70  -2.01 
Calpain 2 CAPN2 -1.29  -1.70  -1.47 
Mitogen activated protein kinase 3 MAPK3 -1.27  -1.63  -1.86 
Hypertrophy 
Actin alpha 1 ACTA1  -1.34  -1.66  -1.73 
Activin A receptor type IIB ACVR2B 1.51 1.22 1.19 
Adrenergic beta 2 ADRB2 3.24 3.08 3.61 
Agrin AGRN -1.54  -1.82  -1.39 
Emerin EMD -1.49  -1.93  -1.84 
Myosin heavy polypeptide 1 MYH1 1.62 1.78 1.99 
Myosin heavy chain 2 MYH2 -5.39  -5.02  -5.85 
Tripartite motif-containing 63 TRIM63 1.40 1.59 1.97 
Desmin DES 1.50 1.30 1.94 
Elastin ELN -4.25  -4.56  -4.30 
Catenin beta 1 CTNNB1 -1.27  -1.29  -1.47 
All DEGs associated with HG + Pal were either statistically significant (p  0.05) or displayed a fold change  
2 in either positive or negative direction. In all instances post-treatment with neither Afriplex GRT™ nor Asp 








Supplementary Table 2. GO enrichment analysis of overexpressed DEGs in HFHS males. 
GO.ID Term Annotated 
Adjusted 
P-value 
GO:2001222 regulation of neuron migration 4 0.018 
GO:0045471 response to ethanol 5 0.025 
GO:0042493 response to drug 13 0.033 
GO:0006357 regulation of transcription by RNA polymerase II 43 0.035 
GO:0045830 positive regulation of isotype switching 2 0.036 
GO:0055003 cardiac myofibril assembly 4 0.037 
GO:0002244 hematopoietic progenitor cell differentiation 3 0.049 
GO:0043627 response to estrogen 3 0.049 
GO:0060048 cardiac muscle contraction 6 0.052 
GO:0090263 positive regulation of canonical Wnt signaling pathway 4 0.054 
GO:0051091 positive regulation of DNA-binding transcription factor activity 8 0.056 
GO:0043410 positive regulation of MAPK cascade 7 0.089 
GO:0001666 response to hypoxia 9 0.094 
GO:0010628 positive regulation of gene expression 41 0.099 









GO:0030182 neuron differentiation 12 0.037 
GO:0051602 response to electrical stimulus 2 0.052 
GO:0014823 response to activity 3 0.054 
GO:0000422 autophagy of mitochondrion 3 0.075 
GO:0046326 positive regulation of glucose import 2 0.077 
GO:0016192 vesicle-mediated transport 27 0.086 
GO:0045184 establishment of protein localization 36 0.088 
GO:0007568 aging 11 0.089 
GO:0006979 response to oxidative stress 15 0.019 
GO:0030855 epithelial cell differentiation 8 0.098 
GO:0042493 response to drug 9 0.100 
GO:0035335 peptidyl-tyrosine dephosphorylation 3 0.104 
GO:0006954 inflammatory response 18 0.028 
GO:0006886 intracellular protein transport 22 0.113 







Supplementary Table 4. GO enrichment analysis of overexpressed DEGs in HFHS females 
GO.ID Term Annotated 
Adjusted 
P-value 
GO:0061077 chaperone-mediated protein folding 6 0.074 
GO:0035264 multicellular organism growth 4 0.093 
GO:0030198 extracellular matrix organization 5 0.097 
GO:0046330 positive regulation of JNK cascade 3 0.1514 
GO:0007229 integrin-mediated signaling pathway 5 0.1111 
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading 2 0.1174 
GO:0033209 tumor necrosis factor-mediated signaling pathway 4 0.1282 
GO:0032755 positive regulation of interleukin-6 production 3 0.1314 
GO:1990090 cellular response to nerve growth factor stimulus 2 0.1012 
GO:0032760 positive regulation of tumor necrosis factor production 2 0.088 
GO:0048013 ephrin receptor signaling pathway 2 0.077 
GO:0032331 negative regulation of chondrocyte differentiation 2 0.1031 
GO:0051209 release of sequestered calcium ion into cytosol 4 0.073 
GO:0042733 embryonic digit morphogenesis 2 0.076 




Supplementary Table 5. GO enrichment analysis of under expressed DEGs in HFHS females 
GO.ID Term Annotated 
Adjusted 
P-value 
GO:0032868 response to insulin 6 0.061 
GO:0032922 circadian regulation of gene expression 3 0.071 
GO:0007565 female pregnancy 4 0.074 
GO:0042127 regulation of cell population proliferation 12 0.089 
GO:0001649 osteoblast differentiation 4 0.103 
GO:0045893 positive regulation of transcription, DNA-templated 14 0.116 
GO:0042438 melanin biosynthetic process 2 0.120 
GO:0001570 vasculogenesis 2 0.121 
GO:0030318 melanocyte differentiation 2 0.137 
GO:0009617 response to bacterium 8 0.080 
GO:0044342 type B pancreatic cell proliferation 2 0.090 
GO:0045944 positive regulation of transcription by RNA polymerase II 12 0.104 
GO:0009749 response to glucose 3 0.161 
GO:0043433 negative regulation of DNA-binding transcription factor activity 2 0.084 









Supplementary Figure 1. M-bias plots of a representative samples generated with Bismark. The percentage methylation is illustrated throughout the read length of 
the forward and the reverse reads.  
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